Application of CRISPR/Cas9 screening to study cancer drivers and to identify novel cancer vulnerabilities by Turner, Gemma
 Application of CRISPR/Cas9 
screening to study cancer drivers and 
to identify novel cancer vulnerabilities 
 
 
 
Gemma Turner 
Wellcome Sanger Institute 
University of Cambridge 
 
 
This dissertation is submitted for the degree of 
Doctor of Philosophy 
 
 
Churchill College                September 2019  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
I would like to dedicate this thesis to maw, paw and Danielle; 
I hope I can make you all as proud of me as I am of you.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Declaration 
 
This dissertation is the result of my own work and includes nothing which is the outcome of 
work done in collaboration except as declared in the Preface and specified in the text. 
 It is not substantially the same as any that I have submitted, or, is being concurrently 
submitted for a degree or diploma or other qualification at the University of Cambridge or any 
other University or similar institution except as declared in the Preface and specified in the 
text. I further state that no substantial part of my dissertation has already been submitted, or, is 
being concurrently submitted for any such degree, diploma or other qualification at the 
University of Cambridge or any other University or similar institution except as declared in the 
Preface and specified in the text. 
 This dissertation does not exceed 60,000 words in length, exclusive of tables, footnotes, 
bibliography, and appendices. 
 
Gemma Turner 
September 2019 
   
 Acknowledgements 
 
When I started my PhD four years ago, I underestimated how challenging it would be, both 
scientifically and personally. I’d like to take this opportunity to thank the many people who 
have helped me get to this stage. 
I would firstly like to thank my supervisor, Dave, who has always found time for me 
despite his crazy schedule. I really appreciate him giving me this opportunity and putting his 
trust in me. Thank you for your advice, patience, understanding and for just caring.  
I would also like to thank Luca Crepaldi, Leo Parts, Helen Davies and Peter Campbell, 
who all gave me their time and support during my rotation projects in my first year at Sanger. 
I learned a lot from them, including many skills that were invaluable throughout my PhD. 
This project would not have been possible without the generosity of various people who 
have given up their time to teach me or help me with my experiments. Thank you to the Gene 
Editing facility for producing my iPSC lines. Thank you to the members of CGaP, especially 
Rebecca and Verity, for making the project run so smoothly and for the many, many hours 
spent in cell culture. Thanks to Vivek Iyer, Francesco Iorio and Emanuel Gonçalves for helping 
me with my data analysis. Thanks also to Fiona Behan and Kosuke Yusa for providing CRISPR 
reagents and advice.  
  I was lucky to have two brilliant scientists as mentors during the first few years of my 
PhD. Marco taught me many things and working with him has undoubtedly made me a better 
scientist. I really appreciate the time, support and friendship he has offered me since the day I 
joined Sanger. I’m very grateful to Clara for sharing her knowledge and experience with me, 
and for being so friendly and welcoming. She put a lot of work into this project before I started 
and it would’ve been a much steeper, more painful learning curve without her supervision.  
Finding the motivation to go to the lab every day would’ve been near impossible if I 
hadn’t been surrounded by such lovely people. Louise, thank you for letting me be involved in 
your project and always providing kind words and light relief with your hilarious stories. Your 
dedication and passion for science is inspiring. Carmen, we come as a pair and I’m so grateful 
that I got to spend the past 3 years with you sat behind me! Thank you for the life chats, snack 
breaks, gym trips, many laughs and endless encouragement; you’ve helped me more than you’ll 
ever realise. Vicky, you’re the most selfless person I know and I’ll be forever grateful to you 
for giving up your weekends to help me. I’m going to miss our chats and your friendly smile! 
Aravind, thanks for just always being there for me and for being a great flatmate and passenger 
 - it would’ve been a lot less fun without you. Annie, thanks for the constant supply of amazing 
sweet treats - they powered me through many a tough time! Thanks also to Agnes, Saskia, 
Andrea and the rest of team 113 for being such great friends and colleagues. 
Arian, thank you for always understanding what goes on in my head. It means so much 
that you’re always there (with an appropriate gif), no matter how long it’s been. Katie, thank 
you for being by my side every day for the past 6 years, through the highs and many lows. I 
really would be lost without you and I’m proud that we got through this challenge together. 
Finally, I’d like to thank my family for being my life-long cheerleaders. Especially my 
mum, dad and Danielle - I can’t put into words how grateful I am for everything. I wouldn’t be 
the person I am today without you. Thank you for never letting me give up. Your constant love 
and support mean the world and I know you’ll get me through whatever life brings. Not 
forgetting my big bear, Rox, for always cheering me up. 
 
 
“Whit’s fur ye’ll no go by ye.” 
 
  
 Abstract 
 
The development of targeted therapies has had a significant impact on cancer survival rates. 
However, targeting cancers that are driven by loss of tumour suppressor genes remains a major 
challenge. One promising approach to treat these cancers is the exploitation of synthetic lethal 
interactions. Synthetic lethality describes an interaction between two genes, where loss of one 
gene alone does not affect viability but loss of both genes induces cell death. Inhibiting the 
synthetic lethal partner of a tumour suppressor gene should specifically kill tumour cells, and 
so these represent potential therapeutic targets. However, very few synthetic lethal interactions 
have been well-established. 
 The aim of this project was to systematically screen for synthetic lethal partners of 
known tumour suppressor genes. To do so, isogenic human induced pluripotent stem cell lines 
were generated, each carrying a loss-of-function mutation in a single tumour suppressor gene. 
These cells have a normal genetic background, thus making it simpler to accurately identify 
interactions. CRISPR/Cas9 technology was applied as it allows for large-scale, unbiased 
screening of genetic interactions. A genome-wide guide RNA library was prepared and 
implemented for knockout screening in the isogenic cell line panel. Analysis was performed to 
identify genes that were specifically essential for cell fitness/survival in the mutant lines. 
Particular focus was placed on four tumour suppressor genes that encode subunits of the 
PBAF/BAF complexes. Approximately 20% of human cancers harbour mutations in subunits 
of these complexes, so identifying dependencies associated with these could have broad 
therapeutic potential. Candidate synthetic lethal interactions with these genes were investigated 
using low-throughput assays in the stem cells and in a cancer cell line. The data obtained 
suggests that screening in stem cells produces highly variable results. Although potential 
vulnerabilities associated with all of the tumour suppressor genes were identified, further work 
is required to validate these and to assess the quality of the results. 
In addition to genome editing, CRISPR/Cas9 has been adapted as a tool for controlling 
gene regulation. In collaboration with Dr Louise van der Weyden, I applied this technology to 
address another challenging area of cancer biology. Metastasis is the main cause of cancer 
mortality, yet we still have a poor understanding of the genes that control this process. 
Considering this, an in vivo CRISPR activation screen was performed to identify novel drivers 
of metastatic colonisation. A mouse melanoma cell line was transduced in vitro with a library 
designed to up-regulate expression of membrane proteins, which represent ideal drug targets. 
 These cells were then used in an in vivo experimental metastasis assay. Enrichment of guide 
RNAs in the lungs was assessed to identify genes that increased pulmonary metastatic 
colonisation when activated. Candidate genes were selected using three analysis strategies, and 
hits from each were tested. Several genes were successfully validated using the experimental 
metastasis assay. The most robust hit was studied further to explore its potential as a therapeutic 
target.  
 Collectively, the work described in this thesis demonstrates how CRISPR/Cas9 
screening can be applied in different model systems to study genes that drive cancer and to 
explore novel therapeutic strategies. 
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Chapter 1 
1 Introduction 
1.1 Targeted therapies for cancer treatment 
In the UK, it is estimated that 1 in 2 people will be diagnosed with cancer in their lifetime.1 
Survival rates are still as low as 1% for some cancer types, but massive improvements have 
been made over the past 40 years.2 These increases in survival are largely due to advances in 
early detection and treatment, particularly targeted therapies. Traditional chemotherapeutic 
agents act by interfering with cell division and inducing cell death. They do not specifically 
target the tumour but have a greater impact on cancer cells as they divide more rapidly than 
most normal cells. Targeting of fast-dividing normal cells, such as hair follicles and cells in the 
stomach, can lead to negative side effects (e.g. hair loss and nausea). Chemotherapies are still 
widely used and have various mechanisms of action. Alkylating agents bind to and modify 
DNA, inducing damage and inhibiting division (e.g. cisplatin forms crosslinks between and 
within DNA strands3). Topoisomerase inhibitors inhibit enzymes that are involved in the 
separation of DNA strands to allow replication (e.g. topotecan binds to topoisomerase I and 
induces double-strand breaks [DSBs]4). Antimetabolites compete with, replace, or inhibit the 
function of metabolites required for DNA synthesis (e.g. fluorouracil is a an analogue of uracil 
which is incorporated into DNA/RNA and causes inhibition of a nucleotide synthetic enzyme, 
thymidylate synthase5). Unlike these chemotherapies, targeted therapies are designed to 
specifically eliminate cancer cells by targeting molecules that are required for tumour growth 
and progression.6 Targeted therapies can be broadly categorised as either small molecules or 
monoclonal antibodies.7 Small molecules can penetrate the cell membrane and act on 
intracellular targets. Monoclonal antibodies bind to tumour-specific antigens presented on the 
cell surface. These therapies have many different mechanisms of tumour cell killing, targeting 
the various hallmarks of cancer.8  
Signal transduction pathways are often hyperactivated in tumour cells and inhibitors can 
be designed to block these (e.g. Cetuximab, an EGFR inhibitor9). Hormone therapies block the 
production of hormones or interfere with their function to impede the growth of  
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hormone-dependent tumours (e.g. Trastuzumab binds to HER210). Tumour cells develop 
mechanisms to evade cell death and so drugs can be designed to induce apoptosis  
(e.g. Venetoclax, a BCL2 inhibitor11). Angiogenesis inhibitors block the growth of new blood 
vessels, which are required by tumours to gain oxygen and nutrients (e.g. Bevacizumab, a 
VEGF inhibitor12). Gene expression is often altered significantly in tumour cells, and drugs 
can be designed to target expression modulators (e.g. Vorinostat, a histone deacetylase 
inhibitor13). A major focus of current research is immunotherapy, which functions by activating 
immune-mediated killing of tumour cells (e.g. Ipilimumab, a CTLA-4 inhibitor14,15).  
Typically, targeted drugs are approved for treatment of a specific tumour type, sometimes 
with an additional indication regarding mutation status or hormone expression. However, 2018 
saw the first initial tissue-agnostic approval based on genetic mutation; Larotrectinib is 
indicated for any solid tumour carrying an NTRK gene fusion.16 
Design of these therapies requires an understanding of the genetic and molecular basis of 
tumour development. At a genetic level, cancer drivers can be broadly classified as oncogenes 
or tumour suppressor genes (TSGs). Proto-oncogenes encode proteins that function to stimulate 
cell division and differentiation, and inhibit cell death.17 Activation (i.e. gain-of-function) of 
these genes transforms them into oncogenes, which drive abnormal cell proliferation and lead 
to tumour development. Examples of oncogenes include BRAF18 and H-/N-/K-RAS.19 TSGs 
encode proteins that function to control cell growth; they inhibit progression through the cell 
cycle, repair DNA errors, and induce apoptosis.20 Inactivation (i.e. loss-of-function, LOF) of 
these genes can result in tumour development. Examples  of TSGs include TP5321 and RB1.22 
 
1.2 Targeting tumour suppressor genes 
Despite the fact that TSGs are frequently inactivated by mutation, deletion, or silencing in 
many cancers, the majority of targeted therapies are oncogene inhibitors.23 This is likely 
because it is inherently more challenging to restore the normal function of a gene than it is to 
inhibit it. However, several strategies have emerged which hold great promise for improving 
therapeutic targeting of TSG-driven cancers.  
The most conceptually simple strategy is to reintroduce a functional copy of the TSG 
using gene therapy techniques. In practise, this has proven to be challenging due to 
inefficiencies in delivery and maintenance of wildtype (WT) protein expression, in addition to 
issues with safety.24 An alternative approach is to target regulators of the inactivated TSG. One 
of the functions of the first identified tumour suppressor, RB1, is to inhibit DNA replication 
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by binding to and repressing E2F transcription factors.25 This can be reversed by 
phosphorylation of RB1 by cyclin-CDK complexes, which often occurs aberrantly in tumour 
cells.26 It has been shown that inhibition of oncogenic kinases can indirectly reactivate RB1 
and restore its repressive functions.27,28 Similarly, targeting of epigenetic modulators that 
inactivate TSGs has shown potential. Many genes are silenced in tumours due to 
hypermethylation or hypoacetylation.29,30 Inhibitors of DNA methyltransferases and histone 
deacetylases are available and can reverse this silencing. However, currently these are not 
specific and induce global changes rather than targeted reactivation of TSGs, which can also 
affect non-malignant cells.24 Another option is to move downstream and inhibit pathways that 
have been activated as a result of TSG function being lost. For example, inactivation of PTEN 
leads to hyperactivation of the PI3K/AKT/mTOR pathway and so downstream inhibition of 
this signalling cascade may reverse the effects.31 However, pathways like this are complex and 
interference would likely alter other associated networks.  
The most promising strategy to date has been exploitation of vulnerabilities induced by 
TSG inactivation, or so-called synthetic lethal interactions (SLIs). Synthetic lethality refers to 
an interaction between two genes, where cells can survive with loss of either gene but loss of 
both induces cell death.32 When a TSG is lost, tumour cells can become dependent on the 
function of a second protein for survival (Fig. 1.1).33 Pharmacological inhibition of this second 
protein would be lethal to tumour cells but, in theory, should have little impact on  
non-malignant cells as they have maintained function of the tumour suppressor. The most 
clinically advanced example of this strategy is inhibition of PARP in BRCA1/2-mutant 
cancers.34 
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Figure 1.1. Exploiting synthetic lethality for cancer treatment. Tumour cells often lose the function 
of a TSG (gene A), but loss of this gene alone does not affect viability. If a synthetic lethal partner of 
gene A is known (gene B), then pharmacological inhibition of this gene should induce death specifically 
in the tumour cells. Inhibition of gene B should not affect viability in non-malignant cells as the function 
of gene A is maintained.   
 
This concept has been expanded to incorporate similar genetic interactions. Synthetic dosage 
lethality describes the situation where overexpression or overactivation of one gene induces a 
vulnerability to loss of another gene.35,36 These interactions could be exploited in tumours that 
are driven by oncogenes, such as KRAS-mutant lung tumours, where pharmacological 
inhibition of the oncoprotein is challenging.37 Deletion of TSGs is often accompanied by loss 
of other genes that are in close proximity in the genome.38 Whilst these are considered to be 
‘passenger’ genes, as their loss usually has no clear role in tumour progression, they can confer 
specific vulnerabilities that could be targeted by drugs.38,39 This concept is referred to as 
collateral sensitivity/lethality. This was first demonstrated in glioma cells, where loss of a 
passenger gene ENO1 (commonly deleted in glioblastomas) induced a specific sensitivity to 
inhibition of ENO2.38 These vulnerabilities offer the potential to develop novel therapies for 
cancers that do not respond to standard treatment and/or are ‘undruggable’ using current 
targeted approaches. 
 
1.2.1 DNA damage response pathways 
One of the key areas of interest in developing synthetic lethal therapies is targeting the various 
DNA damage response (DDR) pathways. Cells have evolved a range of mechanisms to detect 
and repair different types of DNA damage, induced by both endogenous and environmental 
factors. Interference with these mechanisms can cause mutations and genomic aberrations that 
are associated with many human diseases, including cancer.40  
Gene A
Gene B
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Gene B
Gene A
Gene B
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Gene B
Viable Viable Viable Lethal
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Mismatch repair (MMR) is used to detect and repair mismatches and insertions/deletions 
(indels) that occur during DNA replication (as reviewed by Li, 2008).41 The presence of these 
errors is initially detected by MutS complexes (MSH2-MSH6 and MSH2-MSH3), which then 
recruit MutL complexes (MLH1-PMS2, MLH1-PMS1, MLH1-MLH3). A single strand 
incision is made and EXO1 nuclease, polymerases δ and ε, and ligase I act to repair the DNA 
error. Other protein components involved include PCNA, RFC, and RPA. 
 Base excision repair (BER) occurs when DNA glycosylases detect and remove bases 
that have been damaged by oxidation, deamination or alkylation.42 Repair is undertaken by 
APE1 endonuclease, polymerases β, δ and ε, and ligase I or III. Single-strand break repair 
(SSBR) has many overlapping features with BER, as single-strand breaks occur indirectly as a 
result of this process. However, when the break is induced directly, other factors are involved 
in SSBR. Breaks can be detected by PARP1 binding and activation. PARP1 functions by 
adding poly(ADP-ribose) chains to itself and other proteins. It recruits and stabilises the 
complex of proteins required for repair. One of the key proteins involved is XRCC1, which 
acts as a molecular scaffold to stabilise and activate various enzymes involved in SSBR.  
 Nucleotide excision repair (NER) is used to repair damage that disrupts the DNA 
helical structure.43 There are two sub-pathways: transcription-coupled NER acts on lesions that 
block transcription and global-genome NER surveys the whole genome. In transcription-
coupled NER, CSA, and CSB displace stalled RNA polymerase to allow for repair. In global-
genome NER, the XPC-hHR23B complex screens the genome for disrupted basepairing. In 
both pathways, the helicase components of transcription factor TFIIH (XPB and XPD) unwind 
~30 basepairs of DNA around the damage. RPA stabilises the intermediate, then endonucleases 
(XPG and ERCC1/XPF), DNA polymerases, and ligase I act to repair the damage. 
 Non-homologous end-joining (NHEJ) is one of the main mechanisms used to repair 
DSBs.44 The Ku protein recognises DSBs and activates the protein kinase DNA-PKcs. This 
leads to recruitment of end-processing enzymes, polymerases, and ligase IV. NHEJ can operate 
at any cell cycle phase. It is an error-prone process as repair often results in small indels, which 
can be deleterious if they cause a frameshift. 
 Homologous recombination (HR) is another mechanism used in response to DSBs and 
it is also used to repair stalled replication forks and inter-strand DNA cross-links.45 HR 
generally only occurs in S and G2 phase as the sister chromatid sequence is used as a 
homologous template for repair. In HR, proteins such as the MRE11-RAD50-NBS1 complex 
initiate ssDNA generation. BRCA1 is a key player in HR, where it is involved in 5’-end 
resection of the DSB. BRCA1 also interacts with BRCA2 and PALB2 to recruit the 
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recombinase RAD51. This is important for invasion of the undamaged homologous template. 
Polymerases, nucleases, helicases, and ligases act to repair the damage using the template 
sequence. Unlike NHEJ, HR results in a faithful repair of the DNA to its original sequence.  
 The gold standard example of synthetic lethality involves BRCA1/2 and PARP, which 
are major DDR components.46,47 When PARP is inhibited, SSBs cannot be repaired and this 
can lead to stalled replication forks and DSB induction. In normal cells, HR would be employed 
to repair these. However, cells lacking BRCA1/2 have defective HR and are therefore more 
sensitive to PARP inhibition. Signalling pathways mediated by the kinases ATM and ATR can 
also be involved in the repair of DSBs and ssDNA, respectively. Identifying synthetic lethal 
partners of genes such as these important players is a key focus in the field currently.  
 
1.3 Screening for synthetic lethal interactions 
Hartwell et al. first proposed the concept of exploiting synthetic lethality to develop cancer 
therapeutics in 1997.33 Despite two decades of research, the only clinical success has been in 
exploiting the interaction between BRCA/PARP. Four PARP inhibitors have been FDA-
approved for the treatment of BRCA-mutant cancers; three of these are indicated for ovarian 
cancer and two for breast cancer.48-52 For many TSGs, synthetic lethality has not been 
thoroughly explored. Since this concept was first introduced, a range of methods have been 
developed to screen for genetic interactions (Table 1.1). The functional genomics tools we 
currently have available make it more feasible to systematically interrogate synthetic lethality 
on a large scale. 
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Table 1.1. Advantages and disadvantages of approaches to screen for synthetic lethal interactions. 
Screening method Advantages Disadvantages 
Yeast screen Small genome allows testing of a 
large interaction space 
 
 
Easy to genetically manipulate 
Divergence of gene 
functions/interactions in 
humans 
Chemical screen Easier to translate hits to clinic Drugs often have multiple 
targets or unknown targets 
 
Limited to screening 
‘druggable’ targets 
 
Must be performed in plate 
format 
RNAi screen Possible to target every gene in the 
genome 
 
Incomplete knockdown may 
reflect drug inhibition more than 
complete knockout 
 
Does not induce DNA damage 
More off-target effects than 
CRISPR 
 
Difficult to achieve 
complete knockdown 
 
On-target activity of 
si/shRNAs may be variable 
CRISPR screen Can allow for complete knockout 
of gene function 
 
Can be used to target non-coding 
regions, allowing gene inhibition 
and activation 
Off-target effects 
 
 
On-target activity of gRNAs 
may be variable, particularly 
in amplified genomic 
regions 
 
Complete knockout may not 
reflect effects of drug 
inhibition 
 
Induces DNA damage which 
is problematic for screening 
normal cell lines 
Computational 
analysis 
Combines data from multiple 
sources (e.g. sequencing, 
expression data, experimental 
screen data) to provide more 
support to findings 
Additional experiments are 
still required for validation 
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1.3.1 Screening for synthetic lethality in yeast 
Many of the first screens for SLIs were performed in the budding yeast, Saccharomyces 
cerevisiae. Mapping of genetic interaction networks has advanced more in S. cerevisiae than 
in any other organism, due to the fact that its genome is small (12 megabases)53 and relatively 
easy to manipulate.54 The development of Synthetic Genetic Array analysis55 and similar 
methodologies (e.g. dSLAM56,57 and GIM58) has allowed for high-throughput screening of 
synthetic lethality in yeast. The basic concept is to introduce a mutation in a gene of interest 
into a set of single mutant strains (carrying mutations for ~4800 nonessential genes) that are 
each tagged with a unique DNA barcode. This can be done by mating a haploid single mutant 
pool with a different haploid strain that is mutant for the gene of interest,58 or by introducing 
the mutation of interest into a pool of diploid heterozygous mutant strains.56,57 These screens 
rely on competitive growth between the resulting double mutants. The relative abundance of 
each double mutant is analysed by a barcode microarray. If an SLI exists between a pair of 
genes, growth of the double mutant for these genes should be impaired and thus would be 
depleted in the population. One large study involved genome-wide screening in 132 mutant 
strains using SGA technology.59 Approximately 4000 interactions were identified, involving 
~1000 genes. They found that generally, genes that had a negative (synthetic lethal) interaction 
were less likely to physically interact at the protein level. Many associations were identified 
between functionally-distinct pathways. For example, members of the sister chromatid 
cohesion complex were found to be synthetic lethal with genes in spindle checkpoint pathways 
and various pathways involved in DNA repair, damage, and replication.  
 A major limitation of using yeast as a model is that not all genes are evolutionarily 
conserved, and so only a fraction of the findings can be mapped to the human genome.60 Some 
yeast genes have more than one ortholog in humans, and often the functions and interactions 
of the encoded proteins have diverged.60 This can make it difficult to accurately translate 
findings between the species. Despite this, it has been shown that some SLIs are conserved 
between yeast and humans (e.g. CHEK1/2 and WEE1; RAD17 and TOP161). Therefore, these 
screens can be informative for human studies, and the simplicity with which a very large 
interaction space can be tested makes this a valuable model system.   
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1.3.2 Screening for synthetic lethality in human cancer cell lines 
Whilst we can learn a lot from studying model organisms, human cancer cell lines offer a more 
clinically relevant experimental system to identify SLIs. Two general approaches are 
commonly used: screening a cell line panel or screening an isogenic cell line pair.62 Hits from 
screens in a large panel of cell lines can be cross-referenced with the mutational status of the 
lines (Fig. 1.2a). If a vulnerability is consistently identified in cell lines that have a mutant 
TSG, but not in lines that are WT for this gene, this indicates that an SLI may exist. Cell lines 
must be carefully selected to ensure that mutant and WT genotypes are both well-represented. 
To obtain an isogenic pair, a WT parental cell line can be engineered to carry a LOF mutation 
in a TSG, or a parental cell line that is already mutant can be engineered to express the WT 
protein (Fig. 1.2b). Screening of both the parental and derivative can be compared to identify 
vulnerabilities that occur specifically when the gene of interest is lost.  
There are advantages and disadvantages of both strategies. SLIs identified in isogenic 
pairs may be specific to that cell line, whereas screening in a diverse panel would ensure that 
hits are relevant across different backgrounds. Multiple isogenic pairs could be screened to 
remove this context-specificity. However, having an identical genetic background can be 
beneficial as we can confidently infer that any observed effect is due to an interaction between 
the two disrupted genes. In contrast, cell lines in a panel may share other genetic aberrations in 
addition to the one being studied, possibly confounding the results and making it difficult to 
deduce which genes interact. Another caveat to consider is that engineering a mutation in a cell 
line may not accurately reflect the true context in which this genetic change would occur, 
compared to lines that have acquired it naturally. Despite these differences and limitations, 
both approaches have been applied successfully to identify SLIs using various screening 
technologies. 
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Figure 1.2. Approaches to synthetic lethality screening in human cell lines. a) Cell lines can be 
grouped into those that are WT or mutant (MUT) for a gene of interest. Screening is performed to 
identify genes that are essential for cell fitness/survival in each line. The essential genes that overlap in 
all WT lines or overlap in all MUT lines are compared. Synthetic lethal candidates are those that are 
specifically essential in the MUT lines; b) An isogenic derivative of a cell line can be engineered by 
creating a single knockout (KO) in gene A (alternatively, an existing mutation could be corrected). Both 
the parental and KO lines are screened and the results are compared. The synthetic lethal candidates are 
those that are specifically essential in the KO line. 
 
1.3.3 Chemical screening to identify synthetic lethal interactions 
For some time, the only way to screen for SLIs in human cell lines was to use chemical 
compound libraries.63,64 Chemical screens have been used to identify specific vulnerabilities in 
both isogenic cell line pairs and panels of cell lines with common genetic features. For example, 
screening in an isogenic renal cancer cell line pair revealed that VHL-mutant cells were 
specifically vulnerable to a small molecule inhibitor, STF-62247.65 A high-throughput screen 
of colorectal and gastric cancer cell lines identified that loss of MRE11A and ATM are both 
synthetically lethal with FEN1 inhibition.66 The use of candidate molecules provides direct 
clinical relevance to any hits, which is beneficial compared to genetic screens where targets 
may not be druggable. However, chemical libraries can contain molecules with unknown 
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targets and those that are annotated often have multiple targets, both by design and due to off-
target activity.67,68 This can make it challenging to identify which targets are responsible for 
the observed synthetic lethality and to understand the mechanism of action. It could also mask 
potential SLIs, as targeting multiple proteins may lead to general cytotoxicity, where inhibition 
of one alone may have induced synthetic lethality.  
 
1.3.4 RNAi screening to identify synthetic lethal interactions 
The discovery of RNA interference (RNAi)69 made it feasible to study gene-gene interactions 
in human cells on a large scale70 and hence systematically screen for synthetic lethality. This 
can be done using short interfering RNAs (siRNA) or short hairpin RNAs (shRNA), both of 
which inhibit protein translation by promoting degradation of specific messenger RNAs.71 An 
arrayed format can be used with siRNA and shRNA, where each gene is targeted in a separate 
well and the desired phenotype can be measured.72 Alternatively, shRNAs can be labelled with 
barcodes, pooled, and packaged into a single viral library for transduction into cells.73 Changes 
in the relative abundance of the barcodes can be measured after a period of time and used as a 
proxy for shRNA expression.73 Depletion of a given shRNA indicates that knockdown of the 
targeted gene impaired cell fitness. This technology has been widely applied to identify SLIs, 
most notably in two large-scale studies: ProjectDRIVE74 and Project Achilles.75 
 Project DRIVE involved shRNA screening of ~8000 genes across 398 cancer cell lines. 
To overcome issues with off-target effects and limited statistical power, a median of  
20 shRNAs per gene was used. The effects of each shRNA on cell viability were assessed after 
14 days. The study investigated a range of things, including synthetic lethality. They identified 
subsets of interactions where synthetic lethality was associated with a pathway, a paralog, or 
collateral lethality. Reduced expression of a cell death inhibitor, BCL2L1, and increased 
expression of a pro-apoptotic protein, BIM, were predictive of sensitivity to knockdown of the 
anti-apoptotic protein MCL1. Synthetic lethality was also identified in members of separate 
pathways that share downstream connections e.g. cells with LOF in APC were sensitive to 
knockdown of CTNNB1. Synthetic lethal interactions between paralogous genes were also 
identified, based on both mutation and expression. ARID1A mutants were more sensitive to 
ARID1B depletion, and RPL22 mutants were more sensitive to RPL22L1 depletion. Low 
expression of ARF5 predicted a dependency on ARF4. Several cases of collateral lethality were 
identified, including a sensitivity to knockdown of PRMT5 in cells that have lost MTAP, a gene 
that is co-deleted with the tumour suppressor CDKN2A. Some of these findings overlapped 
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with results from the Project Achilles shRNA screens. For this project, 501 cancer cell lines 
were screened using a genome-wide shRNA library. Achilles identified over 80 paralog 
synthetic lethal interactions. For example, cells with low FERMT2 expression had a 
dependency on FERMT1, which has a role in integrin and cytoskeleton regulation. SMARCA2 
was identified as being essential in cancer cell lines carrying a mutation in its paralog 
SMARCA4, with both genes acting as core subunits in the SWI/SNF chromatin remodelling 
complexes. Interestingly, the analysis of the RNAi dataset from Achilles found that most 
dependencies they identified were predicted by differences in gene expression rather than DNA 
mutation. This may be because they had a limited number of cell lines representing mutation 
of any given gene. This bias towards more commonly mutated genes is a major limitation of 
screening projects like DRIVE and Achilles, as they do not offer the opportunity to identify 
SLIs with genes that are mutated less frequently in cell lines. 
 RNAi can also be combined with chemical screening to identify synthetic lethal 
partners of drug targets.76 As with drug screens, RNAi also has several limitations. Despite 
intended targeting of one gene, si/shRNA molecules can have off-target activity which may 
result in false positive results.77,78 Combining multiple molecules to target the same gene can 
reduce the likelihood of this. Additionally, as RNAi functions at a post-transcriptional level, it 
is difficult to achieve complete KO of a target and often only partial knockdown is achieved.79 
Synthetic lethal hits may be missed as a result, but it may represent the clinical context more 
accurately as complete inhibition with a drug can be challenging.80  
 
1.3.5 CRISPR/Cas9 screening to identify synthetic lethal interactions 
1.3.5.1 CRISPR/Cas9 technology 
Whilst RNAi has contributed massively to advances in screening for synthetic lethality, the 
recent development of CRISPR/Cas9 technology has offered an improved and more versatile 
approach. Clustered regularly interspaced palindromic repeats (CRISPR) were first identified 
in E.coli in 198781, but it was not until 2005 that the function of these loci started to become 
clear.82,83 CRISPR/Cas is used as an adaptive immune system by bacteria; they integrate phage 
DNA as CRISPR loci, allowing them to recognise these foreign bodies and prevent further 
infection.82-85 In the years that followed, researchers identified the components and exact 
mechanism of the CRISPR/Cas9 system.86 By 2013, CRISPR/Cas9 was adapted for genome 
editing in human and mouse cells,87,88 and has since been harnessed by scientists across many 
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fields. Advances in our understanding and application of this technology have been rapid and 
constant; it has revolutionised our approach to functional genomics. 
A variety of CRISPR/Cas systems have been identified but researchers most commonly 
use CRISPR/Cas9, the type II-A system employed by Streptococcus pyogenes.89 This has been 
simplified to a two-component system, requiring Cas9 protein and a guide RNA (gRNA) to 
cleave DNA in mammalian cells (Fig. 1.3). In the natural system, two RNA molecules (a 
CRISPR RNA [crRNA]90 and a trans-activating crRNA [tracrRNA]91) are transcribed 
separately and form a duplex that binds to Cas9. A fusion of these can be engineered to produce 
a single gRNA molecule.92 The crRNA provides a sequence homologous to the target DNA, 
and the tracrRNA interacts with Cas9. Cas9 is an endonuclease which creates blunt-end DSBs 
in the targeted DNA region.84,93 The protein recognises a protospacer-adjacent motif (PAM) 
sequence (‘NGG’) adjacent to the gRNA target, unwinds the DNA and cleaves at a position 
three basepairs upstream of the PAM.93 DSBs trigger endogenous repair mechanisms in the 
cell; the two most prominent are non-homologous end joining (NHEJ) and homology-directed 
repair (HDR) via homologous recombination.94 NHEJ is error-prone and introduces indels in 
the DNA, often leading to frameshift mutations which can cause LOF of a gene.44 HDR is less 
efficient but repairs DNA in an error-free manner; this requires a donor template with 
homology to the regions surrounding the break site.45 A donor template can be provided 
simultaneously with the Cas9 and gRNA to enable introduction of specific sequence changes 
via HDR.88  
In addition to genome editing, this technology has been adapted for many applications, 
including gene regulation.95 Mutation of the RuvC and HNH domains in Cas9 deactivates the 
nuclease function of the protein, but still allows it to be guided to a target.96 This derivative, 
called deactivated or dead Cas9 (dCas9), can be fused to transcriptional activation or repression 
domains.97 Targeting of these to gene promoters and enhancers can allow for overexpression 
(CRISPR activation, CRISPRa) or silencing (CRISPR interference, CRISPRi), respectively.97 
Researchers have also generated Cas9 variants that recognise different PAM sequences, 
increasing the targeting capacity.98,99 Other CRISPR/Cas systems have different functions and 
investigation of these is widening the applications of this technology even further.100  
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Figure 1.3. CRISPR/Cas9 genome editing in mammalian cells. Cas9 forms a complex with a gRNA 
and is guided to a specific target DNA region. The gRNA binds to a homologous 20 nucleotide DNA 
sequence positioned immediately downstream of an ‘NGG’ PAM sequence. Cas9 cleaves the DNA 
producing a DSB. The cell then activates endogenous repair pathways. Non-homologous end joining 
can result in insertions and/or deletions which disrupt the gene. Alternatively, in the presence of a donor 
template, homology-directed repair can replace or insert a specific sequence. Figure taken from 101. 
 
1.3.5.2 Pooled CRISPR/Cas9 screening 
One of the most powerful applications of CRISPR/Cas9 is genome-scale, high-throughput 
screening in mammalian cells. CRISPRa and CRISPRi technologies have been applied in 
screens (as reviewed by Kampmann, 2018),102 but design of gRNAs for these is more 
challenging as regulatory regions in the genome are not as well annotated as protein-coding 
regions. Use of the original CRISPR/Cas9 system to screen for the effects of gene knockout is 
more well-established. This can be done in an arrayed format with a single gene targeted per 
well,103 but is most commonly used in a pooled format where gRNAs targeting all genes are 
combined.  
A pooled library of gRNAs targeting all genes of interest can be designed and packaged 
into lentiviral vectors, then transduced into a single population (Fig. 1.4).104,105 Cas9 can be 
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introduced simultaneously with the gRNA library104,106,107 or cells can be engineered to stably 
express Cas9 prior to screening.105,107-111 The transduced population must then be maintained 
for a period of time to allow for proliferation and for the gRNAs to induce a phenotype. Screens 
most commonly focus on cell fitness/survival as a primary phenotype. At the endpoint, the 
abundance of each gRNA can be compared to the abundance in the initial library.104,105 If loss 
of a gene impairs cell fitness, cells carrying gRNAs that target that gene should be under-
represented in the final population and hence have a relative depletion. If loss of the targeted 
gene confers a growth advantage, a relative enrichment of these gRNAs would be observed.  
This technology has made it relatively simple to screen every protein-coding gene in 
the genome in a single experiment. Various analyses can be used to interpret CRISPR/Cas9 
screen data; these are constantly evolving and improving as more data becomes  
available112-118. Each one has a different approach, but the primary aim is generally to 
determine the gene-level significance of any observed changes in gRNA abundance. Two of 
the most widely used packages, Bayesian Analysis of Gene EssentiaLity (BAGEL)114 and 
Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout Gene (MAGeCK),116 will be 
discussed further in Chapter 3.  
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Figure 1.4. Strategy for pooled CRISPR/Cas9 screening. A viral library containing a pool of gRNAs 
is prepared. If Cas9 is not encoded by the library backbone, cells must be engineered to express Cas9. 
Cells are transduced with the pooled gRNA virus at a low multiplicity of infection (MOI). Library 
backbones often have an antibiotic resistance marker to allow for selection of transduced cells. Selection 
for the phenotype of interest is then performed; if the phenotype is cell fitness/survival, cells are simply 
maintained in culture. After a period of time, genomic DNA is extracted, then PCR amplification and 
next-generation sequencing of the integrated gRNAs is performed. Analysis is carried out to identify 
depletion or enrichment of gRNAs, and hits are validated. Figure taken from 119. 
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Whilst it has many advantages, there are challenges associated with CRISPR/Cas9 screening. 
The most prominent are related to gRNA design, in terms of both on-target and off-target 
activity. Many algorithms have been developed to design gRNAs with optimal efficacy, 
considering factors such as position-specific nucleotides and GC content (as reviewed by Cui 
et al., 2018).120 However, sequence-independent factors such as chromatin accessibility and 
epigenetic markers can affect gRNA activity, but these vary between cell lines and are more 
difficult to predict.121 Algorithms have also been designed to predict and reduce the off-target 
activity of gRNAs, with factors such as the position in the gRNA influencing tolerance to 
mismatches.120 Using multiple gRNAs (typically 5-10) to target each gene can help tackle these 
issues, but it is imperative to always consider the potential for false positives and false 
negatives. 
Despite these limitations, CRISPR/Cas9 has been applied successfully to identify SLIs 
in cancer cell lines using both isogenic122,123 and cell line panel strategies.109,124,125 By screening 
two sets of isogenic cell lines that differed by VHL status, one group identified novel SL 
partners, including members of DDR pathways, that could be targeted in clear cell renal cancers 
with inactivated VHL.123 This type of experiment is more low-throughput and targeted; this is 
beneficial as interactions with a specific gene of interest can be identified in clinically relevant 
cell lines. Large cell line panel screens by both the Broad Institute125 and WSI109 independently 
identified that the DNA helicase WRN is a synthetic lethal target in cells that have 
microsatellite instability, which is caused by a defect in DNA mismatch repair. These pan-
cancer cell line studies are limited in the same way as the RNAi projects, in that they depend 
on good representation of a mutant gene to identify potential interactions.  
As with RNAi, CRISPR/Cas9 screens can also be performed in combination with 
drugs.126 Wang et al. (2019) performed screens in cells treated with an ATR inhibitor and 
identified that RNASEH2 deficiency causes increased sensitivity both in vitro and in vivo.126 
Additionally, the recent development of paired gRNA systems has offered a novel approach 
that highlights the versatility of CRISPR/Cas9 technology. Several groups have designed 
vectors that encode two gRNAs under the control of separate promoters in a single  
construct.127-131 By pairing gRNAs targeting different genes, two genes can be perturbed 
simultaneously in a single cell. A paired gRNA library can be applied across a range of cell 
lines to study genetic interactions without the requirement for any existing or engineered 
mutations.128,129,131 However, it is necessary to select candidate synthetic lethal pairs as it is 
unfeasible to screen every possible gene combination. For example, one group performed a 
screen for interactions using a library which paired TSGs with drug targets129, and another 
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randomly paired drug targets.128 Paired library design is more complex than in single gRNA 
screens and requires many gRNA combinations plus additional controls. Analysis and 
interpretation of data from these screens is also challenging. This is a relatively new approach 
but it has already shown promise, and with further development it is likely to be an invaluable 
tool for synthetic lethal screening. 
 
1.3.6 Computational prediction of synthetic lethal interactions 
In addition to experimental approaches, in silico methods have been developed to predict SLIs. 
The majority of these have focused on applying information gained from genetic interaction 
mapping in yeast to predict synthetic lethality in humans.132-135 Validation of interactions 
predicted in this way has been demonstrated in human cell lines, for example between 
SMARCB1 and PSMA4.135 Another approach is to take advantage of large datasets such as The 
Cancer Genome Atlas (TCGA),136 which profile mutations, gene expression, and many other 
features of cancer cell lines and human tumours. Mutual exclusivity identified within these 
datasets has been used to predict SLIs.137 If LOF mutations or deletion of two genes co-occur 
less frequently than expected by chance, this may indicate that losing both genes is detrimental 
to cell fitness and confers a selective disadvantage. Whilst predictions of this kind have been 
validated138, the majority do not. Also, this approach is biased towards pairs of genes that are 
both mutated at a high frequency, which is often not the case as synthetic lethal partners may 
not be drivers themselves.62 Perhaps the most thorough strategy is to integrate several ‘omics 
and experimental datasets. Jerby-Arnon et al. developed the ‘DAISY model’ which infers SLIs 
using three methods: 1) mutual exclusivity of gene inactivation events, 2) associations between 
under-expression/low copy number of genes and essentiality of another gene (from shRNA 
screen data), 3) co-expression of genes, as synthetic lethal pairs tend to be involved in similar 
biological processes and so may have similar expression patterns.139 Known SLIs were 
recognised using this model and they validated novel predicted synthetic lethal partners of VHL 
in human cell lines. Whilst in silico predictions can be useful to identify and prioritise hits, 
experimental validation is still required to confirm any interactions.   
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1.4 PBAF/BAF complexes in cancer 
1.4.1 PBAF/BAF composition and function 
ARID1A, ARID1B, ARID2, PBRM1 and SMARCA4 are all subunits of the BRG-/BRM-
associated factor (BAF) or Polybromo-associated BAF (PBAF) chromatin remodelling 
complexes.140 These complexes use ATP to change the position of histones and other factors 
on chromatin, and hence regulate transcription.141 BAF complexes are composed of an ATPase 
(SMARCA2 or SMARCA4), a DNA-binding protein (ARID1A or ARID1B), and various other 
subunits (Fig. 1.5).140 PBAF complexes differ slightly, most notably with the presence of 
ARID2 in place of ARID1A/ARID1B, and the incorporation of PBRM1 which contains six 
bromodomains.140 Recent analysis of fitness correlations between PBAF/BAF subunits in 
RNAi and CRISPR/Cas9 screen datasets also revealed a previously uncharacterised 
configuration, referred to as non-canonical BAF (ncBAF).142,143 Biochemical investigation 
revealed that ncBAF is composed of common subunits such as SMARCD1 and SMARCA2/4, 
and specific subunits GLTSCR1/1L and BRD9 (Fig. 1.5).143,144 
 
 
 
Figure 1.5. Composition of mammalian PBAF/BAF/ncBAF complexes. Schematic showing the 
subunits present in the mammalian ncBAF, BAF and PBAF complexes. Coloured subunits represent 
those that are specific to a single complex (ncBAF = green, BAF = blue, PBAF = red). Grey subunits 
are those that are shared between multiple complexes. Figure taken from 143. 
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As epigenetic regulators, PBAF/BAF complexes have important roles in a range of biological 
processes including neural differentiation,145,146 cardiac147 and brain148 development, self-
renewal and pluripotency in embryonic stem cells,149 and metabolism.150,151 They also have 
non-transcriptional roles in DNA repair and PBAF complexes specifically have been 
associated with processes that maintain genomic stability.152 The function of these complexes 
varies depending on the subunit composition, and inactivation of individual subunits can lead 
to the development of different cancer types.152 The reason for this variation is not clear, but 
some subunits are mutated more frequently than others. It is estimated that collectively, the 
genes encoding PBAF/BAF subunits are mutated in ~20% of human tumours, making them 
one of the most commonly mutated complexes in cancer.153,154 
 
1.4.2 BAF-specific subunits: ARID1A and ARID1B 
ARID1A (also known as BAF250a) is the most commonly mutated BAF gene.152,153 It encodes 
a protein that contains an ARID DNA-binding domain155 and an uncharacterised domain, 
which may have ubiquitin ligase activity.156 Inactivating mutations in ARID1A are found in 
many different cancer types. Approximately 50% of ovarian clear cell carcinomas (OCCC) and 
endometriosis-associated ovarian carcinomas harbour LOF mutations in ARID1A.157,158 It is 
also frequently mutated in uterine endometrial carcinoma (34%),159 stomach cancer (34%)160 
and bladder cancer (29%),161 amongst others. Although missense mutations do occur, 
mutations are generally truncating (nonsense or frameshift).152 No apparent ‘hotspot’ has been 
identified, with mutations spread throughout the gene.    
  ARID1B (or BAF250b) is very similar to ARID1A, with ~60% sequence homology and 
it also encodes a DNA-binding subunit.162 ARID1A and ARID1B are mutually exclusive; only 
one of these subunits is present in a single BAF complex, but a mixture of complexes 
containing either of them can exist.162 However, mutations in ARID1B are much less 
frequent.152 This may be due to variation in the expression or function of these subunits across 
different cell types; opposing roles for these subunits have been shown.163  
 
1.4.3 PBAF-specific subunits: PBRM1 and ARID2 
PBRM1 (or BAF180) is a protein containing six bromodomains and is specific to the PBAF 
complex. PBRM1 is the second most commonly mutated gene in renal clear cell carcinoma, 
with mutation or loss occurring in ~41% of cases.164 It is primarily inactivated by truncating 
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mutations or deletion. The exact role that PBRM1 plays in the PBAF complex is unclear, but 
it has been shown to be important for genomic stability, with roles in sister chromatid 
cohesion165 and re-priming stalled replication forks.166  
Another PBAF-specific subunit is encoded by ARID2 (or BAF200). Although not a 
homolog of ARID1A/1B, it also has an ARID DNA-binding domain and these subunits are 
mutually exclusive.152 ARID2 mutations occur in a range of cancer types including 
melanoma,167-169 non-small-cell lung cancer170 and hepatitis-associated hepatocellular 
carcinoma.171 ARID2 mutations are rarely found in renal clear cell carcinoma, suggesting that 
the functional importance of these PBAF-specific subunits varies with cell type.152,153 
 
1.4.4 Targeting PBAF/BAF-mutant cancers 
Considering the frequency and range of PBAF/BAF mutations, there is huge interest in finding 
new therapeutic approaches for cancers driven by these complexes. Malignancy is generally 
associated with inactivation of the subunits and so targeting these deficiencies is challenging. 
The main focus of ongoing research is to identify tumour cell vulnerabilities that are induced 
when PBAF/BAF complexes are impaired. The majority of studies thus far have centred around 
ARID1A, but dependencies induced by loss of other subunits have been identified (Table 1.2). 
 
1.4.4.1 Dependencies associated with ARID1A mutation 
Using shRNA data from the large-scale Project Achilles screens, ARID1B was identified as an 
essential gene required for growth specifically in ARID1A-mutant cancer cell lines.172 This 
dependency was more pronounced when considering only lines with inactivating mutations in 
ARID1A, excluding missense mutations. In that study, the interaction was validated 
experimentally, with ARID1B knockdown causing impaired proliferation and colony formation 
in ARID1A-mutant OCCC cell lines but not in WT lines. Various other studies have supported 
this SLI, and this will be discussed further in Chapter 4.  
A recent study found that ARID1A plays a role in the metabolism of glutathione (GSH) 
by enhancing transcription of SLC7A11.173 This gene encodes a cystine transporter and low 
expression in ARID1A-deficient cells is associated with low basal GSH levels. Depletion of 
GSH causes increased reactive oxygen species which can induce apoptosis. Cells lacking 
ARID1A were shown to be specifically vulnerable to inhibition of the GSH metabolic 
pathway.173 In that study, researchers focused on using buthionine sulfoximine, an inhibitor 
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against GCLC which is a rate-limiting enzyme in GSH synthesis. GCLC depletion specifically 
impaired the growth of ARID1A-mutant ovarian cancer cell lines both in vitro and in vivo.  
High-throughput drug screening in OCCC lines revealed that ARID1A mutation is 
associated with increased sensitivity to dasatinib, a kinase inhibitor174. Depletion of ARID1A 
in OCCC, breast and colorectal cancer cell lines confirmed this increased sensitivity. Further 
investigation with siRNAs suggested that this may be due to an SLI with YES1, one of the 
dasatinib targets174. Dasatinib treatment increased G1-S cell cycle arrest and caspase activity 
in ARID1A-deficient cells. Sensitivity to the drug appeared to be dependent on p21 and RB1 
activity. A preliminary experiment with an OCCC tumour xenograft indicated that dasatinib 
impaired growth of ARID1A-mutant tumours in vivo.  
Various studies have associated ARID1A with the PI3K/AKT/mTOR pathway. 
Significant enrichment of activating mutations in PIK3CA and loss of PTEN have been 
observed in ARID1A-mutant endometrial cancer and OCCC.175 Project Achilles identified 
PIK3CA depletion as the second strongest hit for synthetic lethality with ARID1A mutation.75 
Additionally, an mTORC1/2 inhibitor that targets downstream signalling of PI3K/AKT was 
significantly more effective in ARID1A-mutant lines compared to WT.176 PI3K and mTOR 
inhibitors were also screened in a large panel of OCCC cell lines and xenograft models.177 In 
contrast to previous findings, the mutational status of ARID1A was not sufficient to 
discriminate the sensitivities of the cell lines. These conflicting data suggest that targeting of 
the PI3K/AKT/mTOR pathway may not be broadly applicable as a synthetic lethal approach 
in ARID1A-mutant tumours and further investigation is required.  
It was recently shown that ARID1A has a role in homologous recombination via an 
interaction with ATR, a regulator of the DNA damage response.178 ARID1A-deficient cells 
have impaired checkpoint signalling and reduced repair of DNA DSBs. PARP inhibitors are 
known to be lethal in cancer cells that are deficient in DSB repair pathways.46,47 Using an 
isogenic system, it was found that breast, colorectal and ovarian cancer cell lines have increased 
sensitivity to PARP inhibitors when ARID1A is depleted.178 Treatment with a PARP inhibitor 
also specifically suppressed growth of ARID1A-mutant breast and colorectal xenografts in vivo. 
Another study identified increased sensitivity to ATR inhibitors in ARID1A-mutant cancer cell 
lines both in vitro and in vivo.179 Loss of ARID1A function was associated with reduced 
progression through the cell cycle and defects in recruitment of TOP2A to chromatin. 
Inhibition of ATR would affect the repair of DNA damage associated with these defects, 
leading to apoptosis and hence could explain the increased sensitivity to ATR inhibitors. 
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Together, these findings suggest that exploitation of a DSB repair deficiency could be an 
effective strategy to target ARID1A-mutant cancers.  
Using 3D OCCC models, it was shown that ARID1A-mutant cells are more sensitive to 
EZH2 inhibition, with increased induction of apoptosis.180 A similar effect was also observed 
using tumour xenografts. PIK3IP1 is a negative regulator of the PI3K/AKT/mTOR pathway 
and is down-regulated when ARID1A is lost. Subsequent silencing of PIK3IP1 by EZH2-
mediated methylation activates this pathway and increases proliferation. Use of an EZH2 
inhibitor resulted in increased expression of this regulator, reduced proliferation and increased 
apoptosis.180 This would suggest that ARID1A-deficient cells are dependent on PIK3IP1 
inactivation. Further experiments were performed to investigate synthetic lethality with EZH2 
in other tumour cell types.181 Lung, adrenal gland and renal carcinoma cell lines carrying 
mutations in ARID1A, PBRM1 and SMARCA4 were found to be vulnerable to EZH2 inhibition. 
This dependency appeared to be specifically associated with destabilisation of the PRC2 
complex when EZH2 was disrupted. Further to this, repression of SMARCA2 has been shown 
to be a potential biomarker for the efficacy of EZH2 inhibition in SMARCA4 and ARID1A 
mutants.182 These studies suggest that dependency on EZH2 occurs more generally across 
PBAF/BAF-mutant cancers, not just ARID1A mutants.  
Studies have also identified synthetic lethality between ARID1A and other epigenetic 
regulators. One group found that depletion or inhibition of HDAC2 caused re-expression of 
PI3KIP1 in ARID1A-mutant cells, with reduced proliferation and increased apoptosis.183 
HDAC2 is a binding partner of EZH2-containing PRC2 complexes184 and this interaction is 
dependent on ARID1A.183 ARID1A has also been identified as a transcriptional repressor of 
HDAC6.185 HDAC6 represses p53, and inactivation of ARID1A leads to up-regulation of 
HDAC6 and a reduction in p53-mediated apoptosis. ARID1A-mutant OCCC cell lines and 
xenografts are specifically susceptible to pharmacological inhibition of HDAC6.  
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Table 1.2. Candidate synthetic lethal targets in PBAF/BAF-mutant cancers. 
Tumour status Vulnerability Reference 
ARID1A-deficient 
EZH2 inhibition 180-182 
GSH/GCLC inhibition 173 
ARID1B depletion 172 
YES1 inhibition/Dasatinib 174 
PI3K/AKT/mTOR inhibition 75,175,176,177 
PARP inhibition 178 
ATR inhibition 179 
HDAC2 inhibition 183 
HDAC6 inhibition 185 
PBRM1-deficient 
EZH2 inhibition 181 
TIP60 deficiency 186 
SMARCA4-deficient 
CDK4/6 inhibition 187,188 
MAX deficiency 189 
OXPHOS inhibition 190 
SMARCA2 deficiency 191,192 
EZH2 inhibition 181,182 
SMARCB1-deficient 
SMARCA4 deficiency 193 
BRD9 inhibition 143 
ATR inhibition 194 
EZH2 inhibition 181,195-197 
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1.4.4.2 Dependencies associated with loss of other PBAF/BAF genes  
In addition to EZH2 inhibition, various vulnerabilities have been associated with mutations in 
other PBAF/BAF subunits (Table 1.2). SMARCA4-deficient tumours are specifically 
vulnerable to inhibition of CDK4/6 in subtypes of ovarian and lung cancer,187,188 and to 
inhibition of oxidative phosphorylation in lung cancer.190 A recent study identified a synthetic 
lethal interaction between SMARCA4 and MAX, with mutually exclusive mutations present in 
small cell lung cancer.189 MAX-deficient cells were shown to be specifically vulnerable to 
SMARCA4 depletion; it would be interesting to investigate whether MAX is a targetable 
vulnerability in SMARCA4-mutant lung cancers.  
Using an RNAi screen based on a competitive growth assay, TIP60 was implicated as 
a potential synthetic lethal partner of PBRM1.186 Treatment with a TIP60 siRNA caused a 
greater loss of cells expressing an shRNA targeting PBRM1 compared to those expressing a 
control shRNA. TIP60 is a histone acetyltransferase which has a role in response to DNA 
double strand breaks.198 Inhibition of both genes lead to increased micronuclei formation, a 
feature often associated with DNA damage199, which could explain why the double knockdown 
population was depleted. 
Synovial sarcoma and malignant rhabdoid tumour (MRT) cell lines show selective 
sensitivity to suppression of the ncBAF subunit, BRD9.143 In most synovial sarcomas, a 
reciprocal translocation results in an oncogenic fusion between SS18 and one of SSX1/2/4.200 
SS18-SSX1 fusion proteins disrupt BAF complexes by displacing WT SS18 and also another 
subunit, SMARCB1.201 As a result, SMARCB1 is degraded. Homozygous loss of SMARCB1 
is a common feature of MRT.202-204 Researchers found no dependencies associated with any 
other BAF or PBAF subunits, suggesting that the vulnerability in these BAF-perturbed cancers 
is specific to ncBAF disruption.143 This could have clinical potential as inhibitors of BRD9 
have recently been developed.205,206 Expression of SS18-SSX fusion proteins, leading to 
depletion of SMARCB1, has also been shown to induce sensitivity to ATR inhibitors in cell 
lines.194  
Similar to the ARID1A/ARID1B interaction, dependencies between other PBAF/BAF 
subunits have been identified. Various studies have highlighted an SLI between two other 
mutually exclusive components, SMARCA4 and SMARCA2. This was initially shown in non-
small-cell lung carcinoma, where SMARCA2 depletion suppressed growth of SMARCA4-
deficient cell lines in vitro and tumour xenografts in vivo.191,192 Sensitivity to BRM-targeting 
shRNAs was also observed in SMARCA4-mutant ovarian and liver cancer cell lines, suggesting 
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it was not specific to the lung.192 Another study found that tumour cells deficient in SMARCB1 
were dependent on the function of SMARCA4.193 Inactivation of Smarca4 also caused a 
marked reduction in tumour formation in mice that were already mutant for Smarcb1. 
Researchers proposed that tumourigenesis in SMARCB1 mutant cells was not driven by the 
loss of PBAF/BAF function, but rather by an oncogenic effect of residual complexes containing 
SMARCA4.193  
 
1.4.5 Clinical potential of vulnerabilities in PBAF/BAF-mutant cancers 
Many of the SLIs discussed here were identified in a small number of cell lines, often only in 
one tumour type. Further investigation is required to determine how robust and widely 
applicable these are, however some of them do have clinical potential. Several EZH2 inhibitors 
are in clinical trials and could be tested in a range of PBAF/BAF-mutant cancers.207 
Alternatively, the broad HDAC inhibitor Vorinostat could be used for HDAC2 inhibition.13 A 
HDAC6-specific inhibitor, ACY1215, has been tested in multiple myeloma208 and may be 
effective in ARID1A-mutant OCCC patients. Dasatinib and other compounds that target YES1 
are being investigated for several cancer types.209 There are also many clinically advanced 
inhibitors against ATR, PARP and the PI3K/AKT/mTOR pathway which could be re-purposed 
to target PBAF/BAF-deficient tumours.209  
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1.5 Induced pluripotent stem cells as a model 
Induced pluripotent stem cells (iPS cells or iPSCs) are adult cells that have been genetically 
reprogrammed to a state similar to embryonic stem cells.210 They have the potential to 
differentiate into cells belonging to all three germ layers (endoderm, mesoderm, ectoderm). 
Yamanaka et al. were the first to engineer iPSCs by exogenously expressing four genes in 
mouse skin cells: Oct3/4, Sox2, c-Myc and Klf4.210 Soon after this, iPSCs were derived from 
human cells and one group demonstrated that OCT4, SOX2, NANOG and LIN28 were also 
sufficient for reprogramming.211,212 This discovery brought new hope for regenerative 
medicine which has unfortunately yet to be realised. In 2014, the first human trial began using 
cells derived from iPSCs to treat macular degeneration. However, this trial stopped after only 
one participant was treated because two genetic changes were identified in the cells and their 
potential effects were unclear. In the last few years several small-scale trials have been initiated 
to use iPS-derived cells in patients with Parkinson’s disease, spinal cord injury and heart 
disease.213-215 Although progress in the therapeutic field has been slower than expected, iPSCs 
have become an invaluable research tool with many applications. 
 
1.5.1 Genome editing of induced pluripotent stem cells 
Zinc-finger nucleases216 and transcription activator-like effector nucleases217 have been used 
successfully for targeted genome editing in iPSCs, but CRISPR/Cas9 has become the dominant 
technology due to its relative simplicity and versatility. Various strategies for delivering Cas9 
and gRNA to iPSCs for genome editing have been implemented.218 The potential for off-target 
activity is still a concern when using CRISPR/Cas9, but various studies have reported low off-
target effects in human iPSCs.219-227 These studies used both targeted and whole genome 
sequencing approaches to identify differences such as single nucleotide variants and small 
indels in edited iPSCs that were not present in the parental cells. 
CRISPR/Cas9 technology has been used in iPSCs to study the molecular and cellular 
pathological mechanisms of many diseases with a genetic basis.228 Diseases can be modelled 
by knocking out a gene: KO of DNMT3B in iPSCs results in hypomethylation similar to that 
observed in patients with a rare autosomal recessive disorder caused by mutations in 
DNMT3B.229 Disease-associated mutations can also be corrected using HDR in patient-derived 
iPSCs: correction of CYBB mutations in cells from patients with chronic granulomatous disease 
resulted in restoration of ROS activity in iPS-derived monocytes.230 Engineering isogenic 
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derivatives can allow for comparison of WT and mutant iPSCs (or iPS-derived cells) to identify 
genes responsible for disease phenotypes and/or to elucidate disease mechanisms. For example, 
an isogenic line was generated by correcting a SOD1 mutation in iPSCs derived from an 
amyotrophic lateral sclerosis patient. RNA-seq analysis of mutant and WT motor neurons 
revealed both up-regulated and down-regulated genes associated with this mutation.231 
 
1.5.2 Screening induced pluripotent stem cells 
The ability to accurately model disease phenotypes using iPSCs has made them an ideal tool 
for both target-based and phenotypic chemical screening. Over one thousand compounds have 
been screened in iPSC models for various diseases, including candidates that have progressed 
to clinical trials (as reviewed by Shi et al., 2017).232 However, large-scale genetic screening 
has been limited in comparison, with focus primarily on targeted approaches. There have been 
various reports that gene targeting in iPSCs/ESCs is much less efficient than in transformed 
cell lines, which may explain the lack of published high-throughput screens.88,233-235   
Several groups have performed genome-scale RNAi screening236,237 and CRISPR/Cas9 
screening238-240 in human embryonic stem cells (hESCs), but no iPSC screens have been 
published. One shRNA screen identified regulators of self-renewal and pluripotency in hESCs, 
with further validation and functional assays confirming the role of a transcription factor, 
PRDM14.126 Another study carried out differentiation after transduction of hESCs with an 
shRNA library to identify genes required for neural lineage development.125  
Three CRISPR/Cas9 KO screening studies have been performed with the aim of 
identifying genes essential for pluripotent stem cell fitness.238-240 Two of these investigated the 
same hESC line and another used a haploid hESC line. Additionally, one of these studies 
performed screening to identify regulators of pluripotency and to identify genes that suppressed 
dissociation-induced death.238 Although hits from these screens were successfully validated, 
several issues arose in the stem cell screens which had not been described previously in cancer 
cell line screens. A study published prior to these demonstrated that stem cells are highly 
sensitive to DSB-induction mediated by Cas9.241 This correlated with the findings in the 
genome-wide screens, and may further explain the relative lack of literature regarding 
CRISPR/Cas9 screening in iPSCs.  
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1.6 Summary 
The development of targeted therapies has been instrumental in improving cancer survival, but 
this area is dominated by oncogenic inhibitors. Therapies to target cancers driven by 
inactivation of TSGs are relatively scarce. Exploiting vulnerabilities associated with the loss 
of these genes is proving to be a promising therapeutic approach. The development of 
CRISPR/Cas9 technology has revolutionised our ability to screen for genetic interactions on 
an unprecedented scale, and has already improved our understanding of cancer dependencies. 
Many of the large studies thus far have focused on identifying SLIs by associating genetic 
dependencies with mutation/expression in panels of cancer cell lines.  
Isogenic models may offer a more reliable system to identify dependencies, but few 
TSGs have been systematically studied using this approach. Indeed, the ‘gold standard’ SLI 
between BRCA and PARP was first identified in an isogenic model.47 Interestingly, this finding 
was in mouse ESCs rather than in a cancer cell line. Human iPS cells have proved to be a very 
useful tool for disease modelling; a normal genetic background allows for interrogation of 
genetic interactions in the absence of many other aberrations. Considering the lack of robust 
SLIs identified to date, a new approach using a model like iPSCs may address the issues caused 
by the genetic complexities of cancer cell lines. 
The overarching aim of this project is to identify novel synthetic lethal partners of 
known TSGs. To do so, CRISPR/Cas9 screens will be performed in a panel of isogenic human 
iPSCs carrying inactivating mutations in a range of TSGs. Particular focus will be placed on 
PBAF/BAF complex subunits, as therapies targeting these genes are lacking despite the fact 
that they are collectively mutated in ~20% of cancers. Ultimately, we hope to gain a broader 
understanding of the vulnerabilities associated with TSG loss and to highlight novel targets for 
cancers with an unmet clinical need. 
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Chapter 2 
2 CRISPR/Cas9 screening of isogenic iPSCs 
 
2.1 Introduction 
The strategy of exploiting synthetic lethality to selectively kill cancer cells was first suggested 
over 20 years ago,33 yet few interactions have been well established. This may be in part 
because a comprehensive interrogation of SLIs has not been carried out for many genes. The 
development of CRISPR/Cas9 technology has made it possible to screen for interactions on a 
genome-wide scale.104,105 We chose to screen a panel of candidate TSGs using an isogenic 
system i.e. comparing a parental line with a derivative that has a single gene knockout.  As 
cancer cell lines often have many genetic aberrations, we decided to perform these experiments 
using a human iPSC line. Our rationale was that this clean background would reduce the 
confounding factors that may affect an interaction between two genes. This chapter describes 
the establishment of an isogenic iPSC line panel, construction of a genome-wide library and 
the various steps taken to perform CRISPR/Cas9 screening in these cells. 
 
2.1.1 Aims of this chapter 
• To engineer isogenic iPSC lines and confirm gene knockout. 
• To design and construct a gRNA library backbone with a neomycin selectable marker. 
• To generate stable Cas9-expressing iPSC lines. 
• To optimise a CRISPR/Cas9 screening protocol in iPSCs. 
• To understand how the screening process affects iPSCs. 
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2.2 Selection of genes for an isogenic cell line panel 
For our findings to be therapeutically relevant, we decided to screen for synthetic lethal 
partners of TSGs that are already known to be lost in primary tumours. A recent analysis was 
performed on genomic sequences from 7651 tumours, covering 28 tumour types, to identify 
driver genes characterised by LOF mutations.242 This study identified 53 genes that had a 
significant enrichment of nonsense mutations (Fig. 2.1); these included known drivers and 
novel candidate TSGs, likely missed previously due to their low mutation frequency. We 
screened 15 genes from this panel to identify synthetic lethal interactions (dark blue in  
Fig. 2.1). Specific focus was placed on ARID1A, ARID1B, ARID2 and PBRM1 as these are all 
subunits of the PBAF/BAF complexes.140 
 
 
Figure 2.1. Candidate tumour suppressor genes. Wong et al. performed analysis on 7,651 genome 
sequences (352 whole genomes, 7,299 exomes) across 28 tumour types.242 The genes shown had a high 
ratio of observed to expected nonsense mutations (Benjamini-Hochberg’s false discovery rate adjusted 
p-value, q < 0.01). Isogenic knockout lines were engineered for 28 genes (blue) with two independent 
clones for each (BAP1 and ACVR1B had only one clone). Of these, 15 genes were screened (darker 
blue) and 4 genes belonging to the PBAF/BAF complex were prioritised for further study (*). Figure 
adapted from Wong et al. (2014).242 
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2.3 Engineering isogenic iPSC lines 
The Gene Editing facility at the Wellcome Sanger Institute (WSI) produced all of the KO iPSC 
lines described in this thesis, using a human iPSC line called ‘BOB’ (experimental details in 
Section 7.3). BOB was derived from fibroblasts donated by a 65-year old male with an 
autosomal recessive disorder, α1-antitrypsin deficiency.243 This results from a mutation in the 
A1AT gene, which leads to accumulation of the protein in hepatocytes and can cause liver 
damage.244 The BOB cells originally carried a single point mutation in A1AT but this was 
corrected to wildtype by Yusa et al. (2011) before the line was used in this project.245 The 
iPSCs were reprogrammed using an integration-free method with Sendaiviral vectors that 
expressed the pluripotency markers OCT4, SOX2, KLF4 and MYC.245  
 Two gRNAs targeting an early exonic region were designed for each gene. A template 
was designed for each target, with 5' and 3' homology arms flanking a puromycin-resistance 
cassette (Fig. 2.2). In the presence of Cas9, the gRNAs induce DSBs and the puromycin-
resistance cassette can be inserted via HDR. As HDR occurs at a low frequency, it was expected 
that most edited cells would contain only one allele carrying the cassette and the other allele 
would be repaired by NHEJ. NHEJ often results in frameshift indels and, in combination with 
insertion of the puromycin cassette on the other allele, this would induce a homozygous KO of 
the targeted gene. Cells were transfected with both gRNAs, Cas9 and the homology template. 
Puromycin was then used to select for successfully edited clones. PCR and Sanger sequencing 
were performed to identify single-cell clones containing a frameshift indel. Two homozygous 
KO clones were expanded for each gene and transferred to our lab, where all lines were 
maintained in puromycin. We maintained two KO clones for each gene to allow us to cross-
validate any observed effects and ensure that they were not specific to one clone. The knockout 
genotypes were confirmed by Sanger sequencing at various stages of culture (Fig. 2.3, Table 
2.1, Section 7.4).  
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Figure 2.2. Engineering isogenic KO iPSCs. Schematic showing the strategy used to engineer 
isogenic KO iPSCs. A template containing a puromycin resistance cassette flanked by 5’ and 3’ 
homology arms, two gRNAs targeting an exon, and Cas9 were transfected into BOB cells. Edited clones 
had the puromycin cassette in one allele (inserted via HDR), and a frameshift indel in the other allele 
(caused by NHEJ). 
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Figure 2.3. Sequencing of PBAF/BAF mutations in KO iPSCs. PCR and Sanger sequencing were 
performed to confirm the frameshift deletions (shown in red) in ARID1A, ARID1B, PBRM1 and ARID2. 
The WT sequence in the parental was also sequenced for comparison. Traces are shown for one clonal 
line per gene. All KO lines were sequenced in the same way. Primers used for genotyping are detailed 
in Appendix A.1. 
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Table 2.1. Genotypes of screened KO iPSC lines. 
Cell line Mutation Variant genomic position 
APC_F10 8 bp insertion 5:112767214-112767236 
ARID1A_B08 53 bp deletion 1:26760883-26760905 
ARID1A_C09 52 bp deletion 1:26760883-26760905 
ARID1B_C03 53 bp deletion 6:157084690-157084712 
ARID1B_G01 52 bp deletion 6:157084690-157084712 
ARID2_A11 1 bp insertion 12:45811458-45811480 
ARID2_C11 1 bp deletion 12:45811458-45811480 
ATM_A12 1 bp insertion 11:108244867-108244889 
ATM_B11 5 bp deletion 11:108244867-108244889 
B2M_B08 50 bp deletion 15:44715481-44715503 
CUX1_H10 22 bp deletion 7:102104394-102104416 
FAT1_A12 53 bp deletion 4:186636051-186636073 
FBXW7_C01 53 bp deletion 4:152346958-152346980 
MAP2K4_B01 2 bp deletion 17:12110414-12110436 
PBRM1_F08 55 bp deletion 3:52668572-52668594 
PBRM1_F09 52 bp deletion + 1 bp sub 3:52668572-52668594 
PIK3R1_B08 7 bp deletion 5:68293402-68293424 
RASA1_H02 56 bp deletion 5:87349327-87349349 
RB1_C04 8 bp deletion 13:48362829-48362851 
TP53_C05 86 bp deletion 17:7675126-7675148 
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Liquid chromatography-mass spectrometry (LC-MS) was performed on the parental BOB line 
and the KO derivatives chosen for screening (Fig. 2.4, Appendix A.2, Section 7.6). This was 
primarily to confirm loss of the targeted proteins, but could be a useful dataset to understand 
the global effect of knocking out these genes. Clara Alsinet (a postdoctoral fellow in the 
Adams’ lab) prepared the cells for these experiments, and they were processed and analysed 
by Jyoti Choudhary and Theodoros Roumeliotis (previously in the Proteomics Facility at WSI).  
 
 
Figure 2.4. Proteomics of knockout iPSC lines. Log2 (fold-change) of protein abundance in KO lines 
relative to the parental BOB line, as measured by LC-MS. The parental was always analysed in the 
same run as the KO line that it was compared to. (-) indicates that a protein was not detected. FBXW7 
is not shown as the protein was not detected in any run. Values are provided in Appendix A.2.  
 
Western blotting was also performed on the ARID1A, ARID1B, and ARID2 KO lines for 
additional confirmation of protein loss (Fig. 2.5, Section 7.5). We do not have data available 
for the PBRM1 knockout lines due to antibody issues. The quality of these blots was low and 
they should ideally be repeated. However, loss of ARID1A, ARID2 and ARID1B in their 
respective knockout clones was observed in comparison to the parental BOB line. 
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Figure 2.5. Western blotting of ARID1A, ARID2 and ARID1B in iPSCs. Protein lysates were 
extracted from parental BOB cells and both knockout clones for ARID1A, ARID1B and ARID2. Western 
blotting was performed to measure expression of ARID1A (a), ARID2 (b) and ARID1B (c) proteins. 
In each case, expression was measured in the parental BOB lysate for comparison. β-actin (42 kDa) 
was used as a loading control. The ARID1A antibody datasheet predicted the molecular weight within 
the range of 165-320 kDa. ARID1B has a predicted molecular weight of 236 kDa. The ARID2 antibody 
datasheet stated that the observed molecular weight should be 217 kDa. 
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2.4 Construction of a novel gRNA backbone 
There are several human genome-wide gRNA libraries available for CRISPR/Cas9 KO 
screens; we opted to use Kosuke Yusa's library (referred to hereafter as Yusa v1.1) as it has 
been widely used at WSI. Therefore, colleagues had experimental/analytical expertise using 
this library and pipelines were in place for sample processing.109 This library contains 101,090 
gRNAs targeting 18,009 genes, with 1004 non-targeting control (NTC) gRNAs that do not 
match any sequence in the human genome.109 In this vector, gRNAs and a tracrRNA scaffold 
are under the control of a U6 promoter, and a PGK promoter drives a mammalian puromycin-
resistance cassette and BFP, separated by a T2A element (Fig. 2.6a).110 Puromycin can be used 
to select for cells that have been successfully transduced with the library. BFP can also be used 
to select for transduced cells via fluorescence-activated cell sorting (FACS), or it can act as a 
marker of transduction efficiency and puromycin selection.  
As discussed previously, the strategy used to engineer isogenic KO iPSC lines involved 
insertion of a puromycin cassette (Fig. 2.2). Therefore, it was not possible to utilise the 
puromycin selectable marker in the Yusa v1.1 library as our KO lines were already resistant. 
The other commercially available genome-wide libraries (Brunello246, GeCKO107, Toronto247) 
also have a puromycin selectable marker. We trialled sorting BOB cells based on BFP 
expression but changes in cell morphology during the process made it difficult to sort 
efficiently, and so large cell numbers would have been required to maintain good coverage.  
 
2.4.1 Swapping puromycin resistance for neomycin resistance 
We therefore decided to alter the Yusa v1.1 backbone to replace the puromycin resistance with 
a neomycin resistance gene, which allows mammalian cells to survive in an antibiotic known 
as G418.248 All oligonucleotides and primers used during construction of the backbone are 
detailed in Appendix A.1. Experimental details for all steps described here are provided in 
Section 7.7. The backbone was digested with Kpn2I (Fig. 2.6b) to prepare for insertion of a 
901 bp fragment containing the neo gene (fragment A); an additional 120 bp fragment 
(fragment B) was used to provide an overlap with the first Kpn2I restriction site (Fig. 2.6c). 
Gibson Assembly was performed, transformed into E. coli and bacterial colonies were screened 
by Sanger sequencing using primers tiled along the cloning region (results not shown). A single 
successfully edited clone containing neo was taken forward (Fig. 2.6d). 
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Figure 2.6. Cloning of a neomycin-resistant library backbone. a) Schematic showing key features 
of the Yusa v1.1 library backbone, b) agarose gel image showing Kpn2I digestion of the Yusa v1.1 
backbone (marker sizes indicated on left), c) illustration of the oligonucleotides designed for Gibson 
Assembly to insert neo (vector overlaps shown in pink), d) schematic of the resulting neoR backbone. 
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To confirm that the neomycin resistance and BFP were functional in the new backbone 
(referred to hereafter as neoR), the plasmid was packaged into a lentivirus. BOB-Cas9 cells 
were transduced and BFP was measured by flow cytometry after 48 hours. Cells were then 
seeded in 6-well and 12-well plates; one well contained untransduced BOB-Cas9 cells, and all 
other wells contained transduced cells with 0, 0.1, 0.3, 0.6 or 1 mg/ml of G418. After five days 
in culture with G418, cells in the 12-well plate were fixed and BFP was measured by flow 
cytometry. Transduced cells did not survive G418 selection so no data was obtained for these 
conditions. The transduced cells cultured without drug did survive and BFP was stable during 
this period, suggesting that the backbone itself was not inducing lethality (Fig. 2.7a). Cells in 
the 6-well plate were fixed after five days in G418 and staining with crystal violet confirmed 
that there was no survival in the drug (Fig. 2.7b). We concluded that the neomycin resistance 
gene was not functional. 
 
 
Figure 2.7. Testing neoR backbone resistance to G418. a) Flow cytometry plots showing BFP 
expression (450_50 (405)-A) in BOB-Cas9 cells at 2- and 14-days post-transduction with the neoR 
backbone, b) clonogenic assay showing BOB-Cas9 cells stained with crystal violet on day 14 post-
transduction with the neoR backbone. Cells were selected with various doses of G418 from day 9-14. 
Untransduced cells were used as a control to show that transduction itself was not toxic. 
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2.4.2 Alteration of neomycin-resistant library backbone 
We reasoned that there may be an issue with the T2A element that separated the neo and BFP 
coding regions; we were unable to find any commercially available plasmids that contained 
neo followed by a T2A. Coding regions separated by a T2A are transcribed as a single mRNA 
and translated as one protein, then cleaved at the T2A site, leaving a small additional sequence 
on the upstream protein.249 It is possible that the additional sequence left by the T2A interfered 
with the function or folding of the neomycin resistance protein. A colleague at WSI, Luca 
Crepaldi, had successfully achieved G418 resistance using an IRES element downstream of 
the neo gene. Like the T2A, an IRES is used to separate two coding regions; it introduces a 
new translation site and the two proteins are translated separately.250,251 We decided to replace 
the T2A with an IRES to test whether this would provide resistance using our backbone. 
In the original vector, gRNAs were cloned into a region downstream of the U6 promoter 
after linearisation with BbsI.110 The IRES sequence also had BbsI restriction sites; it was 
unclear whether altering this sequence would have a detrimental effect on IRES function so an 
alternative gRNA cloning strategy was planned instead. An insert was designed to replace the 
gRNA cloning region between the U6 promoter and tracrRNA scaffold with a sequence 
containing an AjuI recognition site. AjuI works in a similar way to BbsI and as the surrounding 
sequence would be unaltered, an established PCR protocol (provided by Kosuke Yusa) could 
still be used to amplify gRNAs from the original library for the transfer. The neoR backbone 
(Fig. 2.6d) was digested with BbsI (Fig. 2.8a) and Gibson Assembly was performed to clone 
in the AjuI insert (fragment C, Fig. 2.8b). Bacterial colonies were screened by Sanger 
sequencing (results not shown) and an edited clone was taken forward.  
This vector was digested with RsrII and BsrGI (Fig. 2.8c) to prepare for insertion of 
two fragments. One contained a neo-IRES sequence amplified by PCR from a plasmid 
provided by Luca Crepaldi (fragment D, Fig. 2.8d); the other was synthesised to overlap with 
the IRES and the BFP coding region, extending across the BsrGI site (fragment E, Fig. 2.8e). 
Gibson Assembly was performed, transformed into E. coli and bacterial colonies were screened 
by Sanger sequencing (results not shown). A clone containing the neo-IRES-BFP sequence 
was obtained (Fig. 2.8f). Appendix A.3 shows the complete plasmid map and sequence for this 
plasmid backbone. 
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Figure 2.8. Cloning in AjuI recognition site and an IRES element. a) BbsI digest of neoR backbone, 
b) illustration of the oligonucleotide designed to insert AjuI recognition site via Gibson Assembly, c) 
RsrII/BsrGI double-digest of neoR (AjuI) backbone, d) PCR amplification of neoIRES sequence from 
a plasmid provided by Luca Crepaldi, e) illustration of the neoIRES PCR amplicon and the IRES-BFP 
oligonucleotide designed for Gibson Assembly, f) schematic of the final neoR-IRES backbone. 
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This neoR-IRES backbone was then packaged into a lentivirus and BOB-Cas9 cells were 
transduced. As described in Section 2.4.1, BFP was measured 48 hours post-transduction and 
a clonogenic assay and flow cytometry analysis were performed to test resistance to G418 (Fig. 
2.9). For the clonogenic assay, cells were also transduced with the neoR backbone for 
comparison, to confirm that G418 was effective (Fig. 2.9b). Cells transduced with the neoR-
IRES backbone survived selection with all doses of G418; 1 mg/ml caused the greatest increase 
in BFP positive cells. The neoR-IRES backbone was therefore deemed suitable for use in 
screening.  
 
 
Figure 2.9. Testing neoR-IRES backbone resistance to G418. a) Flow cytometry plots showing BFP 
expression in BOB-Cas9 cells at 2- and 14- days post-transduction with the neoR-IRES backbone. Cells 
were selected with various doses of G418 from day 9-14, b) Clonogenic assay showing BOB-Cas9 cells 
stained with crystal violet on day 14 post-transduction with the neoR or neoR-IRES backbone. Cells 
were selected with various doses of G418 from day 9-14. Untransduced cells were used as a control to 
show that transduction itself was not toxic. 
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2.4.3 Alternative strategies for gRNA transfer 
In preparation for the transfer of gRNAs from the Yusa v1.1 library, the neoR-IRES backbone 
was digested with AjuI. Several digestion protocols were tested, including varying the number 
of enzyme units, digestion volume, DNA:enzyme ratio and digestion time, but complete 
digestion could not be achieved (Fig. 2.10a). Linearised plasmid was extracted from an agarose 
gel and transformed into chemically-competent bacteria. As a control, uncut plasmid was also 
transformed. A large number of colonies were successfully transformed with the extracted 
linearised plasmid (at least 70% of the number with uncut plasmid). This suggested that there 
was incomplete separation on the gel and uncut plasmid was still present. It was vital to have 
a low level of uncut plasmid in the cloning reaction as there was no way to separate this from 
gRNA-containing plasmid. This would decrease the library coverage in the final DNA pool 
and essentially waste space as it would enter cells during a screen but have no function. 
 
 
Figure 2.10. Digestion of neoR-IRES backbone with AjuI. a) neoR-IRES plasmid digested with AjuI 
for (left-right) 15 minutes, 1 hour and 2 hours, b) AjuI digestion of a PCR amplicon across the restriction 
sites. Uncut amplicon = 194 bp; expected bands with 2 cuts = 132 bp, 32 bp, 30 bp; expected bands 
with 1st cut only: 164 bp and 30 bp; expected bands with 2nd cut only: 132 bp and 62 bp. 
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Additionally, as AjuI cut at two sites very close to each other, we wanted to confirm that 
digestion occurred at both. As it was difficult to see such a small size difference from the 
plasmid digest, PCR was performed across the AjuI restriction sites and the amplicon was 
digested. A mixture of single and double cut products was evident (Fig. 2.10b), indicating that 
the enzyme was not efficiently cutting at both sites, which would be necessary for Gibson 
Assembly. High efficiency was desirable due to the scale of transformation required for cloning 
the library. Considering these factors, digesting the backbone with AjuI was unsuitable.  
As an alternative, we tested a strategy involving double digestion with MluI and AgeI 
(sites indicated on Fig. 2.8f). The established protocol for transferring gRNAs from the Yusa 
v1.1 library involved PCR amplification of a region from the end of the U6 promoter to the 
end of the tracrRNA scaffold. Using AjuI, the same protocol could be used. However, MluI 
and AgeI digestion removed a larger fragment and so an amplicon of ~600 bp was required to 
clone gRNAs into the backbone. Digestion appeared to be complete (from gel visualisation, 
Fig. 2.11a) but extraction of the digested plasmid was carried out as a precaution. This product 
was transformed into bacteria and, in comparison to uncut plasmid, < 1% of colonies survived 
with the digested plasmid. This low level of background was ideal for gRNA library transfer.  
 
 
Figure 2.11. Cloning strategy for gRNA library transfer. a) MluI/AgeI double-digest of the neoR-
IRES backbone, b) PCR amplification of gRNAs from the Yusa v1.1 library with two primer sets and 
a gradient of annealing temperatures. 
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PCR was performed to amplify gRNAs from the Yusa v1.1 library plasmid, using primers that 
extended across the MluI and AgeI sites. A protocol provided by Kosuke Yusa was used; the 
annealing temperature was optimised and two primer sets were tested. PCR optimisation was 
performed using the empty Yusa v1.1 backbone as library DNA was limited. Primer set 2 (599 
bp amplicon) with an annealing temperature of 67oC provided the best yield (Fig. 2.11b).  
The optimised PCR reaction was performed on Yusa v1.1 library plasmid DNA. A high-
fidelity polymerase was used for amplification to reduce the likelihood of sequence errors 
being introduced to the gRNAs. To ensure high coverage of all 101,090 gRNAs, ten PCR 
reactions were performed, the products were pooled and the 599 bp band was extracted. Twelve 
Gibson Assembly reactions were performed to insert the gRNA amplicon into the MluI/AgeI-
digested neoR-IRES backbone. These were pooled, column purified and concentrated, then 
electroporated into electro-competent bacteria. Bacteria were expanded in liquid cultures, with 
a small fraction plated on agar to allow measurement of transformation efficiency. Based on 
the colony number, over 2000x coverage of the gRNA library was achieved. 
 
 
2.5 Assessing gRNA library quality 
As an initial quality control measure, 94 bacterial colonies from the library transformation were 
sequenced by Sanger sequencing (as described in Section 7.7.10). Of these, 10 were discarded 
due to low quality sequencing. The majority (83%) had the correct backbone sequence; 9% 
had a single basepair substitution (sub) upstream of the U6 promoter in a region of the plasmid 
with unknown function; 8% had a single basepair substitution in the PGK promoter (Fig. 
2.12a). It was unclear whether these substitutions would affect plasmid function. As they 
occurred at a low frequency and would be randomly distributed in terms of the gRNAs affected, 
we concluded that they were unlikely to have a large impact. In terms of the gRNA, 75% of 
colonies had a correct sequence matching the Yusa v1.1 library and 20% were mixed colonies 
and so were uninformative (Fig. 2.12b). Only 5% had a sequence error but it was not possible 
to determine whether we introduced these errors or if they were present in the original library. 
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Figure 2.12. Sequencing of colonies from gRNA library transfer. Results from Sanger sequencing 
of 84 colonies cultured after the transfer of gRNAs into the neoR-IRES backbone. The error rate was 
calculated for (a) the plasmid backbone (in the area altered by cloning) and (b) the gRNA sequence 
(mixed colony indicates cases with mixed sequencing traces in the gRNA region). 
 
Plasmid DNA was extracted from the bulk bacterial culture and PCR was performed to amplify 
the gRNA region (details provided in Section 7.12). The gRNAs were then sequenced on a 
HiSeq 2500. To assess the quality of the neoR-IRES library, the results were compared with 
independent sequencing of the Yusa v1.1 library and the Yusa v1 library, which has also been 
used successfully in published screens (Table 2.2, Fig. 2.13, Appendix A.4).110  
 
Three key variables were considered: 
1. Sequencing artefacts or errors introduced during cloning (% unmapped reads) 
2. Missing gRNAs (% zero counts) 
3. Distribution of gRNA representation (90th/10th percentile ratio) 
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Table 2.2. Comparison of gRNA library quality. 
 
Yusa v1 Yusa v1.1 neoR-IRES 
% unmapped reads 10% 8% 10% 
% zero counts 0.76% 0.2% 0.14% 
90th/10th percentile ratio 7.7 3.2 3.1 
 
Considering these factors, the neoR-IRES library appeared to be of a similar quality to Yusa 
v1.1, and was equal to or improved upon the Yusa v1 library. It should be noted that the neoR-
IRES library was sequenced at a deeper coverage than the original libraries, with ~3600x 
library coverage based on mapped reads for the neoR-IRES library compared to ~1000x for 
the Yusa v1 and v1.1 libraries. 
 
 
 
Figure 2.13. Comparison of gRNA distribution between libraries. Abundance of gRNAs 
(normalised against the mean) with each read count (normalised against the mean) is shown for the 
Yusa v1, Yusa v1.1 and neoR-IRES libraries. Read counts were obtained from sequencing each plasmid 
on a HiSeq 2500. 
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2.6 Engineering stable Cas9 lines 
As the genome-wide library encoded gRNAs but not Cas9, we generated iPSCs that had stable 
expression of Cas9 to perform screening (experimental details provided in Section 7.10). Cells 
were transduced with a lentiviral plasmid containing Cas9 and blasticidin was used for 
selection.110 All iPSC Cas9 lines used in this project were engineered by myself or Clara 
Alsinet (a postdoctoral fellow in the Adams’ lab). After complete selection, Cas9 activity was 
measured using a fluorescent reporter assay (Fig. 2.14). Cells were transduced with a control 
BFP/GFP-expressing lentivirus or a reporter lentivirus that expressed BFP/GFP and a gRNA 
targeting GFP. In the presence of active Cas9, the gRNA targeted the GFP and produced a 
BFP-only positive population. Cas9 activity was calculated as the % of total transduced cells 
that were positive only for BFP but not GFP, as measured by flow cytometry. All cell lines 
displayed a high level of Cas9 activity (> 70%). 
 
 
Figure 2.14. Cas9 activity in iPSCs. BOB-Cas9 cells were transduced with a control BFP/GFP vector 
(middle), a reporter BFP/GFP/gGFP vector (right) or untransduced (left). BFP and GFP expression 
were measured by flow cytometry at 3 days post-transduction. Untransduced and control cells were 
used for gating. Cas9 activity was calculated as the percentage of BFP positive cells divided by the 
percentage of total cells transduced with the reporter vector. In this case 90% activity was measured. 
These plots are for the parental BOB-Cas9 line and are representative of the other stable Cas9 
derivatives generated for the KO lines. 
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2.7 Genome-wide screening in iPSCs 
2.7.1 NeoR-IRES library lentivirus titration 
For screening, the library plasmid was packaged into a lentivirus (as described in Section 
7.8.1). To ensure that each cell was infected with a single copy of the virus (i.e. cells did not 
carry multiple gRNAs), we aimed to transduce cells with an MOI of 0.3. To this end, each 
batch of library lentivirus was titrated in every cell line to be screened, using BFP as a marker 
(as described in Section 7.8.2). Cells were transduced with various volumes of lentivirus and 
seeded in 6-well plates. After 48 hours, cells were fixed and BFP expression was analysed by 
flow cytometry. The volume of lentivirus required to obtain 30% BFP-positive cells was 
calculated and scaled up for the screens. 
A dose-dependent effect on cell viability was observed during the titration, suggesting 
that the library induced lethality. Significant cell death had not been observed with any other 
lentiviral transductions using these cells. We hypothesised that double-strand breaks created 
upon addition of the gRNA library may have induced toxicity. BOB and BOB-Cas9 cells were 
transduced with various doses of neoR-IRES library lentivirus and BFP expression was 
measured after 3 days (as described in Section 7.13.1). At every dose, BOB cells had a larger 
BFP-positive population than BOB-Cas9 cells, despite being transduced in the same conditions 
(Fig. 2.15). Thus, cells expressing the gRNA (i.e. BFP positive) were depleted in the population 
when Cas9 was active, relative to when Cas9 was absent. This suggested that the activity of 
Cas9 in the presence of targeting gRNAs may have had a negative impact on cell fitness. 
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Figure 2.15. Library titration in BOB vs BOB-Cas9. Flow cytometry plots showing BFP expression 
(450_50 (405)-A) in BOB and BOB-Cas9 cells 3 days post-transduction with various volumes of the 
neoR-IRES library lentivirus. Untransduced cells were used as a control for both lines.  
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2.7.2 iPSC screening protocol 
After the initial titration, a small-scale version of the screen was carried out in BOB-Cas9 cells 
to optimise seeding density and passaging methods. We tested seeding 1x106, 2x106 and 3x106 
cells per 15 cm dish, using 1 mg/ml G418 for selection based on the backbone assay (discussed 
previously, Fig. 2.9). A density of 2x106 cells per 15 cm dish was chosen as this allowed cells 
to grow for 13 days with only one passage required. A brief timeline of the screen is shown in 
Fig. 2.16 and full details are provided in Section 7.11. I used this protocol to screen the parental 
BOB line and four KO lines: ARID1A_C09, ARID1B_C03, ARID2_C11 and PBRM1_F09. 
A further 19 screens, in the parental and additional KO lines, were performed by the Cellular 
Genotyping and Phenotyping (CGaP) facility at WSI. After transfer to CGaP, this protocol was 
adapted to include two passages (on day 6 & 8/9) as cells were growing faster, which may have 
been due to a manufacturer change to the medium. 
 
 
 
Figure 2.16. iPSC screening protocol. Stable Cas9 cells were transduced in suspension with the neoR-
IRES library lentivirus then seeded. After 48 hours, 1 mg/ml of G418 was added. A sample of cells 
(from a small dish seeded in parallel at the point of transduction) was taken for flow cytometry analysis 
to measure BFP expression. On day 8, cells were passaged as clumps and BFP expression was 
measured. On day 13, cells were collected, pelleted and frozen, and BFP expression was measured. 
Additions highlighted in red indicate changes made by CGaP, with an additional passage on day 6. 
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2.7.3 BFP expression as a transduction/selection marker 
In all screens, BFP expression was measured on day 2 to confirm that an acceptable MOI was 
achieved, and on day 8 and day 13 to confirm that G418 selection worked (Fig. 2.17) (as 
described in Section 7.11). On average, there was a ~30% BFP positive population on day 2, 
but some screens had slightly higher or lower levels. G418 appeared to be working as an 
increase in BFP was observed at day 8, but an unexpected plateau occurred in the initial 
screens. The BFP positive populations generally remained stable or dropped after the passage 
rather than increasing with further selection. Considering that cells still survived in G418, we 
hypothesised two explanations for this plateau of BFP expression: 
 a) BFP was being silenced or expressed at a low level 
b) G418 selection stopped working > 50% due to cross-resistance 
 
 
 
Figure 2.17. BFP expression throughout BOB-Cas9 screen. Flow cytometry plots showing BFP 
expression (450_50 (405)-A) in BOB-Cas9 cells on day 2, day 8 and day 13 post-transduction with the 
neoR-IRES library. Untransduced cells were used as a control for gating. This analysis was performed 
for each screen. 
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To investigate this, BOB-Cas9 cells were maintained after screening and seeded at a low 
density. Twenty individual colonies were picked and expanded. Two colonies were picked 
from untransduced BOB-Cas9 cells and 18 were picked from the cell population that had 
undergone screening. All clones were cultured with or without G418 for one week and BFP 
expression was measured by flow cytometry (as described in Section 7.13.2). Of the 18 
colonies, three appeared to be mixed with two separate populations evident and only five had 
complete BFP expression (i.e. almost 100% BFP positive based on gating of untransduced 
cells, Fig. 2.18: clone C). The remaining colonies had lower levels of BFP expression and were 
gated as only partially BFP positive despite being a single population (Fig. 2.18: clones A&B). 
It appeared that many cells were expressing the plasmid at a level sufficient to provide G418 
resistance but with a BFP level that could not be accurately detected. This may be due to 
varying promoter strength at different lentiviral integration sites, but could also be related to 
the IRES element. It is known that the second gene in a polycistronic mRNA separated by an 
IRES (BFP) can have lower expression than the first gene (neomycin resistance).252 
To determine whether cross-resistance was an issue for G418 selection, an 
untransduced clone was mixed in various ratios with a clone with complete BFP expression (as 
described in Section 7.13.3). Flow cytometry was performed at the point of mixing the cells 
and after 5 days in culture with G418 (Fig. 2.19). As a control, cells were also maintained 
without G418 and BFP expression was stable. Selection led to an increase in the % of BFP 
positive cells in all conditions, albeit with a slightly lower increase in those that started with a 
higher % of BFP positive cells.  
Our conclusion from this analysis was that it was more likely the BFP expression was 
not accurately representing the plasmid expression, rather than there being an issue with G418 
selection. During the screens performed by CGaP, the expression of BFP was found to vary 
even further. In some screens, the % of BFP positive cells increased and stabilised above 80%. 
In others, the increase was much lower and a drop in % BFP was observed in some cases 
(similar to that shown in Fig. 2.17) despite continued G418 selection. This could be due to the 
cells silencing BFP expression. In the Cas9 activity test, we also observed that BFP expression 
was low and did not result in a clearly distinct population (Fig. 2.14). The plasmids used for 
this test encoded BFP as the first protein rather than the second (as in our backbone), but it was 
still under the control of a PGK promoter.110 Thus, BFP expression in these iPSC lines may be 
a general issue, not specific to our library plasmid. In future, an antibody against BFP could be 
used to improve detection of expression. These findings indicate that BFP was not a reliable 
marker of library plasmid expression and we may have underestimated the transduction levels.  
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Figure 2.18. Variable BFP expression in clonal transduced lines. Single-cell colonies were picked 
from populations of BOB-Cas9 cells that were either untransduced or had been screened with the neoR-
IRES library. All transduced cells had been selected with 1 mg/ml G418 throughout the screen. Each 
transduced clonal line was maintained with or without 1 mg/ml G418 for 7 days. Cells were fixed and 
BFP expression (450_50 (405)-A) was measured by flow cytometry. Representative plots are shown 
for three colonies. 
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Figure 2.19. Efficiency of G418 selection. Untransduced BOB-Cas9 cells were mixed with a clonal 
transduced BOB-Cas9 line that was previously confirmed to have ~100% BFP expression. Populations 
containing 10%, 30%, 50%, 70% and 100% of the transduced line were prepared. A fraction of each 
population was fixed at the point of mixing, and the remainder were cultured for 5 days with or without 
1 mg/ml G418. Cells from day 0 and day 5 were analysed by flow cytometry to measure BFP expression 
(450_50 (405)-A). 
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2.8 Effect of CRISPR/Cas9 on iPSC karyotype 
Prior to screening, stable Cas9 derivatives of BOB and four PBAF/BAF gene KO lines 
(ARID1A_C09, ARID1B_C03, ARID2_C11, PBRM1_F09) were karyotyped to confirm that 
they were stable over time, and were unaffected by Cas9 expression. To visualise the 
karyotypes, multiplex fluorescence in situ hybridisation (M-FISH) was performed by the FISH 
facility at WSI (as described in Section 7.14). BOB-Cas9 cells were also karyotyped post-
screen, in parallel with untransduced cells cultured for the same time (Fig. 2.20). Karyotypes 
for the KO lines are shown in Fig. B.1, Appendix B. All cells had a balanced translocation 
t(6;8)(p21.1;q24.1), which was previously identified in the parental BOB line by other groups 
at WSI and was likely present in the donor cells used to derive the line. No other chromosomal 
abnormalities were identified. The t(6;8)(p21;q24) translocation has been reported in cases of 
a rare haematological malignancy, blastic plasmacytoid dendritic cell neoplasm.253 These cases 
involved translocation of MYC, which lies on 8q24, but always occurred alongside other 
chromosomal aberrations. Further analysis carried out on the BOB line by others at WSI 
(unpublished) excluded gene disruption and smaller copy number variations at the breakpoint. 
This line was used as it had better survival and a greater tolerance of the editing process than 
more sensitive iPSC lines. However, as BOB was used as a normal cell model, potential effects 
of this chromosomal abnormality should be kept in mind. Results must always be validated in 
an independent cell line to rule out the possibility of cell line-specific effects.  
 Karyotyping using M-FISH gives a high-level view, limited to a resolution of 3-5 Mb, 
thus smaller chromosomal changes would not be detected using this assay. The technique is 
more sensitive at detecting small insertions than it is for small translocations involving 
segments from the end of chromosomes. M-FISH is not ideal for detecting small deletions or 
duplications. Microarray-based comparative genomic hybridisation (array CGH) is a technique 
which offers greater resolution than M-FISH.254 Array CGH uses DNA, rather than cells in 
culture, to identify changes in ploidy compared to a reference sample. However, unlike M-
FISH, this technique cannot detect balanced chromosomal abnormalities. The most thorough 
approach to identifying abnormalities induced by the CRISPR/Cas9 screening process would 
be to perform whole-genome sequencing on the cell lines, but this is an expensive option. It 
may be appropriate to first sequence the parental line after Cas9 transduction/screening to get 
an initial indication of any substantial effects on the genome of these cells. 
 
Effect of CRISPR/Cas9 on iPSC karyotype  58 
 
Figure 2.20. Karyotype of BOB-Cas9 cells. M-FISH of BOB-Cas9 cells that were untransduced or 
had undergone screening with the neoR-IRES library. Ten randomly selected metaphases were analysed 
for each line; a representative karyotype is shown for both. A balanced translocation between 
chromosomes 6 and 8 is indicated. 
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2.9 Effect of CRISPR/Cas9 on iPSC pluripotency 
Transient changes in morphology were observed when cells were transduced with lentivirus 
containing the Cas9 plasmid or the library plasmid. Cells returned to a normal morphology 
after passaging. However, to ensure that the screening process was not affecting the 
pluripotency of the cells, expression of 3 pluripotency markers (OCT4, SOX2, NANOG) was 
measured in BOB-Cas9 cells post-screen and compared with untransduced cells that had been 
cultured for the same period of time. This assay was carried out with the assistance of Mary 
Goodwin (CGaP, WSI) as described in Section 7.15. DAPI was used to stain the nuclei of 
individual cells. Cells were also stained with antibodies to detect OCT4, SOX2 and NANOG 
expression. The percentage of DAPI-positive cells expressing each marker was then calculated. 
No significant difference was observed for any of the markers when comparing untransduced 
and screened cells (Fig. 2.21).  
 
 
Figure 2.21. Expression of pluripotency markers in BOB-Cas9 cells. Cells from two replicates of 
the BOB-Cas9 neoR-IRES screen were maintained separately after the screen endpoint (transduced 
A/B). Untransduced cells from each replicate population were cultured in parallel (untransduced A/B). 
Cells from all conditions were seeded in a 96-well plate and cultured for 72 hours. These were fixed 
and stained for OCT4, SOX2 and NANOG expression; DAPI was used for nuclear quantification. 
Expression of each protein was measured using an ArrayScan VTI HCS Reader. The percentage of 
DAPI-positive cells expressing each marker was calculated. Background expression was measured in 
control wells and was subtracted from each condition. The mean expression values (from four technical 
replicates) are shown for each protein in each cell line. Error bars represent standard deviation. 
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2.10 Summary 
We engineered isogenic derivatives of a human iPSC line, BOB, each carrying LOF of a single 
candidate TSG (29 genes in total). Knockout of each gene was confirmed at the DNA and 
protein level by Sanger sequencing and mass spectrometry, respectively. As the KO lines were 
designed to be resistant to puromycin (the antibiotic resistance marker used in many gRNA 
libraries), we constructed a gRNA library backbone with a neomycin resistance gene. After 
confirming that the backbone was functional, an existing genome-wide gRNA library was 
transferred. Sequencing confirmed that the library was of a comparable quality to the original. 
Each iPSC line was then engineered to constitutively express Cas9. The new gRNA library 
was packaged into a lentivirus and titred in each line. A screening protocol was optimised in 
the parental BOB-Cas9 line before being applied in a further 20 KO lines. Various assays 
indicated that BFP expression from the backbone (used as a marker of transduction and 
selection) was weak and may have caused underestimations. We also found that the screening 
process had a large impact on cell viability, but did not affect karyotype stability or expression 
of key pluripotency markers.  
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Chapter 3 
3 Analysis of iPSC CRISPR/Cas9 screens 
 
3.1 Introduction 
A variety of methods are available to analyse CRISPR/Cas9 knockout screens. There are no 
examples in the literature of genome-wide screens in iPSCs and few in hESCs, but a vast 
amount of data has been published for hundreds of cancer cell line screens. Using insights 
gained from these studies, we analysed data from our screens in the parental BOB and KO 
derivatives. We initially performed basic quality control measures and tested screen 
performance, using published datasets as a reference. To evaluate reproducibility, we compared 
the data from all lines including the results of biological replicates of both the parental and 
TP53 KO lines. Using various filtering strategies, we identified candidate SLIs for all 15 of the 
TSGs studied. In addition to exploring genes that were required for cell fitness in the iPSCs, 
we also identified genes that, when lost, appeared to provide a proliferative advantage. 
 
3.1.1 Aims of this chapter 
• To assess the quality of our iPSC screen data and evaluate the performance of the 
screens in terms of recall of known fitness genes. 
• To assess the reproducibility of the screens by comparing the results of all lines, with a 
particular focus on biological replicates of the same lines. 
• To filter for dependencies that were specific to KO lines and identify candidate SLIs. 
• To investigate enrichment of genes in the iPSC screens.  
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3.2 Screen data quality control 
3.2.1 Sequencing coverage  
In total, 24 screens were performed as part of this project: I performed 5 screens and a further 
19 were performed by Rebecca McRae and Verity Goodwin (CGaP, WSI). As discussed in 
Section 2.7.2, these screens were performed using the same protocol and library but added an 
additional passage was added by CGaP. Each screen was carried out in technical triplicate, 
with the exception of the FAT1 KO line which had only two replicates due to unexplained cell 
death in one replicate. All samples were processed in the same way and gRNAs were sequenced 
on a HiSeq 2500, with 6 samples multiplexed per run. There was slight variation in sequencing 
depth between different samples and runs, which was accounted for by normalisation prior to 
further analysis. An average of 4.07x107 read counts per replicate mapped to the gRNA library 
(Fig. 3.1). This was equivalent to ~400x coverage of the library, with no samples dropping 
below 200x coverage (Fig. 3.1).  
 
 
Figure 3.1. Sequencing coverage across all iPSC screens. PCR was performed to amplify gRNAs 
present in the genomic DNA of each screened cell line. gRNAs were then sequenced on a HiSeq 2500 
and mapped to the library. The number of mapped reads is plotted for each replicate in every screened 
cell line (left y-axis). The corresponding library coverage that was achieved is also shown (right y-axis). 
The dotted line indicates the mean across all samples. BOB, BOB_2 and BOB_3 refer to replicate 
screens of the parental BOB line. TP53 and TP53_2 refer to replicate screens of the TP53 KO line. 
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3.2.2 Enrichment of non-targeting controls 
When looking at the initial gRNA read count data prior to analysis, it was noted that there was 
an enrichment of non-targeting control (NTC) gRNAs in the screen samples compared to the 
library plasmid. The log2(fold-change) in abundance between plasmid and screen for the 
targeting gRNAs was distributed around 0, whereas NTC gRNAs were enriched (an average 
of 1.2 for the screens shown in Fig. 3.2). The NTC gRNAs do not target any region in the 
genome, hence Cas9 would not induce DSBs in cells expressing these gRNAs. In line with our 
previous observation of Cas9-induced toxicity (Section 2.7.1), we hypothesised that cells 
expressing NTC gRNAs had a proliferative advantage due to the lack of DNA damage. 
Therefore, widespread depletion of cells expressing targeting gRNAs but not those expressing 
NTC gRNAs would cause this observed enrichment of the controls. This effect was also 
observed in the TP53 KO line screen (Fig. 3.2), suggesting that depletion of TP53 was not 
sufficient to avoid this toxicity. Other studies have since reported similar findings (discussed 
in Section 5.2.2). We decided to remove the NTC gRNAs from all further analysis as they 
skewed the results rather than acting as controls. 
 
 
Figure 3.2. Fold-changes of non-targeting and targeting gRNAs. The log2(fold-change) in read 
count between the screen and the library plasmid was calculated for NTC gRNAs and all other targeting 
gRNAs. Results are shown for screens in the BOB, ARID1A_C09, ARID1B_C03, ARID2_C11, 
PBRM1_F09 and TP53 cell lines. The values shown were calculated using the average read count of 
the technical replicates in each screen.  
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3.2.3 Correlation between technical replicates 
The correlation of gRNA read counts between technical replicates was measured for each cell 
line using Pearson’s Correlation Coefficient. The average R value was calculated for each line, 
with a median of 0.82 across all screens (range 0.6-0.9) (Fig. 3.3a). In a recent study of 324 
cancer cell lines using the Yusa v1.1 library, a median R of 0.8 was achieved.109 However, it 
was noted that this correlation was not sufficient to distinguish between replicates of the same 
cell line and any two random cell lines. To gain a better measure of reproducibility, in that 
study they selected gRNAs that had an average pairwise Pearson’s Correlation of > 0.6 across 
all screens when comparing the count fold-changes at the screen endpoint vs the plasmid 
library. For each replicate, they then calculated the average gene-level fold-change for only the 
genes targeted by these ‘reproducible gRNAs’. Pearson’s Correlation of these fold-changes 
was assessed between all replicates across all screens, and a reproducibility threshold was 
defined that would allow distinction between replicates of the same cell line and random lines. 
We repeated this analysis on our screens and identified 279 gRNAs that were reproducible 
(average R > 0.6). However, this measurement assumes that the cell lines being compared are 
independent, but the cell lines we screened were almost genetically identical. Unsurprisingly, 
the correlation between cell lines was still not distinct from that observed between replicates. 
Based on the reproducibility threshold identified in the cancer cell line screens (R=0.68), the 
majority of our screens passed this quality control test (Fig. 3.3b). A more thorough approach 
could be to repeat this analysis using a combined set of data from the iPSC screens and cancer 
cell line screens. Comparing the iPSCs to independent lines may provide a more reliable 
threshold to assess replicate reproducibility. 
 Notably, the initial 5 screens had the lowest correlations in both analyses, suggesting 
that the screen quality was improved by the addition of a passage. This may be due to a 
reduction in the cell death that occurred when the cells approached confluency. We also noted 
that replicate A of the ARID1A_C09 screen negatively impacted the average correlation. 
Replicates 1 and 2 had R = 0.83 for all gRNA counts and R = 0.76 for reproducible gRNA 
fold-changes. During this screen, the level of transduction in replicate 1 was higher and more 
cell death was observed, which may explain the lower correlation. We therefore decided to 
exclude replicate 1 of the ARID1A_C09 screen from further analysis. 
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Figure 3.3. Correlation between screen technical replicates. a) Pearson’s Correlation values were 
computed between technical replicates of each cell line using gRNA read counts. The average R value 
for each screen is shown, with the median represented by a dotted line, b) Pearson’s Correlation values 
were computed between technical replicates of each cell line using the gene-level fold-changes only for 
reproducible gRNAs. The average R value for each screen is shown. The dotted line represents the 
reproducibility threshold that was defined by Behan et al. based on screens in cancer cell lines.109  
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3.3 Identifying effects of gene loss on cell fitness 
Several methods are available for analysis of CRISPR/Cas9 knockout screen data. We chose 
two of the most well-established methods, described below, to identify genes that were 
significantly depleted in our screens. These analyses allowed us to compare our data to 
previously published cancer cell line screens that were processed in the same way after 
screening with the same gRNAs.109 Our library had an average of 5 gRNAs/gene but, for a 
subset of ~2000 cancer-related genes, there were 10 gRNAs/gene. This may have caused a bias 
towards genes that were better represented and we were unclear how to account for this, so we 
removed the data for all additional gRNAs before further analysis. 
 
3.3.1 Bayesian Analysis of Gene EssentiaLity 
Bayesian Analysis of Gene EssentiaLity (BAGEL) is an algorithm developed to analyse 
genetic perturbation screens using a priori known training sets of ‘essential’ and ‘nonessential’ 
genes.114 The 360 essential genes were defined based on their essentiality in at least 50% of a 
set of shRNA screens, and constitutive expression in a panel of cell lines. Using the same panel, 
the 972 nonessential genes were defined as those which generally lacked expression in these 
lines. Firstly, median-ratio normalisation is performed on all raw read counts to account for 
differences in sequencing coverage. A log2(fold-change) is then calculated for each gRNA, 
comparing the abundance at the screen endpoint to that in the library plasmid. The average 
log2(fold-change) for each gRNA is calculated across screen replicates. BAGEL then uses the 
fold-change distribution of all gRNAs targeting the essential and nonessential genes (Fig. 3.6) 
to calculate the likelihood that a given gRNA belongs to either set, based on the observed fold-
change. The output of this probability calculation is a value termed the Bayes Factor (BF); 
every gRNA is assigned a BF. A recently published R implementation (BAGELR) calculates 
the gene-level BFs by taking the average of the gRNA values.109 The original Python version 
of BAGEL calculated a sum rather than an average value.114 A positive BF indicates that the 
gene is likely to be essential for cell fitness.  
Bayes Factors were computed using BAGELR for all of our screens (Appendix A.5). 
To determine statistical significance, a threshold of 5% False Discovery Rate (FDR,  
1- Precision) was defined for each screen. Genes were assigned a scaled BF (Appendix A.6), 
which was calculated by subtracting the BF at the 5% FDR threshold for that screen from the 
original BF. Any gene with a scaled BF > 0 was considered to be significantly depleted.  
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3.3.2 Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout  
Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) is an algorithm 
which, unlike BAGEL, identifies significant differences in gRNA abundance using no prior 
knowledge.116 Median-normalisation is performed on the read counts to account for differences 
in sequencing depth across replicates and conditions, and the gRNA variance is estimated. 
Replicates can be analysed together, with a mean read count calculated for every gRNA. Using 
a negative binomial model, MAGeCK then determines whether the abundance of a gRNA is 
significantly different between the control and treatment; in our analysis this was the library 
plasmid vs the screen endpoint. A robust ranking aggregation (RRA) algorithm is used to rank 
gRNAs by the p-value obtained from the negative binomial model (Fig. 3.4).  
 
 
Figure 3.4. Robust rank aggregation. A negative binomial model is used to determine the significance 
of any change in gRNA abundance compared to control. gRNAs are then ranked based on their p-value. 
If a gene is essential, gRNAs targeting it should be ranked highly more often than expected. If a gene 
is nonessential, gRNAs targeting it should be uniformly distributed. Figure taken from 116. 
 
If a gene has no effect on fitness, the assumption is that gRNAs targeting this gene will be 
evenly distributed in the rankings. If several gRNAs targeting a gene are ranked higher than 
expected, this gene would be considered significant. Each gene is assigned a p-value and an 
FDR is computed using the Benjamini-Hochberg method. MAGeCK can be used for bi-
directional analysis; from one screen it can identify genes whose knockout impairs cell fitness 
(negative selection) and genes whose knockout induces cell proliferation (positive selection). 
Genes under negative selection would have a significant depletion of gRNAs compared to the 
control. Those under positive selection would have significant enrichment of gRNAs compared 
to the control. MAGeCK analysis was performed on all of our screens to calculate depletion 
values for every gene (Appendix A.7). A threshold of negative FDR 0.1 was applied to identify 
significant hits. 
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3.4 Assessing screen performance 
3.4.1 Receiver Operating Characteristic & Precision-Recall curves 
As a measure of the sensitivity and specificity of the screens, receiver operating characteristic 
(ROC) and precision-recall (PrRc) curves were computed (Fig. 3.5). This was done using the 
gene-level count fold-changes, with the average taken across technical replicates for each 
screen. Using the pre-defined sets of BAGEL essential and nonessential genes, these analyses 
can indicate how well a screen performed. ROC curves plot sensitivity (i.e. true positive rate) 
against specificity (1 - false positive rate). The area under the curve (AUC) is a measure of how 
accurately the essential and nonessential genes were identified as distinct groups. If these genes 
cannot be separated, the AUC would be 0.5. A screen with 100% specificity and sensitivity 
would have an AUC of 1. PrRc curves plot recall (i.e. true positive rate, the same as sensitivity) 
against precision (i.e. positive predictive value). Precision and specificity are slightly different: 
precision measures how many of the predicted positives are actually true positives; specificity 
measures how many of the expected negatives are called as negative. Similar to the ROC curve, 
a high AUC for the PrRc curve indicates good performance with high precision and recall. 
Based on these models, performance across all of the screens was fairly consistent. The median 
area under the ROC curve was 0.91 (Fig. 3.5a) and area under the PrRc curve was 0.87 (Fig. 
3.5b). These results were similar to those obtained in the Behan et al. (2019) study of cancer 
cell lines (0.92 and 0.9, respectively).109  
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Figure 3.5. Assessment of screen performance. ROC (a) and PrRc (b) curves were plotted for all 24 
screens. These were obtained by classifying the pre-defined BAGEL essential (n=354) and nonessential 
(n=747) genes using the gene-level fold-changes. The median AUC across all screens is shown for both. 
These were computed using the ROC and PrRc functions in the CRISPRcleanR package.255 
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3.4.2 Distributions of BAGEL essential and nonessential genes 
Another indicator of screen performance is the separation between the results for the BAGEL 
essential and nonessential genes. We analysed the distribution of gene-level fold-changes (Fig. 
3.6) and scaled BFs (Fig. 3.7) for each of these sets across all screens. There was a slight 
separation between the essential and nonessential genes but the overlap was high, although this 
was improved in the scaled BF distributions. It may be the case that some of these genes were 
not essential in this iPSC line, as these genes were identified in immortalised cell lines. We 
also analysed the fold-change distribution for genes encoding ribosomal proteins, which we 
would expect to be vital for cell function regardless of the cell type (Fig. 3.6). These were 
slightly more depleted and separated from the nonessential genes compared to the essentials, 
but in some cases (e.g. PBRM1_F09) there was still high overlap. It appeared that depletion 
was simply not large enough to clearly separate the sets, suggesting this was most likely an 
issue with screen performance. For reference, the fold-changes (Fig. 3.6) and scaled BFs (Fig. 
3.7) for an ovarian cancer cell line, A2780ADR, are shown. This cell line was screened by 
Behan et al. (2019) using the same library and the data was processed in the same way.109 This 
cell line passed all quality control tests and had high AUC values for the ROC (0.93) and PrRc 
(0.93) analyses, thus we considered it to be a good representation of a high-quality screen. For 
this cell line, the fold-changes for essential and ribosomal genes spread further and were more 
distinct from the nonessential population than in our iPSC screens. There was also a greater 
separation between the scaled BFs for the essential and nonessential genes in the A270ADR 
screen, with the majority of essential genes being correctly called as essential. Of all the lines 
we screened, the results for the TP53 knockout line were most similar to this cancer cell line, 
indicating that this was the best performing screen. 
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Figure 3.6. Distribution of fold-changes for BAGEL essential and nonessential genes. The fold-
change of each gRNA was calculated for every screen replicate relative to the library plasmid. The 
average of the replicates was calculated for each cell line, and then a gene-level fold-change was 
calculated by taking average of the values for all of the gRNAs targeting each gene. The distribution of 
log2(fold-changes) of the BAGEL essential (n=354) and nonessential (n=747) genes are plotted for the 
parental BOB, ARID1A_C09, ARID1B_C03, ARID2_C11, PBRM1_F09 and TP53 screens. For 
comparison, results are also shown for the A2780ADR ovarian cancer cell line, screened by Behan et 
al. using the same library.109 Distributions are also shown for the genes that encode ribosomal proteins.  
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Figure 3.7. Distribution of scaled Bayes Factors. BAGEL was applied to compute BFs for all genes 
in every screen, calculating an average across replicates. The values were scaled using a 5% FDR 
threshold, with a value > 0 representing a significant hit. Plots show the distributions of the scaled BFs 
for the BAGEL essential (n=354) and nonessential (n=747) genes, and all other genes (unknown, 
n=16,906). Results are shown for the parental BOB, ARID1A_C09, ARID1B_C03, ARID2_C11, 
PBRM1_F09 and TP53 screens. For comparison, results are also shown for the A2780ADR ovarian 
cancer cell line, screened by Behan et al. using the same library109.  
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3.4.3 Recall of known fitness genes 
Whilst the ROC and PrRc curve models performed well, the distribution analyses indicated 
that we may have had issues with detecting known fitness genes and that performance was 
variable. In the Behan et al. (2019) pan-cancer study, a set of 552 pan-cancer core fitness genes 
were identified109, providing an additional reference set for comparison. Using both the 
BAGEL and MAGeCK analyses outputs, we assessed exactly how many of the BAGEL 
essential genes and pan-cancer core fitness genes were called as hits in our screens (Table 3.1). 
Although these gene sets were identified in cancer cell lines, the pan essentiality across many 
cell types suggests that they are likely required for general cell fitness and survival, regardless 
of tissue type or tumourigenicity. Considering this, it was expected that many of these should 
also be essential in our iPSCs. As our KO lines were all derived from the same parental, we 
also expected that there should be a large overlap in the essential genes identified. Consistently 
more of the pan-cancer core fitness genes were detected than the BAGEL essential genes 
(Table 3.1). This may be because the BAGEL gene list was derived from shRNA screen data 
rather than CRISPR/Cas9 screen data. However, in general the number of essential genes 
identified in the parental and KO iPSC screens was highly variable. In several screens, 
including one of the parental screens (BOB_2), there was a high recall of core fitness genes. 
This suggested that many of the core genes identified in cancer cell lines were also essential in 
this iPSC line, but the ability to consistently detect them was impeded by variable screen 
performance.  
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Table 3.1. Recall of pre-defined essential genes in iPSC screens. MAGeCK and BAGEL were 
applied to identify significantly depleted genes in each screen. The % of pan-cancer core fitness genes 
(n=552) and BAGEL essential genes (n=354) that were called as hits are shown, based on the results of 
both analyses. Increasing colour intensity reflects increasing % recall. 
 
 
 
 
 
 
 
 
 
 
 
Cell line Core fitness BAGEL essential Core fitness BAGEL essential
APC 63% 48% 63% 47%
ARID1A_B08 36% 25% 15% 12%
ARID1A_C09 28% 21% 47% 35%
ARID1B_C03 44% 34% 65% 48%
ARID1B_G01 42% 31% 49% 38%
ARID2_A11 57% 42% 30% 22%
ARID2_C11 15% 10% 26% 17%
ATM_A12 67% 52% 66% 50%
ATM_B11 52% 39% 10% 9%
B2M 72% 54% 91% 66%
BOB 18% 13% 41% 32%
BOB_2 47% 36% 80% 60%
BOB_3 47% 35% 13% 12%
CUX1 60% 45% 83% 62%
FAT1 29% 21% 51% 39%
FBXW7 39% 28% 39% 28%
MAP2K4 53% 40% 58% 43%
PBRM1_F08 43% 33% 61% 46%
PBRM1_F09 6% 5% 30% 24%
PIK3R1 40% 29% 33% 21%
RASA1 61% 47% 80% 60%
RB1 68% 52% 53% 40%
TP53 70% 53% 95% 68%
TP53_2 69% 51% 91% 66%
MAGeCK BAGEL
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3.5 Comparison of MAGeCK and BAGEL 
The inconsistent detection of established core fitness genes indicated that there may be high 
variability in the overall essentiality profiles of these cell lines. As described previously, both 
MAGeCK and BAGEL were used to identify genes that were significantly depleted in the 
parental and KO lines. We calculated the total number of significant hits in each screen and 
compared the results from both analyses (Table 3.2). For many lines, the number of hits called 
by MAGeCK and BAGEL varied considerably. However, the overlap of the genes that were 
identified was generally high. In screens where BAGEL detected less than MAGeCK, the 
majority of the hits detected by BAGEL were also identified by MAGeCK, and vice versa. It 
is not surprising that these analyses identified different hits and it was reassuring to see that 
many of these were shared. However, it is not clear why there was no trend in the variability: 
MAGeCK detected more hits in some screens but BAGEL detected more in others. This was 
also reflected in the detection of a priori known essentials discussed earlier, with inconsistent 
variability between both analyses. The results of these analyses are dependent on the chosen 
significance threshold. Here, a threshold of FDR 0.1 was used for MAGeCK and FDR 0.05 
was used for BAGEL. These can be adjusted to alter the stringency of the analysis; increasing 
the stringency too far will result in identification of very few hits and decreasing it may 
introduce noise and cause a high false positive rate. The most robust hits are likely to be those 
that were identified by both analyses, although this may lead to an increased false negative 
rate. For subsequent analysis, we considered the outputs from both MAGeCK and BAGEL 
rather than excluding data. 
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Table 3.2. Number of significantly depleted genes identified in iPSC screens. MAGeCK and 
BAGEL were applied to identify significantly depleted genes in each screen. The number of genes 
called as hits by MAGeCK using an FDR of 0.1 and by BAGEL using an FDR of 0.05 are shown for 
each cell line. The overlap of hits that were identified by both analyses is also shown. 
Screen MAGeCK hits BAGEL hits Overlap 
APC 1068 863 713 
ARID1A_B08 490 156 116 
ARID1A_C09 413 671 343 
ARID1B_C03 715 962 589 
ARID1B_G01 654 637 435 
ARID2_A11 1009 353 319 
ARID2_C11 232 343 144 
ATM_A12 1235 995 848 
ATM_B11 872 95 86 
B2M 1244 1506 1109 
BOB 264 625 228 
BOB_2 758 1379 714 
BOB_3 820 151 128 
CUX1 981 1384 875 
FAT1 475 832 419 
FBXW7 671 541 383 
MAP2K4 930 885 689 
PBRM1_F08 675 905 565 
PBRM1_F09 86 528 75 
PIK3R1 680 429 326 
RASA1 1029 1244 868 
RB1 1258 683 613 
TP53 1178 1656 1100 
TP53_2 1079 1468 991 
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3.6 Assessing screen reproducibility 
3.6.1 Comparison of biological replicates 
All screens were carried out in technical triplicate (or duplicate for the FAT1 KO) with cells 
split into three populations at the passage prior to setting up the screen, and then transduced 
and maintained separately throughout. However, we considered that biological replicates may 
be more informative with regards to reproducibility. For the parental BOB line and the TP53 
KO line, screening was repeated weeks apart using cells thawed from different vials. The data 
was analysed as described previously, and the overlap of the results was assessed (gene lists 
are provided in Appendix A.8).  
I carried out the initial parental BOB screen and two further biological replicates were 
performed by CGaP using their adapted protocol. Using MAGeCK, only 185 genes were 
significantly depleted in all replicates (Fig. 3.8). A further 314 hits were detected in both the 
second and third screens, but not in the first. Using BAGEL, fewer genes were identified in 
BOB_3 but almost all of them overlapped with BOB_2 (Fig. 3.8). Similarly, the majority of 
hits from BOB were also found in BOB_2. The detection of core fitness and BAGEL essential 
genes was higher in BOB_2 than in the others (Table 3.1). Thus, the incomplete overlap may 
be due to poorer performance in the BOB and BOB_3 screens.  
The replicates of the TP53 KO line (referred to as TP53 and TP53_2) had a greater 
correlation, with a higher overlap between the hits identified using both BAGEL and MAGeCK 
(Fig. 3.9). BAGEL detected more significantly depleted genes in both replicates, but these 
included almost all of the genes detected by MAGeCK. When the overlap of both replicates 
from both analyses were compared, 847 genes were found to be significantly depleted, in 
comparison to only 62 in the parental overlap. 
Assessing screen reproducibility  78 
 
Figure 3.8. Overlapping hits in biological replicates of the parental BOB screen. The parental BOB 
cell line was screened three times, with technical triplicate in each case. MAGeCK and BAGEL were 
applied to identify genes that were significantly depleted compared to the library plasmid. The outputs 
for all three screens were compared to find common hits. The overlapping MAGeCK hits were 
compared with the overlapping BAGEL hits to assess the correlation of the two analyses. Diagram 
created using Venny.256 
MAGeCK hits BAGEL hits
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Figure 3.9. Overlapping hits in biological replicates of TP53 KO line screen. A TP53 KO derivative 
of BOB was screened twice, with technical triplicate in both experiments. MAGeCK and BAGEL were 
applied to identify genes that were significantly depleted compared to the library plasmid. The outputs 
for both screens were compared to find common hits. The overlapping MAGeCK hits were compared 
with the overlapping BAGEL hits to assess the correlation of the two analyses. Diagram created using 
Venny.256 
 
 
 
 
 
 
 
 
 
MAGeCK hits BAGEL hits
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3.6.2 Comparison across all screens 
As all of the cell lines differed by only a single genetic change, we considered that results from 
screening different lines could also act in some way as biological replicates. Thus, we 
compared the results across all screens as another measure of reproducibility and to further 
define core fitness genes in the BOB iPSC line. We anticipated that the majority of the hits 
would be shared, however very few were identified in every screen (25 using BAGEL, 17 using 
MAGeCK) and 18% of genes were called only once (Fig. 3.10). We analysed all of the genes 
that were significant in 20-23 (out of 24) screens to determine whether specific screens 
consistently failed to identify common hits (Fig. 3.11). Using the BAGEL output, 5 screens in 
particular (ARID2_C11, PBRM1_F09, BOB_3, ARID1A_B08 and ATM_B11) consistently 
failed to detect hits that were identified by the majority of the other screens. The results were 
slightly different using the MAGeCK output, with the ARID2_C11, PBRM1_F09, BOB and 
ARID1A_C09 screens accounting for the majority of missed hits. Whilst BAGEL and 
MAGeCK differed, the results correlated well with their respective detection of known 
essentials/fitness genes. The screens that failed to detect the highest number of common hits 
also had the poorest recall (Table 3.1). In line with the previous data, this indicated that the 
screens were not highly reproducible. This limited our ability to accurately define core essential 
genes for the BOB iPSC line.  
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Figure 3.10. Frequency of significantly depleted genes across all iPSC screens. Across all screens, 
a total of 2371 genes were identified as significantly depleted by BAGEL, and 2105 by MAGeCK. 
Some of these hits were specific to one screen, but many were identified in multiple screens. These 
plots show the frequency with which genes were identified by one or more screens.  
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Figure 3.11. Detection of common gene hits in iPSC screens. Considering only genes that were 
significantly depleted in 20-23 of the iPSC screens, this plot shows the number of these genes that were 
not detected by each screen. Results are shown for both BAGEL and MAGeCK outputs.  
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3.7 Filtering for KO-specific dependencies 
Despite the variability in the data, the results were not completely inconsistent and there were 
indications that known essentials could be detected. Therefore, we decided to continue using 
these data for our primary aim of identifying SLIs. To do so, we were interested in finding 
genes that were specifically essential in the TSG KO lines but not in the parental line. To 
identify KO-specific hits, we compiled lists of genes that were significantly depleted in each 
KO line and removed any genes that were also significant in the parental. For simplicity, I will 
discuss filtering using only the BAGEL outputs, but the same could be performed on the 
MAGeCK outputs or the overlap of both. As data was obtained for 3 biological replicates of 
the parental, various strategies were possible. One approach was to remove genes that were 
hits in every parental screen, ensuring that only high confidence hits in the parental were 
discarded. Another option was to exclude all genes that came up in any of the parental screens, 
accounting for the fact that detection of some genes may have been affected by some replicates 
performing poorly. A final strategy was to filter based only on the hits from BOB_2, which 
appeared to be the highest quality screen. Table 3.3 indicates the number of KO-specific genes 
identified in each screen using all of these filtering approaches. These gene lists are provided 
in Appendix A.9.  
The screen which had the highest recall of established core fitness genes was ‘TP53’, 
closely followed by the biological replicate ‘TP53_2’ (Table 3.1). With this in mind, I have 
selected these screens to provide an example of the KO-specific gene lists. Table 3.4 shows the 
scaled BFs for the 20 top-ranking genes in the ‘TP53’ screen, excluding genes that were hits 
in any of the parental BOB screens and removing established core fitness genes. Of these, 19/20 
genes were also significantly depleted in the ‘TP53_2’ replicate screen. It has been previously 
shown that one of these genes, ATR, is synthetically lethal with TP53 (as reviewed by Qiu et 
al., 2018).257 This warrants further validation of the other genes, particularly those with a higher 
ranking, to identify novel SLIs with TP53. 
In Chapter 4 I will discuss more advanced filtering of results from screens in the 
PBAF/BAF gene KO lines, and subsequent experimental validation of these genes. 
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Table 3.3. Number of KO-specific screen hits. The scaled BFs computed by BAGELR analysis of all 
screens were used to identify significantly depleted genes (scaled BF > 0). Genes that were significantly 
depleted in all BOB screens OR in at least one BOB screen OR in the BOB_2 screen, were removed 
from the list of significant hits in each KO line screen. The number of remaining genes are shown for 
each screen, based on each filtering strategy. 
Screen Not in every BOB screen Not in any BOB screen Not in BOB_2  
TP53 1536 453 496 
TP53_2 1346 329 367 
ARID1A_C09 560 73 87 
ARID1A_B08 86 1 5 
ARID1B_C03 848 126 150 
ARID1B_G01 528 53 72 
ARID2_A11 238 5 9 
ARID2_C11 262 31 42 
PBRM1_F09 448 153 168 
PBRM1_F08 781 90 107 
FAT1 715 106 126 
APC 741 60 77 
FBXW7 436 66 81 
ATM_A12 872 93 120 
ATM_B11 41 0 1 
MAP2K4 763 86 111 
PIK3R1 330 27 38 
RB1 564 32 43 
CUX1 1260 272 308 
RASA1 1121 208 239 
B2M 1384 327 366 
 
 
 
 
 
 
 
 
 
 
 
 
Filtering for KO-specific dependencies  85 
Table 3.4. Candidate synthetic lethal partners of TP53. The scaled BFs obtained by BAGELR 
analysis of the first TP53 KO line screen were ranked from highest to lowest. The top 20 genes are 
shown, with scaled BFs noted for both biological replicates of this line.  
Gene TP53 TP53_2 
SBNO1 2.12 0.51 
HIST2H3A 2.11 2.62 
SNAP23 2.06 1.57 
HSD17B7 1.95 1.40 
RINT1 1.90 1.53 
ALDOA 1.88 1.25 
HIRA 1.88 0.68 
MED14 1.84 1.90 
DR1 1.74 0.56 
SOX2 1.73 0.54 
MRPS12 1.71 1.11 
ATR 1.67 0.36 
ALG10 1.65 -0.47 
RPP21 1.65 0.90 
MRPL23 1.62 0.34 
PRIM1 1.58 0.87 
HNRNPA1 1.54 0.36 
PRR13 1.53 1.67 
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3.8 Gene enrichment in iPSC screens 
As described previously, MAGeCK can also be applied to identify significantly enriched genes. 
Considering that we observed an enrichment of NTC gRNAs in our initial data analysis 
(Section 3.2.2), we were interested to see whether any targeted genes were also enriched. 
Eleven genes were recurrently significantly enriched in at least 50% of the screens (Fig. 3.12a) 
(all MAGeCK enrichment values are provided in Appendix A.10). Five of these encoded for 
proteins that are involved in activation of apoptotic signalling in response to DNA damage, 
including TP53. Thus, it is logical that knockout of these genes would provide a proliferative 
advantage by preventing an apoptotic response to Cas9-induced DSBs.  
 
 
Figure 3.12. Enriched genes in iPSC screens. a) MAGeCK was applied for all iPSC screens and 
enrichment scores (positive FDR values) were computed for each gene. Genes with a positive FDR 
value < 0.1 were compared across all screens. Eleven genes were significantly enriched in at least 50% 
of the screens, b) The proteins encoded by these genes were analysed using STRING258 to identify any 
interactions. Lines between the nodes indicate known/predicted interactions between proteins. Nodes 
highlighted in red are involved in apoptotic signalling pathways. 
a.
b.
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3.9 Summary 
We performed CRISPR/Cas9 KO screens in 21 iPSC lines, with 3 biological replicates of the 
parental BOB line, 2 biological replicates of the TP53 KO line and a single screen in 19 other 
KO lines. Due to an unexpected enrichment of non-targeting controls, which we attributed to 
Cas9 toxicity in the presence of targeting gRNAs, we had to remove these controls from our 
data. Initial quality control and screen performance tests produced results similar to published 
screens in cancer cell lines. However, further analysis indicated that the iPSC screens were 
highly variable and this made it difficult to confidently deduce which genes were essential for 
cell fitness. In some screens there was high recall of previously established core fitness genes, 
indicating that true positives could be identified but there was evidently a high risk of false 
negatives. Our aim was to identify genes that were specifically essential in the KO lines, and 
hence could be potential synthetic lethal partners. This variability made it challenging as there 
was a high possibility that genes identified in the KOs may be universally essential but were 
missed due to screen performance in the parental. Equally, low performance in the KO line 
screens may have led to false negatives and missed interactions. Despite this, we computed 
lists of KO-specific genes identified in each screen and hence have identified candidate SLIs. 
Results from the TP53 KO line screen included a known SLI, which provides more confidence 
to the findings. However, validation is critical for any conclusions to be drawn from these 
datasets. As an aside, we also identified genes that were recurrently enriched in the screens. 
These may be informative with regards to iPSC biology and more specifically, their response 
to the CRISPR/Cas9 screening process.  
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Chapter 4 
4 Validation of candidate synthetic lethal 
interactions with PBAF/BAF genes 
 
4.1 Introduction 
By screening parental and KO derivatives of an iPSC line, BOB, we identified a number of 
candidate synthetic lethal partners for four PBAF/BAF complex genes: ARID1A, ARID1B, 
ARID2 and PBRM1. Many of these were specific to one gene, but some overlapped in two or 
more KO lines. Several synthetic lethal partners of ARID1A have been published but the other 
genes have not been well studied (as discussed in Section 1.4.4). We initially sought to validate 
an interaction between ARID1A and ARID1B, which has been previously reported in cancer 
cell lines. We then chose a panel of genes to validate from our screens, focusing on those that 
were significant hits in at least two KO lines, as these would be more widely applicable. We 
tested these interactions in iPSCs using a competitive growth assay. Validation was also carried 
out in a cancer cell line (HAP1), as we aimed to find hits that were relevant in cancer and not 
specific to iPSCs. Further analyses were performed to identify candidate interactions using 
published cancer cell line CRISPR/Cas9 screen datasets. 
 
4.1.1 Aims of this chapter 
• To investigate whether an SLI exists between ARID1A and ARID1B in BOB iPSCs. 
• To select a gene panel for validation of candidate SLIs with PBAF/BAF genes. 
• To validate the selected panel of genes in iPSCs using a competitive growth assay. 
• To validate the selected panel of genes in HAP1 cells using a competitive growth assay. 
• To analyse cancer cell screen data for dependencies associated with PBAF/BAF 
mutations. 
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4.2 ARID1A/ARID1B synthetic lethality 
ARID1A and ARID1B are mutually exclusive subunits of the BAF complex and it has been 
reported that they have antagonistic functions.163 They are the only known DNA-binding 
proteins in the complex. It has been shown that ARID1A-deficient cancer cell lines are 
specifically vulnerable to loss of ARID1B.74,172,259 Helming et al. (2014) analysed genome-
wide loss-of-function shRNA screen data from Project Achilles to identify dependencies 
caused by ARID1A mutations in cancer cell lines.172 They identified ARID1B as one of the top 
genes essential for cell growth in mutant lines. Using ovarian cancer cell lines, they confirmed 
that depletion of ARID1B impaired proliferation and colony formation in ARID1A-mutant cells 
but not in WT cells. In the Project DRIVE study, deep shRNA screening of ~8000 genes was 
performed in 398 cancer cell lines and ARID1B was identified as a specific dependency in lines 
with inactivating ARID1A mutations.74 Some cell lines and primary tumours harbour mutations 
in both genes, but in these cases at least one allele of either gene is retained.172  
These findings suggest that in the absence of ARID1A, cells are dependent on ARID1B 
to maintain a functional BAF complex. In our iPSC screens, ARID1B was not essential in either 
ARID1A KO line (Fig. 4.1). Equally, ARID1A was not essential in either ARID1B KO line, 
although the values for ARID1A were closer to the significance thresholds than in most of the 
other screens. This indicated that there was no SLI between ARID1A and ARID1B in the BOB 
iPSC line.  
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Figure 4.1. Gene essentiality scores for ARID1A and ARID1B in iPSC screens. Scaled BFs (a) and 
MAGeCK negative FDR values (b) are shown for ARID1A and ARID1B in the 24 iPSC screens (21 cell 
lines total with 3 replicates of the parental and 2 replicates of the TP53 KO). The ARID1A values in the 
ARID1B KO lines (A1B_C03/A1B_G01), and the ARID1B values in the ARID1A KO lines 
(A1A_C09/A1A_B08), are highlighted in red. The dotted lines represent the thresholds for significance: 
using BAGELR, BFs were scaled based on an FDR of 0.05 so any value > 0 was considered significant; 
using MAGeCK, any negative FDR value < 0.1 was considered significant. Scaled BFs are detailed in 
Appendix A.6, and MAGeCK depletion values are in Appendix A.7. 
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4.2.1 Experimental validation of ARID1A/ARID1B SLI in iPSCs 
To confirm the lack of interaction observed in the screens, a fluorescence-based competition 
assay was performed. gRNAs were selected from the neoR-IRES library used for the screens, 
cloned into the Yusa v1.1 library backbone and packaged into lentiviruses (as described in 
Section 7.16.2). BOB-Cas9 cells were transduced simultaneously with two lentiviruses 
containing a gRNA targeting ARID1A and a gRNA targeting ARID1B (as described in Section 
7.16.3.1). As a control, each of these targeting gRNAs was also transduced alongside a gRNA 
targeting AIPL1 or ACCSL. These genes were chosen as neither had a significant effect in the 
genome-wide screens. ARID1A and AIPL1 gRNAs were cloned into a version of the backbone 
expressing BFP; ARID1B and ACCSL were cloned into in a backbone expressing mCherry. 
Cells were transduced at an MOI that generated four populations: untransduced, BFP positive, 
mCherry positive, and double positive. By measuring the abundance of each population at day 
2 and day 14 post-transduction, any growth effects caused by the gRNAs could be assessed. 
The relative abundance of each population was calculated by normalising against the 
untransduced population. To assign a value for the growth phenotype, the log2(fold-change) of 
relative abundance was calculated between day 14 and day 2.  The expected growth phenotype 
of knocking out two genes that do not interact was calculated as the sum of the phenotype of 
both single knockouts (based on the principles of the Bliss independence model260). If the genes 
were synthetic lethal, the double KO should have had a more negative growth phenotype than 
this expected value. All single gRNAs caused a negative growth phenotype, likely due to cell 
toxicity as a result of Cas9-induced double-strand breaks (Fig. 4.2). There was no significant 
difference between the observed and expected phenotypes for any of the control double KOs 
(ARID1A+AIPL1, ARID1B+ACCSL, AIPL1+ACCSL). However, there was also no significant 
effect when the ARID1A and ARID1B targeting gRNAs were combined, supporting the results 
of the screens. 
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Figure 4.2. Validation of ARID1A/ARID1B SLI using a double gRNA strategy. BOB-Cas9 cells 
were transduced with two gRNA lentiviruses simultaneously (one expressing BFP, one expressing 
mCherry) to give four populations. Cells were analysed by flow cytometry on day 2 and day 14. To 
calculate the growth phenotype, the % of the single and double positive populations were normalised 
against the untransduced population (relative abundance), and the log2(fold-change) in relative 
abundance was calculated between day 14 and day 2. The growth phenotypes of gRNA X, gRNA Y 
and gRNA X+Y (expected (sum of X + Y phenotypes) and observed) are shown. This assay was 
performed in technical duplicate. Error bars show standard deviation. P-values were calculated using a 
two-tailed paired t-test. ARID1A = A1A, ARID1B = A1B, AIPL1 = AIP, ACCSL = ACC. 
 
We considered the possibility that this SLI may depend on the cells adapting to either ARID1A 
or ARID1B depletion over a longer period, rather than loss of both genes being induced 
simultaneously. Thus, we performed a similar assay using the parental BOB-Cas9 line (WT), 
one of the ARID1A KO iPSC lines (ARID1A_C09-Cas9) and one of the ARID1B KO iPSC 
lines (ARID1B_C03-Cas9) (as described in Section 7.16.3.2). The BFP- and mCherry-
expressing gRNA lentiviruses prepared in the previous assay were used. Rather than 
transducing two gRNAs simultaneously, the WT and KO lines were transduced in parallel, 
with a single control or targeting gRNA (Fig. 4.3).  
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Figure 4.3. Strategy for single gRNA SLI validation. WT and KO stable Cas9 cells were transduced 
with a lentivirus expressing a gRNA and a BFP or mCherry marker. Expression was measured by flow 
cytometry on day 2 and day 14. Three outcomes were possible: if the gRNA targeted a nonessential 
gene, fluorescence would remain stable in the WT and KO; if the gRNA targeted an essential gene, 
cells would die and fluorescence would drop in the WT and KO; if the gRNA targeted a synthetic lethal 
partner of the KO gene, fluorescence would drop in the KO line but remain stable in the WT. 
 
BOB-Cas9 cells were transduced with the ARID1A, ARID1B and AIPL1 gRNAs. 
ARID1A_C09-Cas9 cells were transduced with the ARID1B and AIPL1 gRNAs, and 
ARID1B_C03-Cas9 cells with the ARID1A and AIPL1 gRNAs. BFP/mCherry expression was 
measured on day 2 and day 14. The log2(fold-change) in expression was calculated between 
the two timepoints. Similar to the previous assay, a decrease in expression was observed with 
each gRNA in all lines (Fig. 4.4). The KO lines had a larger decrease than WT but the 
differences were not statistically significant, and a difference was also observed with the 
control AIPL1 gRNA. We did not test the expression of ARID1A or ARID1B in these validation 
assays to confirm that the knockout was functional. The data obtained here suggests that loss 
of ARID1A and ARID1B is not synthetic lethal in BOB iPSCs, but confirmation of protein loss 
would be required to confirm this. Further experiments could also be carried out using different 
gRNAs, alternative assays or technologies such as si/shRNA. 
WT KO
nonessential essential synthetic lethal
+ gRNA
WT KO WT KO WT KO
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Figure 4.4. Validation of ARID1A/ARID1B SLI using a single gRNA strategy. WT BOB-Cas9, 
ARID1A_C09-Cas9 and ARID1B_C03-Cas9 were transduced with lentiviral gRNAs targeting AIPL1 
(BFP-tagged), ARID1A (BFP-tagged) and ARID1B (mCherry-tagged). All gRNAs were transduced in 
separate wells. BFP/mCherry expression was measured on day 2 and day 14. The log2(fold-change) in 
expression between the two timepoints was calculated. Error bars show standard deviation. P-values 
were calculated using a two-tailed unpaired t-test using Welch’s correction.  
 
4.2.2 ARID1A/ARID1B interaction in cancer cell lines 
The ARID1A/ARID1B interaction was originally identified through analysis of shRNA screen 
data.172 With a vast amount of CRISPR/Cas9 genome-wide screen data now available, we 
performed similar analyses to determine whether the interaction could be identified in cancer 
cell line datasets. Colleagues at the Sanger Institute screened 324 cancer cell lines using the 
Yusa v1.1 gRNA library.109 The same pipeline (CRISPRcleanR and BAGELR) was used to 
process raw data from 342 cancer cell lines screened at the Broad Institute using the Avana 
gRNA library.261 This processing was performed by Clare Pacini, a postdoctoral fellow in 
Francesco Iorio’s group at WSI. These datasets included cell lines carrying LOF mutations 
(frameshift indel or nonsense) in ARID1A, ARID1B, ARID2 and PBRM1 (Table 4.1). The 
scaled BFs for ARID1B across all screens in each dataset were separated into two groups: 
ARID1A WT and ARID1A mutant cell lines (Fig. 4.5a-b). If the scaled BF was > 0, ARID1B 
was considered to be essential; the outcome for each cell line was categorised as ‘essential’ or 
‘nonessential’. 
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Table 4.1. PBAF/BAF mutant cell lines screened by the Sanger/Broad Institute. The number of 
screened cancer cell lines containing frameshift indels or nonsense mutations in ARID1A, ARID1B, 
PBRM1 and ARID2 is indicated. The number of cell lines that were screened by both institutes is 
indicated. The names of all lines are detailed in Appendix A.11. 
 ARID1A mut ARID1B mut PBRM1 mut ARID2 mut 
Sanger Institute 33 11 8 14 
Broad Institute 44 14 14 8 
Overlapping lines 17 7 3 2 
 
A Fisher’s exact test was then applied to determine whether there was an enrichment for 
ARID1B essentiality in the ARID1A-mutant cell lines (Fig. 4.5c-d). Benjamini-Hochberg 
correction was applied to correct for multiple testing. The same process was repeated for 
ARID1A essentiality in ARID1B-mutant lines (Fig. 4.6). ARID1B was essential in a statistically 
significant number of ARID1A-mutant lines in both datasets (Sanger adjusted p-value = 0.0486, 
Broad adjusted p-value 0.000029). Conversely, ARID1B-mutant lines were not significantly 
enriched for ARID1A essentiality in either dataset (adjusted p-values = 1).  
This inconsistency could be due to both groups screening approximately 3-fold more 
ARID1A-mutant cell lines. However, even without statistical significance, there appears to be 
no trend towards enrichment in the ARID1B mutants. Another possibility is that the ARID1A-
targeting gRNAs in both libraries had low efficacy and the gene was not depleted, but further 
investigation would be needed to confirm this. LOF mutations in both ARID1A and ARID1B 
were present in 6 of the cell lines screened by Sanger and 9 lines screened by Broad. We 
considered the possibility that these double mutants may have adapted to loss of both proteins 
and so targeting of either gene would have no effect i.e. the genes would not be synthetic lethal. 
If true, this would leave only 5 ARID1B lines in each dataset that could be reliably analysed 
for ARID1A dependency. However, some double mutants (2/6 in Sanger, 3/9 in Broad) were 
sensitive to ARID1B depletion, suggesting that synthetic lethality can still occur in these lines. 
In support of this, it is interesting to note that no other studies have demonstrated a dependency 
on ARID1A in ARID1B-mutant cells.  
 To understand this potential inconsistency in synthetic lethality between ARID1A and 
ARID1B, it is important to consider the similarities and differences between the subunits. The 
exact roles of ARID1A and ARID1B in tumourigenesis are still unclear, as are the reasons for 
the difference in mutation rate of these genes and the cancer types that they are associated with. 
ARID1A and ARID1B have been shown to have similar DNA binding affinities262 and both 
bind in a non-sequence-specific manner.162 ARID1A and ARID1B expression vary during cell 
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cycle progression, with accumulation of ARID1A during the G0/G1 phase but constant 
expression of ARID1B throughout.263 Various studies have investigated the effects of these 
subunits on transcription, although more focus has generally been placed on ARID1A. 
 A recent study found that knockout of ARID1A in HCT116 colorectal cancer cells had 
a large impact on chromatin state across the genome, with increased or decreased accessibility 
at thousands of sites.264 Interestingly, knockdown of ARID1B had no effect in wildtype cells 
but caused changes at hundreds of sites in cells that had also lost ARID1A. ARID1A was more 
abundant than ARID1B in HCT116 cells which might explain the difference, as wildtype cells 
may have more BAF complexes containing ARID1A. No change in ARID1B expression levels 
was observed in the ARID1A knockout cells, suggesting that the effect was not due to 
compensatory upregulation of ARID1B. Decreased accessibility after ARID1A and ARID1B 
loss was more common, implying that these proteins predominantly function to maintain open 
chromatin. Accessible sites that appeared to be ARID1A/1B-dependent were primarily located 
in enhancers rather than promoters. A study in OCCC cells found that loss of ARID1A causes 
repression of RNA polymerase II transcription as a result of impaired polymerase pausing.265 
This effect appeared to be greater than the impact on chromatin accessibility in these cells. 
Upregulation of ARID1B occurred to compensate for this, but transcription of some genes was 
specifically dependent on ARID1A and could not be rescued. Many of the genes that were 
dependent on ARID1A were also targets of p53. Raab et al. (2015) mapped the localisation of 
complexes containing ARID1A, ARID1B and ARID2 in HepG2 cells.266 There was a high 
level of overlap between the regulatory sites bound by each of these subunits. This study also 
investigated the interactions between the subunits. Hundreds of genes were found to be 
cooperatively repressed by both ARID1B and ARID2. Competitive interactions were also 
identified, with ARID1A activating genes that are repressed by ARID2/ARID1B.  
 It is evident that these subunits have both overlapping and independent roles in 
regulating transcription. It is likely that the effects of loss of either subunit will be largely 
dependent on the predominant subunit composition in a given cell type. The functional studies 
have largely been performed in a single cell type; repetition across multiple lines would be 
valuable to determine whether the function of these subunits varies with cell type. Gaining 
more insight into the functional relationships between different PBAF/BAF complexes is vital 
to understanding the synthetic lethal interactions between subunits. It is difficult to speculate 
why ARID1A mutants may be more dependent on ARID1B than ARID1B mutants are on 
ARID1A. It may be logical to assume that if a cell has BAF complexes predominantly 
composed of ARID1A, a mutation in ARID1B would not be tumourigenic, and vice versa. 
ARID1A/ARID1B synthetic lethality  97 
Therefore, all ARID1A-mutant cell types may have originally been composed of ARID1A-BAF 
complexes and ARID1B-mutants composed of ARID1B-BAF complexes. If true, these 
different compositions may cause variation in the functional dynamics between complexes and 
could explain the potential unidirectional synthetic lethality. Given the cooperation identified 
between ARID1B and ARID2266, it is possible that cells originally driven by ARID1B-BAF 
complexes compensate for ARID1B loss by upregulating PBAF complexes containing ARID2. 
Conversely, cell types that predominantly carried ARID1A-BAF complexes may primarily 
default to using ARID1B for compensation. Investigating the subunit composition in lines that 
have existing mutations in each gene would be the first step in understanding these differences. 
Analysis of additional data such as RNAseq and proteomics could also be used to elucidate 
any common alterations in ARID1B-mutant lines that differ from ARID1A mutants. 
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Figure 4.5. ARID1B essentiality in ARID1A-mutant cancer cell lines. BAGELR was used to process 
data from 324 cancer cell lines screened by the Sanger Institute and 342 lines screened by the Broad 
Institute. Cell lines were grouped into ARID1A mutant (lines containing a frameshift indel or nonsense 
mutation in ARID1A) or ARID1A WT (all other lines). Scaled BFs for ARID1B were calculated in both 
the Sanger (a) and Broad (b) datasets. A Fisher’s test was applied to compare the number of WT and 
mutant lines where ARID1B was essential or nonessential in the Sanger (c) and Broad (d) datasets. 
Adjusted p-values were calculated using Benjamini-Hochberg correction for multiple testing. Scaled 
BFs for the Sanger screens are detailed in Appendix A.12, and for the Broad screens in Appendix A.13. 
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Figure 4.6. ARID1A essentiality in ARID1B-mutant cancer cell lines. BAGELR was used to process 
data from 324 cancer cell lines screened by the Sanger Institute and 342 lines screened by the Broad 
Institute. Cell lines were grouped into ARID1B mutant (lines containing a frameshift indel or nonsense 
mutation in ARID1B) or ARID1B WT (all other lines). Scaled BFs for ARID1A were calculated in both 
the Sanger (a) and Broad (b) datasets. A Fisher’s test was applied to compare the number of WT and 
mutant lines where ARID1A was essential or nonessential in the Sanger (c) and Broad (d) datasets. 
Adjusted p-values were calculated using Benjamini-Hochberg correction for multiple testing. Scaled 
BFs for the Sanger screens are detailed in Appendix A.12, and for the Broad screens in Appendix A.13. 
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4.3 Selection of candidate SLIs for validation 
Although the interaction between ARID1A and ARID1B was not observed in our screens, there 
were other genes that appeared to be specifically depleted in the PBAF/BAF gene KO lines. 
For each subunit, we selected several candidate synthetic lethal partners to validate. At the 
point of validation, we had prioritised analysis using BAGELR and candidate genes were 
chosen using this dataset. Four criteria were set for filtering hits: 
 1. The gene must not be essential in the parental BOB screen. 
 2. The gene must be essential in at least two of the KO screens. 
3. The gene must not be significantly essential in more than two of the six unrelated  
        KO screens (APC, ATM, TP53, RB1, FAT1, FBXW7 knockout BOB lines). 
4. The gene must not be a core fitness gene, as annotated by Behan et al. (2019) using  
                cancer cell line screen data. 
 
At this stage we did not have replicate screen data for the parental line. Therefore, criteria (3) 
was used to filter out genes that may be essential in this cell line background but were missed 
in the first parental BOB screen. This was based on the assumption that it was unlikely for a 
gene to also have a synthetic lethal interaction with 3+ other genes that are not involved in the 
PBAF/BAF complexes. These KO lines were chosen because, at the time of validation, these 
were the only screens that we had data for. This filtering strategy produced a candidate list of 
66 genes (Fig. 4.7, Appendix A.14). 
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Figure 4.7. Filtering of PBAF/BAF gene SLIs for validation. All genes with a scaled BF > 0 were 
noted for ARID1A_C09 (A1A), ARID1B_C03 (A1B), ARID2_C11 (A2), and PBRM1_F09 (PBR). 
These went through four filtering steps. (1) Any genes that also had a scaled BF > 0 in the parental 
BOB screen were removed. (2) The lists were overlapped and any genes that were present in only one 
of the four lines were removed. (3) Any genes with a scaled BF > 0 in more than 2 of the APC, ATM, 
TP53, RB1, FAT1, FBXW7 KO line screens were removed. (4) Any gene that was called as a core fitness 
gene in the Behan et al. study109 was removed. The final gene list is provided in Appendix A.14. 
 
4.3.1 Gene enrichment analysis of candidate genes 
To explore whether the list of 66 candidate genes shared common features, a gene enrichment 
analysis was performed based on various parameters using Enrichr.267,268 We tested for 
enrichment of ontologies (GO Biological Process and GO Molecular Function, Table 4.2) and 
pathways (WikiPathways, Reactome, Table 4.3). For ontologies, there was one significant 
enrichment observed and this was for genes that were annotated to have a role in RNA binding 
(Table 4.2). Several pathway annotations were significantly enriched in the gene set, mainly 
related to DNA damage response and roles in the cell cycle (Table 4.3), but few genes 
contributed to these enrichments.  
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Table 4.2. Gene set enrichment analysis: ontologies. Top 15 results, ranked by p-value, based on 
‘GO Biological Process 2018’ and ‘GO Molecular Function 2018’ annotations. Analysis performed 
using Enrichr.267,268 
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Table 4.3. Gene set enrichment analysis: pathways. Top 15 results, ranked by p-value, based on 
‘WikiPathways 2019’ and ‘Reactome 2016’ annotations. Analysis performed using Enrichr.267,268 
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4.4 Validation of screen hits in iPS cells 
From this filtered list of 66 genes, we selected 20 genes to experimentally validate in the 
screened iPSC lines. The previously described single gRNA competitive growth assay was 
used for validation (Fig. 4.3). For each candidate gene, a gRNA from an independent library 
(i.e. different to those used in the screen) was selected (Appendix A.1, Section 7.16.4). All 
gRNAs were obtained from the Sanger Human Whole Genome CRISPR arrayed library, which 
uses a backbone that expresses a BFP marker.103 A gRNA targeting THAP3 was chosen as a 
negative control as this gene had a low scaled BF across all screens. A gRNA targeting 
TWISTNB was chosen as a positive control as this gene was consistently significant across the 
screens. gRNAs were packaged into lentiviruses and cells were transduced with each gRNA 
individually in 6-well plates (as described in Section 7.16.5). Parental BOB (WT) cells were 
transduced with all gRNAs; KO lines were transduced only with gRNAs targeting genes that 
were hits in the respective screen (Table 4.4). 
Cells were passaged on day 2 and some cells were fixed for analysis of BFP expression 
by flow cytometry. Transduction was successful, with a high % of BFP (average ~85%) in all 
conditions. Some cell death was observed which was likely due to initial toxicity induced by 
the Cas9 cutting. After 5 days, cells were passaged again. Further cell death had occurred in 
some conditions, suggesting that gRNAs were having an effect, so the split ratio was altered 
for each well accordingly. However, very few cells survived this passage across all conditions. 
This assay was repeated several times, varying density and trying to limit the stress to the cells 
during passaging, but the same issue occurred. The level of cell death appeared to be variable, 
with no clear trend to suggest that KO lines were more susceptible than the WT. Cells carrying 
the negative control gRNA were also affected. Due to unforeseen issues with the iPSC medium 
and time restrictions, we were unable to progress further with this validation.  
The transduction levels were high so the first step would be to repeat this assay with 
less lentivirus in an attempt to improve cell survival. The backbone used in this assay contained 
a piggyBac transposon, so transfection of the plasmids with a transposase could be trialled as 
an alternative to lentiviral transduction. The toxicity may have been caused by Cas9-induced 
DSBs; this effect has been observed previously but not to the extent seen here. It was surprising 
that toxicity related to the lentivirus or Cas9-cutting occurred at this later stage. It would be 
expected that these effects would occur in the days immediately after transduction. However, 
the cells that survived the first passage may have had impaired fitness but were able to continue 
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proliferating until the stress of the next passage. An alternative targeting method such as 
si/shRNA could be used to validate the candidates, removing the complication of DSB toxicity. 
We must consider the possibility that all of the genes chosen were in fact essential in 
the WT and KO lines, hence the universal cell death. In support of this, 37/66 of the filtered 
genes were significantly depleted in a repeat screen of the parental BOB line (data obtained 
after validation experiments). These included 12 of the 20 genes chosen for validation 
(indicated by an * in Table 4.4). Although this does not explain the toxicity observed for the 
other 8 genes and the negative control, it does indicate that there was a lot of noise in the screen 
data which may affect validation rates. Repeating the assay in the ways discussed here should 
elucidate whether the issue was technical or due to false positives.  
 
Table 4.4. Genes selected for SLI validation. Each gene selected for validation was assigned an ID 
number. The KO lines in which they were tested are indicated. * indicates genes that were found to be 
significantly depleted in the second screen of parental BOB cells. 
Gene gRNA ID KO lines 
THAP3 1 Positive control, all lines 
PDPR* 2 ARID1A + ARID2 
TWISTNB 3 Negative control, all lines 
SLC9B1 4 ARID2 + PBRM1 
MRPL17 5 ARID1A + ARID1B + PBRM1 
RHOA 6 ARID1A + ARID1B 
AK4* 7 ARID1B + ARID2 
HMGB1* 8 ARID1B + PBRM1 
BTBD7* 9 ARID1A + ARID1B + ARID2 
COIL* 10 ARID1A + ARID1B 
PARN 11 ARID1B + PBRM1 
DGCR8* 12 ARID1A + ARID1B 
KRT86 13 ARID1B+ARID2+PBRM1 
CCAR1* 14 ARID2 + PBRM1 
OTUB1* 15 ARID1A + ARID1B 
WDR25* 16 ARID1A + ARID2 
OBP2B* 17 ARID1A + ARID1B 
ATP5G2 18 ARID1A + ARID1B 
ACIN1* 19 ARID1A + ARID1B 
ADH5* 20 ARID1B + PBRM1 
ZRSR2 21 ARID1A + ARID1B 
KRTAP4-8 22 ARID1B + PBRM1 
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4.5 Validation of screen hits in HAP1 cells 
The aim of this project was to find SLIs that could be exploited to treat cancer and so it was 
important to confirm that any interactions we identified were not specific to iPSCs. Therefore, 
in parallel to validation in BOB iPSCs, we also performed validation in a cancer cell line. 
HAP1 is a near-haploid adherent human cell line derived from KBM7, a male chronic 
myelogenous leukaemia line.269 The advantage of using haploid cells for gene editing 
experiments is that they only have one copy of each gene, and so LOF mutations can be 
introduced more efficiently. Also, isogenic KO derivatives of HAP1 are commercially 
available. Considering these factors, we chose to validate our iPSC screen hits in HAP1 cells, 
using parental and ARID1A/ARID1B/ARID2/PBRM1 KO derivatives. HAP1 cells were 
purchased from Horizon; PCR and Sanger sequencing were performed to confirm that the 
correct mutations were present in each line (Fig. 4.8) (as described in Section 7.16.1 and 7.4). 
Stable Cas9 lines were engineered and a Cas9 activity test was performed after blasticidin 
selection, confirming that all lines had high activity (Fig. 4.9) (as described in Section 7.10). 
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Figure 4.8. Genotypes of PBAF/BAF knockout HAP1 lines. PCR and Sanger sequencing were 
performed on the edited region in ARID1A, ARID1B, ARID2 and PBRM1 KO HAP1 cell lines. For each 
gene, WT HAP1 cells were also sequenced for comparison. The red areas indicate frameshift deletions. 
Primers used for genotyping are detailed in Appendix A.1. 
WT HAP1
ARID1A KO
WT HAP1
ARID2 KO
WT HAP1
ARID1B KO
WT HAP1
PBRM1 KO
13 bp
13 bp
7 bp
8 bp
Validation of screen hits in HAP1 cells  108 
 
Figure 4.9. Cas9 activity in HAP1 cell lines. After blasticidin selection, Cas9-expressing WT and KO 
HAP1 cells were transduced with a control vector (BFP/GFP) or a reporter vector (BFP/GFP/gGFP). 
Fluorescence was measured by flow cytometry at 3 days post-transduction. (a) Untransduced cells and 
cells transduced with the control vector were used to gate for expression of BFP and GFP. Plots are 
shown for the WT HAP1-Cas9 line, (b) Cas9 activity was calculated as the percentage of BFP positive 
cells divided by the percentage of total cells transduced with the reporter vector (i.e. BFP+(BFP/GFP)). 
 
4.5.1 Competition assay in HAP1 cells 
In parallel with validation in iPSCs, the fluorescence-based competition assay was also 
performed in the HAP1 cell lines using the same gRNAs (as described in Section 4.4 and 
7.15.4-5). WT and KO HAP1 cell lines were transduced with a single gRNA per well in a 12-
well plate. As with the iPSC validation, WT cells were transduced with all gRNAs and each 
KO line was transduced only with the genes that were hits in the respective KO iPSC screen 
(Table 4.4). Passaging and analysis of BFP expression were performed on day 2. Unlike the 
iPSCs, HAP1 cells survived after further passaging and were maintained until day 14 post-
transduction. Some cell death was observed but this was minimal in comparison to the iPSCs, 
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indicating that HAP1 cells were not as sensitive to Cas9-induced DSBs. BFP expression was 
analysed again on day 14 and the log2(fold-change) in expression between both timepoints was 
calculated (Fig. 4.10). Many of the gRNAs had no effect in either the WT or KO lines. Some 
conditions had a greater loss of BFP expression in the KO compared to WT (ATP5G2 and 
ZRSR2 in ARID1A KO; MRPL17 in ARID1B KO; THAP3 and TWISTNB in ARID2 KO; 
THAP3, TWISTNB and KRTAP4-8 in PBRM1 KO). Further replicates are needed to determine 
any statistical significance for these differences. In many conditions, a larger reduction in 
expression was observed in the WT compared to the KOs. Some of these results were 
substantial and were observed in multiple KOs (particularly gRNAs 13 and 16).  
This was unexpected and there are a number of ways that this could be interpreted. Loss 
of PBAF/BAF subunits may make HAP1 cells less dependent on these genes, although in most 
cases a negative phenotype was also observed in the KO, albeit much less prominent. Genome 
editing may be less efficient in the KO lines, resulting in fewer cells losing expression of the 
targeted gene. Further investigation and repetition of the assay would be needed before any 
conclusions can be made regarding interactions between these genes. If it was confirmed that 
the WT cells are more susceptible to gRNA activity in general, then the differences between 
effects in WT and KO may be more substantial than they appeared in this assay. Initial focus 
for follow-up should be placed on those genes that induced a more negative phenotype in the 
KO line. It would also be essential to repeat this with different gRNAs, or use an alternative 
strategy such as shRNA, to confirm that the phenotype was caused by depletion of a given gene 
and not due to an off-target effect. 
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Figure 4.10. Validation of candidate SLIs in HAP1 cells. WT and KO HAP1 Cas9 cells were 
transduced with a single BFP-expressing gRNA lentivirus per well in a 12-well plate. BFP expression 
was analysed by flow cytometry on day 2 and day 14 post-transduction. The log2(fold-change) in 
expression between the two timepoints was calculated. Plots show the log2(fold-changes) measured in 
each KO line, with results for each gRNA tested in that line; the corresponding results in the WT line 
are plotted for comparison. Due to technical issues, no data was obtained for gRNAs 7 or 8 in any lines, 
or gRNA 17 in the ARID2 KO. 
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4.6 Further analyses to identify candidate SLIs 
4.6.1 Re-analysis of PBAF/BAF SLIs using additional iPSC screen data 
As stated previously, the genes for validation were chosen before all of the iPSC screens were 
completed, including two additional replicates of the parental line and an independent KO line 
for each PBAF/BAF gene. We performed further analysis to determine how the results changed 
with the inclusion of this new data (Fig. 4.11). We initially removed any gene that had a scaled 
BF > 0 in at least one of the three BOB screens. One of these screens, BOB_2, had an improved 
performance compared to the other two and resulted in exclusion of many more genes. As 
discussed in Section 3.7, there are various other ways that the parental screen data could be 
used to filter for KO-specific dependencies. 
 
 
Figure 4.11. Filtering of PBAF/BAF gene SLIs using additional data. All genes with a scaled BF  
>0 were noted for ARID1A_C09/B08, ARID1B_C03/G01, ARID2_C11/A11, and PBRM1_F09/F08. 
These went through four filtering steps. (1) Genes that also had a scaled BF > 0 in any of the three 
parental BOB screens were removed. (2) Genes that were a hit only in one of the KO clones for each 
subunit were removed. (3) Any gene that was considered to be a core fitness gene in the Behan et al. 
study109 was removed. (4) The remaining genes were cross-referenced to identify hits common to more 
than one subunit. 
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375 genes remained that were significant in at least one PBAF/BAF line. The majority (297) 
of these were specific to one subunit. We then filtered for genes that were hits in both knockout 
clones of a PBAF/BAF subunit, removing genes previously annotated as core fitness: 11 genes 
were significant in both ARID1B clones; 12 were significant in both PBRM1 clones; none were 
significant in both ARID1A or ARID2 clones. Only 2 genes (KRT86 and KCMF1) were 
significant in both knockouts of more than one PBAF/BAF subunit. These data can be filtered 
in many ways by altering various parameters, but one would assume that the most reliable hits 
are those that are supported by more than one knockout clone. Experimental validation of 
candidates from different filtering methods can be used to determine the most robust way of 
analysing the data.  KRT86 was a hit in both ARID1B and PBRM1 knockout clones, and in one 
knockout clone of ARID1A and ARID2. KRT86 encodes a type II keratin protein, involved in 
the formation of hair and nails. There are no known alternative roles for this protein and so it 
is unclear why loss of this gene would be synthetic lethal with the PBAF/BAF genes. KCMF1 
was also a hit in both ARID1B and PBRM1 knockout clones, and in one of the ARID2 knockout 
clones. Potassium channel modulatory factor 1 (KCMF1) is a poorly characterised E3 ubiquitin 
ligase. Upregulation of the protein in gastric cancer has been linked to fibroblast growth factor 
signalling pathways.270 KCMF1 has also been reported to play a pro-oncogenic role in 
pancreatic cancer271 and knockdown was associated with reduced cell proliferation and colony 
formation in colon cancer stem cells.272 The lack of literature regarding its function makes it 
difficult to speculate on the mechanism of synthetic lethality with the PBAF/BAF genes but 
given its association with several cancers, KCMF1 may be a more interesting candidate to 
investigate further. 
 
4.6.2 Dependencies associated with PBAF/BAF mutation in cancer cells 
As discussed in Section 1.4.4, few synthetic lethal partners of ARID1A, ARID1B, ARID2 and 
PBRM1 have been robustly established in cancer cells. We performed further analyses of the 
Sanger and Broad CRISPR/Cas9 screen datasets to determine whether any additional 
interactions could be identified, and to cross-reference these with the iPSC screen data. As 
described in Section 4.2.2, lines were separated into WT and mutants, based on LOF mutation 
status in ARID1A, ARID1B, ARID2 or PBRM1. Genes were categorised as ‘essential’ or 
‘nonessential’ based on the scaled BF. For each subunit, a Fisher’s test was applied for all 
genes to identify any that were essential in a significantly greater number of mutant lines 
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compared to WT. Benjamini-Hochberg correction was used to correct for multiple testing, and 
each gene was assigned an adjusted p-value.  
No genes were enriched in the ARID1B, ARID2 or PBRM1 mutant lines in either 
dataset. In addition to the previously identified enrichment for ARID1B essentiality in the 
ARID1A mutants (Section 4.2.2), WRN was also significantly enriched in both datasets (Sanger 
adjusted p-value = 2.23x10-9, Broad adjusted p-value = 0.0025). RPL22L1 was significant in 
the Sanger screens (adjusted p-value = 0.0015) but not in the Broad screens, after the multiple 
testing correction (p-value = 0.0006, adjusted p-value = 1). Neither of these genes were 
identified in the iPSC screens. 
 It has been shown that dependency on WRN is highly associated with microsatellite 
instability (MSI) status109,125. In the Sanger dataset, 27/324 lines were MSI-high; 18 of these 
were ARID1A mutants and 15/18 had a WRN dependency. Considering this, the association 
between ARID1A and WRN could be an artefact caused by the enrichment of MSI-high status 
in ARID1A mutants. Indeed, when MSI-high ARID1A mutants were removed, there was no 
significant association between ARID1A mutation status and WRN essentiality.  
 We cannot assume from these analyses that no SLIs occur with the PBAF/BAF genes, 
especially considering that other dependencies in ARID1A mutants have been published. The 
small sample size available for these mutants is likely a limiting factor. It is also possible that 
many dependencies may be specific to a few cell lines or subtypes, and so cannot be identified 
in such a broad dataset.  
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4.7 Summary 
Based on data from screening BOB iPSCs that were knockout for ARID1A, ARID1B, ARID2 
or PBRM1, we attempted to validate genes that were specifically essential in the KO lines but 
not in the parental line. We initially sought to validate an interaction between ARID1A/ARID1B 
that was previously identified in cancer cell lines. Our preliminary data suggests that loss of 
these genes is not synthetic lethal in BOB cells. Analysis of CRISPR/Cas9 screen data from 
two large cancer cell line studies also indicated that the interaction may be uni-directional, with 
an apparent lack of dependency on ARID1A in ARID1B-mutant lines. Further investigation 
would be required to confirm and characterise this.  
 We selected a list of candidate SLIs to validate in both iPSCs and a cancer cell line, 
HAP1. We were unable to complete validation in the iPSCs; this may be because the candidates 
were false positive hits, but technical issues made it difficult to make any conclusions so further 
experiments are required. Validation assays in the HAP1 cells produced unexpected results, 
with the WT line appearing to be more dependent on many genes than the PBAF/BAF gene 
KO lines. Several candidates did appear to be more essential in the KO lines and warrant further 
investigation. HAP1 cells were chosen as a model to ensure that any SLIs that we identified 
were not specific to iPSCs. However, it may be more informative to validate SLIs in a large 
panel of cancer cell lines, with particular focus on those that have existing mutations in the 
PBAF/BAF genes as these are most clinically relevant. As demonstrated by the 
ARID1A/ARID1B data, SLIs are not consistently observed in every mutant cell line, thus 
finding the right context for validation may be challenging. 
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Chapter 5 
5 Discussion and future directions 
5.1 Summary of findings 
In this project, we performed genome-wide CRISPR/Cas9 knockout screens in a panel of 
isogenic iPSCs with the aim of identifying novel synthetic lethal partners of 15 tumour 
suppressor genes. We engineered a panel of iPSC lines that each had LOF in a single TSG, 
prepared a genome-wide gRNA library suitable for screening in these cells and optimised a 
protocol to do so (discussed in Chapter 2). We screened the parental iPSC line and 21 KO lines. 
Analysis of the data revealed that whilst known fitness genes could be identified, the outputs 
were highly variable, even in replicates of the same cell line (discussed in Chapter 3). It was 
evident that this variability was likely caused by Cas9-induced toxicity, as a result of DSB 
formation. Despite this, we performed further analysis to identify candidate synthetic lethal 
partners of each TSG. Focusing on four TSGs that were members of the PBAF/BAF complex, 
we then attempted to experimentally validate hits from the screens (discussed in Chapter 4). 
Due to experimental issues, we were unable to complete validation in iPSCs but preliminary 
results in an independent cancer cell line highlighted several candidates for further study. We 
also analysed published cancer cell line screen datasets to identify potential SLIs involving the 
PBAF/BAF genes but found no novel significant associations. 
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5.2 CRISPR/Cas9 screening in iPSCs 
5.2.1 Comparison with published stem cell screens 
In the last 18 months, three groups have published genome-wide screens in hESCs,238-240 but 
no iPSC screens have been published. Due to the lack of available literature at the start of this 
project, we did not anticipate the challenges that arose during iPSC screening. However, it is 
evident from these recent publications that the issues we faced were not specific to this project. 
In each of these studies, screens were performed with different lentiviral genome-wide gRNA 
libraries.238-240 There were various other experimental differences which may influence the 
comparability of these studies, such as the substrate used to culture the cells, the Cas9 system 
and the library coverage (Table 5.1). Mair et al. (2019) repeated screening in the same cells 
using two different culture systems (mouse embryonic fibroblast feeder cells (MEFs) and 
laminin) and found that the results differed considerably. This highlights the fact that culture 
conditions can influence the identification of genes required for cell fitness, emphasising the 
need for cross-validation of results from CRISPR/Cas9 screens.  
 
Table 5.1. Comparison of stem cell screens. 
Study Cell line 
Culture 
substrate Cas9 system 
Target library 
coverage 
This project BOB, human iPSC line Vitronectin Constitutive Cas9 ~150x 
Yilmaz et al. 
(2018) 
h-pES10, haploid 
hESC line 
MEFs Delivered in same 
vector as gRNAs 
~700x 
Mair et al. (2019) H1, hESC line 
MEFs and 
laminin Inducible Cas9 ~400 
Ihry et al. (2019) H1, hESC line Vitronectin Inducible Cas9 ~100x 
 
The outputs of these screens were analysed using similar but not directly comparable systems. 
To allow for comparison, Mair et al. (2019) re-processed the results from the other studies to 
match their analysis and calculated Bayes Factors for each gene. They assessed the overlap 
across all screens. Additionally, they considered the overlap with 1580 core fitness genes 
previously established by Hart et al. (2015) using CRISPR/Cas9 knockout screens in 
immortalised cell lines. Excluding these core fitness genes, a total of 36 genes were found to 
be essential for cell fitness in all of the stem cell screens. By cross-referencing these with genes 
that were significantly depleted in any of our three BOB screen replicates (based on BAGELR 
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analysis), 17 genes were common to our iPSC line and the hESC lines (Table B.1, Appendix 
B). As discussed in Section 3.3.1, BAGELR varies slightly from the original BAGEL and so 
re-processing of either our data or the published datasets may allow a more direct comparison 
and could increase this overlap. It is reassuring that we identified overlapping hits and our data 
may help in establishing a list of core stem cell fitness genes, which could be a useful reference 
for future studies. Colleagues at the WSI are performing genome-wide knockout screening in 
iPSCs from different human donors. They are using an alternative library using fewer 
gRNAs/gene and screening at a larger coverage than we did. It will be interesting to compare 
with their results, particularly as they may have significant variability between donors. This 
may also allow us to identify hits that are common to iPSCs but differ from ESCs. 
 
5.2.2 Technical issues with screening stem cells 
The largest issue we faced in our screens was Cas9-induced toxicity, which manifested in 
several ways. Vast cell death occurred in the days immediately following transduction, and 
there was a significant enrichment of NTC gRNAs (Section 3.2.2) and gRNAs targeting genes 
such as TP53, which play a role in the DNA damage response (Section 3.8). Another group 
recently published similar findings regarding the toxicity of Cas9 in a hESC line and explored 
this in more depth.241 Using 47 gRNAs targeting 16 genes, they found that editing was highly 
efficient but the majority of cells did not survive. They selected a gRNA targeting a gene that 
was not expressed in the cell line and compared this with an NTC gRNA. The targeting gRNA 
caused a decrease in confluence over time, whereas cells expressing the NTC gRNA had 
increased confluence. They considered the possibility that this effect could be due to off-target 
activity, but found no evidence of editing at the top 6 predicted off-target sites. They also 
trialled transient Cas9 exposure and use of a Cas9 with enhanced specificity to reduce off-
target activity, but toxicity was still observed.  
In the same study, a high coverage (1000x) screen was performed using a library with 
13,000 gRNAs, both in the presence and absence of Cas9 activity. In cells where Cas9 was not 
induced, the fold-changes for most gRNAs were evenly distributed, but they observed a  
1.3-1.4 enrichment of NTC gRNAs when Cas9 was active. This suggested that there was a 
global depletion of targeting gRNAs. Mair et al. (2019) also observed toxicity when Cas9 was 
induced during screening, and noted an enrichment of non-targeting gRNAs. These data 
correlate well with the enrichment of NTC gRNAs observed in our screens (Fig. 3.2). Ihry et 
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al. (2018) analysed the fold-change of NTC gRNAs in screens of immortalised or tumour cell 
lines and found little enrichment, indicating that this toxicity effect is heightened in stem cells.  
Ihry et al. (2018) demonstrated that CRISPR/Cas9 knockout did not affect expression 
of pluripotency markers, which supports data produced in this project (Section 2.8) and in a 
previous study.273 Using RNA-seq analysis, they compared cells expressing a targeting gRNA 
vs an NTC gRNA and found that many genes involved in apoptosis were up-regulated in the 
DSB-induced cells. Interactome analysis indicated that p53 was linked to many of the 
expression changes associated with DSBs. They demonstrated that TP53-mutant cells 
increased in confluency despite DSB induction. However, the growth was ~50% less than in 
cells where Cas9 was not induced, suggesting that there was still an effect on cell fitness. In 
our screens, the NTC gRNAs were also enriched in a TP53 KO line (Fig. 3.2), indicating that 
the toxicity effect was not solely dependent on the p53-mediated DNA damage response. 
However, we did find that the TP53 KO screens were more reproducible than the parental 
(Section 3.6.1), had the highest recall of known core fitness genes (Section 3.4.3) and showed 
greater separation of established essential and nonessential genes (Section 3.4.2).  
Similar to our findings, all of the published genome-wide screen studies in hESCs 
observed enrichment of TP53-targeting gRNAs.238-240 Other genes were also identified, 
including PMAIP1 and CHEK2, which we found to be recurrently enriched in our iPSC screens 
(Fig. 3.12). Ihry et al. (2019) performed further analysis of PMAIP1, a pro-apoptotic regulator 
downstream of p53, and found that this enrichment appeared to be specific to stem cells. 
Experimental validation confirmed that mutation of PMAIP1 reduced Cas9-induced toxicity.238  
 
5.2.3 Potential improvements to screening in iPSCs 
Our findings and those of the few other related studies have been informative with regards to 
the ways in which stem cell screening protocols could be improved in future. Data regarding 
gene enrichment provides a better insight into the toxic response observed in stem cells and 
could provide strategies for improving the application of CRISPR/Cas9 in these cells. For 
example, transient inhibition of these DNA damage response pathways could help improve 
survival. However, even temporary interference with these genes would likely alter the results 
of any screen and would need to be considered when interpreting any results. Another key 
revelation is that NTC gRNAs are not an ideal control, which may also be relevant for other 
cell types. As an alternative, safe-targeting gRNAs could be used. These target genomic regions 
which have no functional impact, but still induce DSBs and so would act as a better control.  
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One option to improve the quality of our iPSC data would be to increase the coverage (i.e. 
transduce and maintain more cells per gRNA), potentially making it easier to differentiate 
between general depletion due to Cas9 toxicity and specific depletion due to gene essentiality. 
As discussed in Section 5.2.1, our initial coverage was much lower than others have used. The 
scale of our screening protocol was largely dictated by G418 selection, as the antibiotic did not 
work effectively when transduced cells were seeded densely. Untransduced iPSCs were highly 
sensitive to G418 selection regardless of density, but we found that the presence of resistant 
cells in the population impaired the selection capability. Cells were seeded sparsely to allow 
selection to occur and for cells to proliferate for more than a couple of days post-transduction. 
Due to the issues with measuring BFP expression (Section 2.7.3), it was difficult to confirm 
that selection was complete and if so, when this was achieved. However, there appeared to be 
no significant cell death after 1 week. In comparison to puromycin, G418 was much less 
efficient. Previous work in our lab (not described here) has shown that puromycin can 
effectively select these cells within 48 hours, at a density 4-fold higher than that used in our 
screens. Thus, it is not surprising that the majority of available gRNA library backbones have 
a puromycin selectable marker.  
We were unable to use a puromycin-resistant library backbone because the KO iPSC lines 
were engineered to carry a puromycin cassette (Section 2.3). The cells were also resistant to 
blasticidin, which was used as a selectable marker for Cas9 expression (Section 2.6). In 
addition to G418, hygromycin B and zeocin antibiotics can also be used for selection of 
mammalian cells. Based on past experience, colleagues informed us that zeocin was difficult 
to use. Clara Alsinet had previously tested hygromycin B in the BOB iPSC line (data not 
shown) and found that G418 worked better, hence our decision to use this antibiotic. The cost 
of screening in iPSCs was significant due to the requirement for vitronectin coating on all 
culture dishes and daily medium changes. Performing screens at this scale also required a lot 
of time and incubator space. Thus, increasing the scale of the screen to improve library 
coverage was not feasible. However, if we had used puromycin selection, approximately 4-
fold greater library coverage could have been achieved with more cells seeded per dish. In 
hindsight, using an alternative selectable marker for the KO iPSCs would have been preferable 
but engineering of these lines began before the screening aspect of this project was planned.  
Another option to address the toxicity issue could be to screen with CRISPRi technology, 
which inhibits gene expression by fusing repression domains to a catalytically inactive Cas9. 
This would avoid the complication of DSB-induced toxicity as Cas9 would not cut the DNA. 
In theory, this should improve the quality of screen data by removing noise associated with 
CRISPR/Cas9 screening in iPSCs  121 
Cas9 toxicity. A higher library coverage could be achieved without the necessity to scale up to 
account for cell death, saving both time and money. One potential limitation of CRISPRi is 
that transcriptional repression may be less effective at reducing protein expression than a loss-
of-function mutation. Mandegar et al. (2016) compared CRISPRi with CRISPR knockout in 
iPSCs using gRNAs targeting OCT4 and NANOG. They found that CRISPRi was in fact more 
efficient, with almost complete loss of protein expression, whereas approximately a third of 
cells maintained expression using CRISPR knockout. Sequencing analysis highlighted that 30-
50% of these cells had in-frame indels, which would explain the lack of protein knockout. 
Various others have shown successful application of CRISPRi in iPSCs and iPS-derived 
cells.274-279 However, these studies have involved either targeted genes or more focused 
screens, not on a genome-scale. In future, a genome-wide CRISPRi screen could be performed 
in the parental BOB line to compare the results with our knockout screens.  
Despite the challenges we faced, in some of our screens we were able to detect known 
essential genes and identify genes that were identified as being specific to stem cells in 
published studies. However, considering our aim was to identify specific genetic changes 
between isogenic cell lines, the variability we observed was a significant limitation. The 
potential improvements discussed here may improve the reproducibility of iPSC screens and 
allow more reliable identification of genetic interactions.   
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5.3 Screening for PBAF/BAF dependencies 
To date, research into targeting PBAF/BAF mutant cancers has been largely focused on the 
most commonly mutated subunit, ARID1A. None of the previously reported dependencies 
associated with ARID1A loss were identified in our iPSC screens. This could be due to the 
quality of the screen data, as the ARID1A KO screens did not perform as well as others (Section 
3.4). However, it could also be due to context-specificity of the previously identified synthetic 
lethal interactions. The most widely validated synthetic lethal partner of ARID1A is ARID1B. 
As we did not detect this in our screens, we performed further experiments to test this but found 
no evidence of an interaction (Section 4.2.1). More extensive validation could be performed, 
using more gRNAs or possibly using si/shRNA technology, however it is possible that this 
interaction does not occur in the BOB cell line. Many of the other ARID1A dependencies were 
found in OCCC cell lines and were not broadly validated in other tissue types, therefore it is 
possible that they are also specific to certain cell lineages. No studies have demonstrated 
systematic screening for synthetic lethality in ARID1B, ARID2 or PBRM1 mutants so we had 
little reference for comparing the output of our screens. We analysed large-scale pan-cancer 
CRISPR/Cas9 screen datasets but found no dependencies associated with LOF mutation in any 
of these 3 genes, although this may be due to the small number of mutants (Section 4.6.2). 
In our screens, we identified candidate SLIs for all 4 PBAF/BAF subunits and 
reassuringly, some hits were identified in two independent KO clones for the same gene 
(Section 4.6.1). Due to the variability of our data and incomplete validation, it is difficult to 
draw any conclusions regarding these. Further experiments are required to confirm that these 
interactions occur in the iPSCs, and then these must be assessed in cancer cell lines to confirm 
they are not stem cell-specific. We chose to validate in a haploid CML line (HAP1) and had 
potentially promising preliminary data for some hits (Section 4.5) but repetition of this assay 
and further validation is needed. For clinical relevance, it would be ideal to instead focus on 
cell lines that represent the tissues most commonly affected by loss of these genes e.g. ovarian 
cancer for ARID1A and renal cancer for PBRM1. One possible strategy would be to harness the 
available CRISPR/Cas9 screen data to select cell lines for validation. Hits could be cross-
referenced with screen data from PBAF/BAF mutant cancer lines. This may give an indication 
of whether a hit would validate without having to test a large panel of cancer cell lines. 
Although the small sample size could be an issue here, and it must be kept in mind that false 
negatives can occur in these screens so some hits may be missed.  
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5.4 Isogenic models for SLI screening 
Choosing the right context to identify and validate candidate SLIs is one of the biggest 
challenges of not only this project, but synthetic lethality studies in general. In this project we 
chose iPSCs as a model as they have a clean genetic background and should therefore have 
limited confounding factors. Considering the limitations discussed in Section 5.2, further 
validation experiments are needed to assess how effective they were as a model. However, I 
expect that although technical improvements may be required, screening in iPSCs can be used 
to identify novel genetic interactions with higher confidence than in a cancer cell line with 
many genetic aberrations. The main barrier may not be the model, but rather that screening in 
any single cellular context is not sufficient to identify broadly applicable SLIs. 
Analysis we performed on pan-cancer CRISPR/Cas9 screen datasets supported 
previous findings that ARID1A mutant cells are dependent on ARID1B (Section 4.2.2). 
However, it is clear from these analyses that, even though this was the strongest association 
identified in ARID1A mutants, this interaction is not fully penetrant. In this context, penetrance 
refers to the fraction of tumour cell lines harbouring a genetic mutation that are sensitive to 
inhibition of a synthetic lethal partner.62 In the Sanger screen dataset, only 15% of ARID1A 
mutant lines were dependent on ARID1B; this was slightly higher at 30% in the Broad dataset 
(Fig. 4.5). This is not a unique observation; many SLIs have incomplete penetrance, and this 
is likely one of the main reasons that only one interaction has progressed to the clinic.62 For 
example, several large-scale screens have been performed to identify synthetic lethal partners 
of KRAS, but few hits have replicated across multiple studies (as reviewed by Downward, 
2015).280 It is possible that the lack of reproducibility is due to technical issues, but even studies 
using the same screening method in different cell lines have shown a high degree of cell line-
specificity for SLIs.129 It is likely that many SLIs are either cell-type specific or specific to a 
certain genetic context, with other genes interfering with the interaction.  
Screening across a panel of cancer cell lines and associating results with genetic 
mutations has evidently been useful in identifying SLIs such as the ARID1A/ARID1B pairing. 
However, this is limited by the number of cell lines available with existing mutations. The large 
genetic heterogeneity also makes it difficult to confidently deduce which, if any, single genetic 
change is responsible for the effect observed across all lines. The results in an isogenic system 
can be interpreted more clearly. Going forward, I would propose that an alternative strategy 
could be to combine both strategies by screening across multiple isogenic pairs. I would select 
cell lines that have naturally occurring LOF mutations in the PBAF/BAF genes but are 
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otherwise genetically heterogenous. CRISPR/Cas9 could then be used to correct the mutation 
and engineer a wildtype derivative. This strategy would allow robust identification of SLIs that 
are not specific to one cell line or tissue type, which is vital for any potential targets to be 
widely applicable in the clinic.  
 
5.5 Future perspectives 
In this project we produced a large amount of iPS cell screen data; screening in this cell type 
has not been shown in the literature and there are very few datasets from other pluripotent cells. 
Our data has given an insight into the significant variability that occurs when screening this 
cell type. This has been valuable in emphasising how important it is to replicate and validate 
screens thoroughly. In Section 5.2.3 I proposed several ways to address the issues we faced 
and I would recommend that increasing library coverage and/or using a technology such as 
CRISPRi would be the best approaches to deal with the issue of cell death. It was also evident 
that non-targeting gRNAs were poor controls as they did not induce a DNA damage response 
and were positively selected. For future screens, safe-targeting gRNAs which cut DNA may 
be a better control. We tested the pluripotency of the cells post-screen but in hindsight, it would 
have been valuable to measure expression of pluripotency markers during the screen whilst the 
cells were stressed and undergoing morphological changes. Our aim was to use this as a model 
rather than to understand the biology of the stem cells, but validating the state of the cells would 
be particularly pertinent for researchers interested in using screen data to study iPSCs. We did 
not have the opportunity to screen another iPSC line for comparison, but another group at WSI 
is screening multiple lines using a higher coverage and an independent library. We hope that 
integration of these datasets will provide a starting point for identifying core and patient-
specific genes that are essential for iPS cell fitness. 
 Further validation is needed to determine the utility of our data for identifying synthetic 
lethal interactions. Whilst there may be true interactions present in the results, the variability 
makes the data difficult to interpret with confidence. It would have been valuable to do 
additional biological replicates of the knockout lines, as we did with the parental line. We did 
not detect known interactions with the PBAF/BAF genes but as these were not tested 
independently in our cell line, we could not conclude that this was a fault of the screen. We 
performed experiments to test the ARID1A/ARID1B interaction but going forward I would 
repeat this and test other published interactions using other methods e.g. siRNA and chemical 
inhibitors. Confirming the presence or absence of these interactions in the BOB cell line would 
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be a good indicator of screen performance. For future validation, I think it would be most 
valuable to test our candidate hits in cancer cell lines that have existing mutations in the gene 
of interest e.g. ARID1A-mutant ovarian cancer cell lines. Although HAP1 has technical 
advantages, it does not reflect the clinical setting that these interactions occur in. As a haploid 
cell line, it also removed our ability to identify interactions with haploinsufficient genes. 
 
When it became clear that CRISPR/Cas9 KO screening in iPSCs would be challenging and the 
initial data was variable, I also became involved in another project in the Adams’ lab. In doing 
so, I gained experience using a different screening technology in a different model system. I 
performed these experiments in parallel with my own project, whilst I analysed my screen data 
and carried out validation assays. In Chapter 6 I have detailed the background to this additional 
project, the results we obtained and the subsequent work that is ongoing.  
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Chapter 6 
6 In vivo CRISPR screening to identify 
tumour cell intrinsic regulators of 
metastatic colonisation 
 
6.1 Introduction 
6.1.1 What is metastasis? 
It is estimated that 90% of cancer-associated deaths are caused by metastasis.281 Metastasis is 
a process whereby cancer cells spread from the primary tumour to a secondary organ. Multiple 
stages are involved: invasion of surrounding tissue, intravasation and survival in the circulatory 
system, extravasation and proliferation in a distant tissue (in a process known as ‘colonisation’) 
(Fig. 6.1). Metastasis is controlled by both tumour cell intrinsic factors and extrinsic factors in 
the tumour microenvironment (reviewed by Liu, et al., 2017).282 Many studies have been 
carried out to identify such factors but we still have a lot to learn about this process, particularly 
the colonisation step.   
 
6.1.2 Metastasis models 
Due to the biologically complex nature of this process, animal models are critical for studying 
metastasis. In particular, the role of the immune system in metastasis makes it difficult to 
accurately study this process in vitro. Research has shown that the immune system can act both 
to inhibit and promote metastasis at various stages of the cascade. Cytotoxic CD8+ T cells, NK 
cells and M1-like macrophages have inhibitory roles and will recognise and kill tumour cells.283 
However, tumour cells can develop mechanisms to evade the immune response, for example 
by downregulating the expression of MHC class I molecules which are recognised by CD8+ T 
cells.284 T regulatory cells and M2-like macrophages can also help to promote metastasis by 
inhibiting CD8+ T cells and NK cells.283 Immune cells play various roles throughout the 
metastatic cascade (as reviewed by Blomberg, et al., 2018).285 In the early stages of 
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dissemination from the primary tumour, immune cells regulate the extracellular matrix, 
formation of blood and lymph vessels, and can promote migration. After intravasation, 
circulating tumour cells are under further attack by NK cells and T cells and must adapt to 
evade these responses. However, some immune cells can aid survival and assist with 
extravasation to distant sites. For example, interaction with platelets in the circulation can 
shield tumour cells from NK cells286,287 and can also promote an invasive phenotype in the 
tumour cells.288 If cells survive these pressures, they must then establish another 
immunosuppressive environment at the secondary site to allow further growth. The interaction 
between tumour cells and the host environment, particularly the immune system is pivotal in 
determining the success of metastasis. Identifying proteins that are up- or down-regulated in 
tumour cells to allow them to metastasise is vital for developing therapies to prevent this. 
 One of the most common in vivo strategies is to transplant cancer cell lines or tissues 
into mice.289 This can be done using cells/tissues derived from an animal with the same genetic 
background (syngeneic) or using human cells/tissues in immunocompromised mice 
(xenograft). The interaction between the tumour and the host is critical in metastasis. The 
syngeneic model is ideal for studying this as the tumour cells are from the same species as the 
host, whereas human xenograft models may face species-specificity issues.  
Two experimental approaches are used with transplantable models: experimental 
metastasis assays (injection of tumour cells directly into the circulation) and spontaneous 
metastasis assays (injection of tumour cells into a tissue from which they then have to enter the 
circulation). Experimental metastasis assays allow analysis of the later stages of metastasis 
(extravasation and colonisation), whereas spontaneous assays follow all stages from the 
primary site. The spontaneous model is more clinically relevant but the experimental model is 
quicker and avoids issues with the primary tumour mass growing too large (and the mouse 
having to be sacrificed) before the cells have had time to enter the circulation and metastasise.  
One of the most commonly used experimental models involves intravenous injection 
of B16 mouse melanoma cells into the tail vein, typically leading to pulmonary metastases.290 
B16 tumour cells were derived from a spontaneous melanoma that occurred in the C57BL/6 
mouse strain. Several derivatives of this line have been generated with varying metastatic 
potential and sites of colonisation.291,292 This model (using B16-F10 cells; a highly metastatic 
derivative290) has been used extensively in the Adams’ lab.293 
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Figure 6.1. Metastatic cascade. Tumour cells acquire an invasive phenotype (a), begin to invade 
surrounding tissue and then intravasate into the vasculature (b). Circulating tumour cells (CTCs) travel 
through the circulatory system (c) until they extravasate into a distant tissue (d). Here, they must survive 
challenges such as the innate immune system (e) and adapt to the new microenvironment, allowing 
them proliferate and form metastases (f). Figure taken from 281. 
 
6.1.3 Screening for regulators of metastasis 
By applying high-throughput screening strategies to established in vivo models, we can 
interrogate the metastatic process in a systematic and unbiased manner. A recent study 
identified tumour extrinsic (‘host’) factors that regulate metastasis by carrying out an 
experimental metastasis assay in 810 genetically-modified mouse lines.293 Tumour intrinsic 
factors have also been identified by applying functional genomic approaches, such as shRNA 
and cDNA libraries, to cells in vitro then observing the phenotypic effect in in vivo metastasis 
models.294-296 More recently, CRISPR/Cas9 technology has been used for various loss-of-
function screens in vivo,297-299 including the study of regulators of tumour growth and 
metastasis in mice.300   
 
6.1.4 CRISPR activation  
Originally a tool developed to allow for genome editing87,88, CRISPR/Cas9 has been 
repurposed for many applications, including gene regulation. A catalytically inactive version 
of Cas9 (dCas9) was engineered by introducing point mutations into the RuvC1 and HNH 
nuclease domains.96 dCas9 is unable to cleave DNA but can still be targeted to a genomic 
region by a gRNA. By fusing transcriptional regulation domains to dCas9, the expression of 
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targeted endogenous genes can be controlled.96,97,301 Thus, CRISPR/Cas9 can be used to 
investigate phenotypes associated with gene activation as well as silencing (Fig. 6.2). In 
comparison to KO screens, so-called CRISPR activation (CRISPRa) is still in its infancy, with 
few published in vivo studies.302-304 When combined with an in vivo experimental model, 
CRISPRa technology offers a novel approach to screen for regulators of metastasis.  
 
 
Figure 6.2. CRISPR-mediated transcriptional regulation. Catalytically inactive dCas9 can be fused 
to an effector domain and when bound to a gRNA, the protein is directed to a specific genomic region. 
Depending on which effector domain is used, transcriptional activators or repressors will be recruited, 
leading to regulation in expression of an endogenous gene. [Figure adapted from Qi et al.] 96 
 
6.1.5 Aims of this project 
The genes and signalling pathways that must be initiated in order for a melanoma cell to survive 
and proliferate at a secondary site are not well understood. In this project, we aim to identify 
and characterise the genes that are upregulated in a melanoma cell in order for it to effectively 
colonise the lung. To do this we will: 
• Use a CRISPRa library of gRNAs against mouse cell surface genes. We have chosen to 
specifically target cell surface proteins as they represent clinically tractable targets for 
immunotherapy, similar to the rationale for Trastuzumab (Herceptin), in which the 
monoclonal antibody binds to the HER2 receptors on breast cancer cells and both inhibits 
the normal function of the HER2 receptor and induces immune-mediated killing.10 
• Use the B16-F0 mouse melanoma cell line. We chose this cell line as it is weakly 
metastatic, thus only having a low level of ability to effectively colonise the lung after tail 
vein dosing, and will allow us to identify genes that can enhance this ability. 
• Perform a CRISPRa screen in vivo using the experimental metastasis assay. We chose this 
assay as using an in vivo protocol will ensure key regulators of metastatic colonisation are 
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present (the immune system, stroma, etc.) and the experimental metastasis assay avoids the 
gRNAs also having an effect on primary tumour growth (which would have been an issue 
with the spontaneous metastasis assay).  
• Develop a suitable analysis pipeline for in vivo CRISPRa screen data. 
• Validate candidate enhancers of metastatic colonisation identified by the screen. 
 
This project was led by Dr Louise van der Weyden (LvdW), a Senior Staff Scientist in the 
Adams’ lab. I carried out all lentiviral production, transductions, cell culture and flow 
cytometry during the in vitro phase of the screen and subsequent validation experiments. All 
other work was performed by LvdW, who has kindly allowed me to include this unpublished 
information. 
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6.2 Results 
6.2.1 Preparation for genome-wide CRISPRa screen 
The Weissman lab designed a genome-scale gRNA activation library targeting the mouse 
protein-coding transcriptome, designated mCRISPRa-v2.305 This was designed using a 
comprehensive model to predict gRNAs with high activity, based on features such as 
nucleosome occupancy and TSS position. They also established subpools of this CRISPRa 
library which target specific functional gene groups. As we were interested in cell surface 
genes, for this project we used the ‘membrane proteins (m6)’ subpooled library; this consists 
of 10,975 gRNAs targeting 2,104 genes that encode for membrane proteins, and 250 non-
targeting control gRNAs.  
The m6 library was acquired from Addgene and expanded as described in Section 
7.17.2 (backbone shown in Fig. 6.3). Plasmid DNA was extracted and packaged into a lentiviral 
vector. LvdW transfected B16-F0 mouse melanoma cells with an activator construct that 
contained two VP64 activation domains fused to dCas9 (Addgene #113341).306 Blasticidin was 
used to select for and maintain the dCas9-expressing population (termed ‘B16-F0-dCas9’ 
cells). A titration was performed by transducing B16-F0-dCas9 cells with various volumes of 
the m6 library lentivirus (as described in Section 7.17.3). After 48 hours, BFP expression was 
measured by flow cytometry. The aim was to achieve an MOI of 0.2-0.5, to ensure that each 
cell carried only a single gRNA. The volume of lentivirus required to obtain an MOI of 0.3 
(30% BFP-positive cells) was calculated and scaled up for the screen.  
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Figure 6.3. pCRISPRia-v2 plasmid map. The key features of the Weissman lab library backbone 
plasmid are shown. gRNAs are under the control of a mouse U6 (mU6) promoter. An Ef1a promoter 
drives expression of puromycin resistance (puro-t2A) and BFP.  
 
6.2.2 Screening in an experimental metastasis model 
The highest library coverage we could achieve per mouse was 50x (5.5x105 cells), as tail vein 
administration of a higher amount of this cell line could result in a tumour embolism that would 
be lethal to the mouse. We aimed for a higher in vitro coverage to minimise loss of coverage 
prior to moving in vivo. The initial target was ~300x and so 12x106 cells were transduced at an 
MOI of 0.3. Details of the full screening protocol are provided in Section 7.17.4. After 48 
hours, cells were passaged and puromycin was added to select for successfully transduced cells. 
A small sample was taken for flow cytometry; a transduction rate of 20% was achieved i.e. 
200x library coverage (Fig. 6.4). Although lower than expected, this was still largely in excess 
of the required 50x and so we proceeded with the screen. Cells were passaged after 4 days in 
culture with puromycin and flow cytometry confirmed that selection was complete, with an 
almost 100% BFP-positive population (Fig. 6.4). Cells were collected for dosing at 9 days post-
transduction, allowing enough time for the lentivirus particles to be cleared and for gene 
activation to occur.  
 
mU6 promoter (modified)
modified gRNA constant region
BFP
puro-t2A
Ef1a promoter
EGFP_NT2
AmpR
8904 
bp
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Figure 6.4. Expression of CRISPRa library. B16-F0-dCas9 cells were transduced with the m6 library 
lentivirus and analysed by flow cytometry on day 2 post-transduction. Puromycin was added and cells 
were analysed again on day 6 post-transduction. BFP expression (450_50 (405)-A) was measured, using 
untransduced cells as a control to gate the positive population.  
 
After dilution in phosphate-buffered saline (PBS), 5.5x105 cells were intravenously 
administered into the tail veins of 70 mice. As a control, some cells were also pelleted and 
frozen so that the baseline gRNA abundance could be measured. Activation of some genes may 
have altered cell proliferation/survival in vitro, therefore it was important that these effects 
were accounted for and did not interfere with the signal from gRNAs that impacted metastatic 
ability in vivo. Lungs were collected from mice at 2 timepoints: 35 mice were collected at 4 
hours post-dosing (to determine what proportion of gRNAs successfully made it into the lungs) 
and 35 mice were collected at day 19 post-dosing (by this point culling was necessary as mice 
began to show symptoms associated with pulmonary tumour burden, such as rapid breathing). 
The entire lungs were collected and homogenised, and a portion of the homogenate taken for 
genomic DNA (gDNA) extraction. PCR was performed on the gDNA to amplify the gRNAs 
present in each sample (lung). PCR was also performed on gDNA from the cells that were 
collected on the day of dosing, and on the library plasmid DNA. The gRNAs present in each 
sample were identified by sequencing on a HiSeq 2500. 
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6.2.3 Analysis of CRISPRa screen data 
As there is no well-established method for analysing in vivo CRISPRa screens, Vivek Iyer (a 
senior bioinformatician in the Adams’ lab) trialled three independent analysis strategies to 
identify potential hits. The results from these methods were variable with little overlap overall. 
Design of gRNAs for CRISPR activation is challenging as transcription start sites are not well 
annotated for many genes. A pilot experiment performed by LvdW demonstrated that only 1 
in 5 of the gRNAs in the m6 library that targeted the CD8a gene caused up-regulation of the 
CD8a protein (Table 6.1). Considering this, combined with the additional noise of doing a low 
coverage screen in a difficult setting (in vivo), two of the three bioinformatic analyses focused 
on the individual gRNAs rather than combining gRNAs to get a ‘per gene’ result. 
 
Table 6.1. Up-regulation of CD8a using m6 library gRNAs. B16-F0-dCas9 cells were transfected 
with gRNAs targeting CD8a or non-targeting controls (NT_1-3). Expression of BFP and CD8a were 
measured by flow cytometry, using untransfected cells as a control for gating. BFP was used as a 
measure of the transfection rate, acting as a proxy for gRNA expression. The % of cells that were 
positive for each protein is shown. This experiment was performed by LvdW. 
gRNA % BFP+ % CD8a+ 
untransfected 0.11 0 
NT_1 77.4 0.13 
NT_2 31.6 0 
NT_3 86.1 0.14 
CD8a_1 86.4 63.8 
CD8a_2 71.2 0.2 
CD8a_3 78.6 0.19 
CD8a_4 75.8 0.51 
CD8a_5 51.2 0.7 
 
6.2.3.1 ‘98th percentile’ method 
For each day 19 mouse sample, gRNAs were ranked by their relative abundance (based on read 
count) and those in the 98th percentile (top 2%) were recorded. Those gRNAs that ranked highly 
in multiple mice were of most interest. Any gRNA which was present in < 50% of the day 19 
samples, regardless of ranking, was disregarded. Additionally, a Z-score was calculated for 
each gRNA, comparing read counts from day 19 to the cells collected prior to dosing (day 0): 
 
Z-score = (average read count at day 19) - (average read count at day 0) 
   Standard Error of the Mean for day 19 samples 
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To identify potential hits, gRNAs were first ranked by the number of mice in which they were 
present in the 98th percentile, and then by their Z-score (Table 6.2). 
 
Table 6.2 Screen analysis: ‘98th percentile’ method. Top 10 hits from analysis using the 98th 
percentile method. 
gRNA 
Present in 98% 
percentile (no. of 
mice) 
Present in day 19 
sample (no. of 
mice) 
Z-score 
Lrrn4cl_+_8850757.23 4 17 3.19 
Slc4a3_+_75546398.23 3 20 3.92 
Tmem194b_+_52630698.23 2 23 2.97 
Zmynd12_+_119422735.23 2 19 2.09 
Fut2_-_45666416.23 2 14 2.09 
Smco3_+_136835494.23 2 22 2.05 
Tango6_+_106683055.23 2 14 2.01 
Gpr27_+_99692177.23 2 26 1.78 
Olfr1360_+_21675377.23 2 18 1.67 
Gpr75_-_30885367.23 2 21 1.67 
 
6.2.3.2 JACKS method 
A second analysis using the JACKS package112 produced a different list of potential hits, with 
results obtained for genes rather than single gRNAs. A Z-score was calculated as described for 
the ‘98th percentile’ method, but the average read count in the lung samples at 4 hours post-
dosing was subtracted rather than using the read count in the pre-dosing cell samples from day 
0 (Table 6.3). 
 
Table 6.3. Screen analysis: JACKS method. Top 10 hits from analysis using the JACKS method. 
Gene Z-score 
Lrrn4cl 0.76 
Slc22a30 0.21 
Tm4sf19 0.60 
Kcnd1 0.77 
Olfr323 0.76 
Tmem54 0.48 
Kcna5 0.47 
Rhbdd2 0.39 
Rxfp2 0.49 
Scn8a 0.43 
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6.2.3.3 ‘Appearance vs enrichment’ method 
A third analysis developed by Felicity Allen (a colleague in the Parts’ lab, WSI) produced 
another list of potential hits. This analysis independently considered two factors: ‘appearance’ 
and ‘enrichment’. ‘Appearance’ describes how many lung samples at day 19 carried a given 
gRNA; the presence of NTC gRNAs was used as a control to determine whether a targeting 
gRNA appeared significantly more than expected by chance. ‘Enrichment’ describes the 
abundance of a gRNA in a lung sample at day 19 relative to the abundance in the cells prior to 
administration to the mice on day 0. An ‘enrichment’ score was calculated by considering the 
difference in abundance and the variability of the data for this gRNA across all samples. For 
‘enrichment’, the p-values for each gRNA were combined across all samples that the gRNA 
was present in. If a gRNA was significantly abundant in the lungs, or was simply present in a 
significant number of lungs, this could suggest that activation of that gene was advantageous 
for metastatic colonisation. The ranking of gRNAs varied depending on the weight given to 
each factor. Some gRNAs had high ‘enrichment’ but low ‘appearance’, and vice versa (Fig. 
6.5). Others had moderately high scores for both factors. As this was a novel analysis strategy, 
we were unsure which ranking method was appropriate so we considered all possibilities.  
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Figure 6.5. Screen analysis: ‘appearance vs enrichment’ method. Log-transformed ‘enrichment’ 
and ‘appearance’ scores are plotted for all gRNAs in the library. Several gRNAs of interest are 
highlighted and annotated. 
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6.2.4 Potential regulators of metastasis  
We selected candidate genes from each of the three analyses for further validation (Table 6.4). 
From the ‘98th percentile’ analysis, we chose to validate the top four scoring gRNAs which 
targeted Lrrn4cl, Slc4a3, Tmem194b and Zmynd12. Lrrn4cl was also the top hit in the JACKS 
analysis, and from this we additionally selected the third and fourth ranked genes, Tm4sf19 and 
Kcnd1. The second ranked gene was Slc22a30, which appears to be a mouse-specific gene that 
arose from a recent duplication event307; we decided not to pursue this due to lack of human-
relevance. From the third analysis we chose to validate gRNAs targeting Pttg1ip (high 
appearance), Sorcs2 (high enrichment), Celsr2 and Lrrn4cl (highest combined appearance and 
enrichment). The Lrrn4cl gRNA was different to the one identified by the other analyses. The 
Slc4a3, Tmem194b and Zmynd12 gRNAs selected from the first analysis also had moderately 
high scores for both appearance and enrichment. 
 
Table 6.4. Candidates selected for validation. The gRNAs chosen for validation are listed and the 
analysis method used to select each of these is indicated. 
Gene gRNA ID Analysis method 
Lrrn4cl Lrrn4cl_+_8850757.23-P1P2 98th percentile 
Slc4a3 Slc4a3_+_75546398.23-P1P2 98th percentile 
Tmem194b Tmem194b_+_52630698.23-P1P2 98th percentile 
Zmynd12 Zmynd12_+_119422735.23-P1P2 98th percentile 
Tm4sf19 Tm4sf19_-_32400563.23-P1P2 JACKS 
Kcnd1 Kcnd1_-_7822209.23-P1P2 JACKS 
Pttg1ip Pttg1ip_+_77581600.23-P1P2 Appearance vs enrichment 
Sorcs2 Sorcs2_-_36398240.23-P1P2 Appearance vs enrichment 
Celsr2 Celsr2_-_108415977.23-P1P2 Appearance vs enrichment 
Lrrn4cl Lrrn4cl_+_8850685.23-P1P2 Appearance vs enrichment 
 
 
6.2.4.1 Biology of candidate genes 
All of the genes selected for validation have a human homologue but the functions of many of 
the proteins are not well understood. Leucine Rich Repeat Neuronal 4 C-terminal-like 
(LRRN4CL) is a single-pass type I membrane protein. TMEM194B, also known as NEMP2, 
encodes for nuclear envelope integral membrane protein 2. ZMYND12 encodes for Zinc finger 
MYND domain-containing protein 12. TM4SF19 encodes for Transmembrane 4 L Six Family 
Member 19. Currently there is no literature regarding the biological function of these four 
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proteins, but all had consistently low expression in RNA-seq analysis of 27 normal human 
tissues.308 Solute Carrier Family 4 Anion Exchanger Member 3 (SLC4A3) is a plasma 
membrane protein involved in exchange of chloride and bicarbonate.309 It is most abundantly 
expressed in the brain and heart, and has been associated with idiopathic generalised epilepsy310 
and regulation of cardiac function.311 Potassium Voltage-Gated Channel Subfamily D Member 
1 (KCND1) is a multipass membrane protein. It is a pore-forming subunit of voltage-gated A-
type potassium channels, which create currents in neurons and cardiac myocytes.312 PTTG1IP 
is a single-pass type I membrane protein that binds to pituitary tumour-transforming 1 protein 
(PTTG1) and promotes its translocation to the nucleus.313 It has been identified as an oncogene 
in endocrine cancers such as thyroid cancer,298 and overexpression has also been shown in 
cancers such as breast314 and colorectal.300 It is has been to shown to decrease p53 stability by 
ubiquitination.315,316 One study demonstrated that PTTG1IP interacts with CTTN to induce 
cellular invasion and migration in thyroid and breast cancer cells317. SORCS2 encodes for 
vacuolar protein sorting 10 domain-containing receptor protein. It has roles in neuronal 
function and viability,318,319 and has been linked to diseases such as bipolar disorder320 and 
schizophrenia.321 Cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2) has been shown 
to have roles in ciliogenesis and neuronal development, including neuron migration and axon 
guidance.322 Mutations in CELSR2 have been associated with poor prognosis in endometrial 
cancer but there is no functional evidence for this.323 PTTG1IP is the only candidate that has a 
clear functional association with metastasis, but several of the genes are not well characterised 
and may have interesting functions that have not been identified yet. 
 
6.2.4.2 Validation of candidate genes 
LvdW cloned a gRNA targeting each candidate gene into the library backbone and packaged 
into lentiviral vectors (as described in Section 7.17.7.1). Three random NTC gRNAs from the 
library were also cloned, pooled and packaged into a single lentiviral vector for use as a 
negative control. All lentiviruses were titred in B16-F0-dCas9 cells (as described in Section 
7.17.3). Each gRNA was transduced independently and cells were processed as in the screen: 
BFP was measured and puromycin was added after 48 hours, BFP was measured again on day 
6 to confirm complete selection and on day 10 cells were collected for intravenous 
administration (as described in Section 7.17.7.2). Each mouse was dosed with 2x105 cells, with 
9-10 mice/condition. Lungs were collected after 10 days and melanocytic metastases were 
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counted by eye (as described in Section 7.17.7.3). Validation experiments were performed in 
batches with different mice cohorts, but the NTC was repeated in every batch.  
 Mice dosed with cells carrying the Lrrn4cl, Slc4a3, Tmem194b and Zmynd12 gRNAs 
developed significantly more pulmonary metastases compared to the NTC (Fig. 6.6a). 
Similarly, cells expressing the Tm4sf19 gRNA formed significantly higher numbers of 
metastases compared; the Kcnd1 gRNA had a significant effect in one cohort (p < 0.0001), but 
not in another (p = 0.5401) (Fig. 6.6b&c). Mice dosed with cells carrying the second gRNA 
targeting Lrrn4cl or the Sorcs2 gRNA had statistically significantly more metastases than the 
NTC, but a gRNA targeting Celsr2 had no significant effect (Fig. 6.6d). Finally, there was no 
significant difference in the number of metastases formed by cells carrying a Pttg1ip gRNA 
compared to the NTC (the first Lrrn4cl gRNA was repeated in parallel as a positive control, 
Fig. 6.6e). 
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Figure 6.6. In vivo validation of top scoring gRNAs from CRISPRa screen. B16-F0-dCas9 cells 
were transduced with lentiviruses containing single targeting gRNAs, or a pool of NTC gRNAs. 
Transduced cells were intravenously administered to at least 8 mice per condition. On day 10 post-
dosing, lungs were collected from the mice and metastases were counted by eye. The number of 
pulmonary metastases present in mice dosed with each gRNA are plotted; the mean is indicated by a 
line and error bars show the standard deviation. Each graph represents a single cohort. A Mann-Whitney 
test was performed to compare each gRNA with the NTC (p-values shown). Lrrn4cl and Tmem194b 
validated in 2 additional cohorts. Slc4a3 validated in one independent cohort. Zymnd12 was repeated 
in a further 4 cohorts, and validated in 3 of these. Data is not shown for these extra cohorts. 
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6.3 Discussion and future directions 
In this project, we established a protocol for carrying out a pooled CRISPRa screen in B16-F0 
melanoma cells. We extended this to an in vivo setting using an experimental metastasis model, 
allowing us to screen for genes that enhance metastatic pulmonary colonisation. The transfer 
from in vitro to in vivo was successful and using various analyses, we could identify gRNAs 
that were enriched in the lungs of mice. Despite little overlap in the results of the analysis 
strategies, several hits from all of them did validate in the experimental metastasis assay. As 
more data is produced, analysis of CRISPRa screens will undoubtedly become more accurate 
and refined but the approaches applied here were sufficient to identify true hits. Improvements 
to CRISPRa gRNA design should also increase the reliability of these data; variability in 
efficacy currently means that hits are often not supported by data from multiple gRNAs. 
Results from the ‘appearance vs enrichment’ method were the least robust, but it was unclear 
how best to interpret these data prior to validation. The strongest candidate gene was Lrrn4cl, 
which was a hit in all analyses; cells carrying gRNAs targeting this gene consistently formed 
more pulmonary metastases than any of the others.  
Our data suggest that overexpression of Lrrn4cl enhances the ability of B16-F0 
melanoma cells to colonise the lung. LvdW repeated the experimental metastasis assay using 
a Lrrn4cl cDNA (and empty vector as a control) as an alternative over-expression strategy and 
the result was replicated. This assay was also performed in immunodeficient mice lacking an 
adaptive immune system (B cells, T cells, NK cells) and a significant phenotype was still 
observed. LvdW repeated the cDNA assay in three additional melanoma cell lines, plus a 
breast, a colorectal and a bladder cancer cell line. Pulmonary metastases were increased in all 
lines, suggesting that the effect of Lrrn4cl activation is not specific to B16-F0 cells. The 
Lrrn4cl gene has a human ortholog with the same name (LRRN4CL) which encodes for a 
single-pass type I membrane protein. LvdW confirmed that this effect was not mouse-specific: 
enhanced pulmonary colonisation was observed in immunodeficient mice dosed with two 
human melanoma cell lines expressing a human LRRN4CL cDNA.  
These findings suggest that LRRN4CL could be a potential target to reduce the 
development of pulmonary metastases in human cancer. RNA expression data from primary 
tumours indicates that LRRN4CL is highly enriched in melanoma (Fig. 6.7). Thus, it could have 
clinical relevance for the treatment of melanoma patients. Its location on the cell membrane 
also makes it an ideal drug target. To explore this, LvdW and Victoria Harle (a postdoc in the 
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Adams’ lab) are investigating whether knocking out LRRN4CL in human melanoma cell lines 
can reduce pulmonary colonisation in mice.  
 
 
 
Figure 6.7. Expression of LRRN4CL RNA in cancer. RNA-seq data from 17 cancer types, reported 
as the median FPKM (number of Fragments Per Kilobase of exon per Million reads), was generated by 
TCGA. Graph taken from the Human Protein Atlas (available at proteinatlas.org/ENSG00000177363-
LRRN4CL/pathology). 
 
Limited information is available regarding this gene/protein in both mouse and human. In 
normal human tissues, the gene appears to be expressed at a low level (Fig. 6.8). As its normal 
cellular function is unclear, it is difficult to infer the mechanism by which activation of this 
gene could cause increased metastatic colonisation. Elucidation of any proteins that interact 
with LRRN4CL could reveal a wider network of genes with a similar role in metastasis. LvdW 
observed the Lrrn4cl phenotype in immunodeficient mice suggesting that, at least in mouse, 
increased colonisation is not due to an interaction with the adaptive immune system. Further 
investigation is required to understand the role of LRRN4CL in regulating metastatic 
colonisation and its potential as a therapeutic target. 
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Figure 6.8. Expression of LRRN4CL RNA in normal tissue. HPA RNA-seq data from 172 normal 
tissue samples. Expression is reported as mean pTPM (protein-coding transcripts per million), 
corresponding to mean values of the individual samples for each tissue type. Graph taken from the 
Human Protein Atlas (available at https://www.proteinatlas.org/ENSG00000177363-
LRRN4CL/tissue). 
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6.4 Final conclusion 
CRISPR/Cas9 screening is proving to be an invaluable tool for functional genetic studies. 
Whilst its application in identifying fitness genes in cancer cell lines is fairly well-established, 
it has potential for many other uses that are still in their infancy. In this thesis, I have discussed 
two applications of CRISPR/Cas9 which have not been widely explored: knockout screening 
in iPSCs and activation screening in an in vivo model. Both of these proved to be technically 
challenging and produced lower quality data than more established strategies. We gained 
insights into the issues associated with screening in iPSCs and with further work, the data 
quality could be improved and these cells could be a useful model for studying genetic 
interactions. Analysis of in vivo screens and CRISPRa screens is not well-established but will 
undoubtedly become more refined as more data is produced. Despite this, our results were very 
promising and we successfully validated several hits that could further our understanding of 
metastatic colonisation. As the CRISPR toolkit improves and expands, so too will our ability 
to explore areas of cancer biology in a way that was not possible with other technologies. 
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Chapter 7 
7 Materials and Methods 
7.1 General molecular biology  
7.1.1 Agarose gel electrophoresis 
Agarose powder was dissolved in TAE (generally at 1% i.e. 1 g of agarose/100 ml buffer). 
Ethidium bromide was added (5 µl/100 ml) by heating and the gel was poured into a mould 
with a gel comb. When set, the gel was transferred to an electrophoresis tank and covered with 
TAE. Samples were mixed with loading dye and loaded into each well, with a molecular weight 
marker run in parallel (HyperLadder 1 kb (#BIO-33053, Bioline)). Samples were run at ~120V 
for 20-45 minutes and visualised using a Gel Doc XR+ System (Bio-Rad). 
For instances when the DNA was to be extracted from the gel, ethidium bromide was not 
used. Post-electrophoresis staining was carried out using SYBR™ Green I Nucleic Acid Gel 
Stain (#S7563, Invitrogen) diluted in TAE; gels were incubated at room temperature for 30 
minutes in darkness. An LED-based trans-illuminator (Nippon Genetics) was used to visualise 
the gel and the desired band was excised using a scalpel.  
 
7.1.2 Digest/PCR product purification 
7.1.2.1 Column purification 
For column purification, DNA/PCR products were purified using either the QIAquick PCR 
Purification Kit (#28104, QIAGEN) or the Monarch® PCR & DNA Cleanup Kit (5 µg) 
(#T1030S, NEB), following the manufacturer’s protocol.  
 
7.1.2.2 Gel extraction 
DNA/PCR products were extracted from agarose gel using the QIAquick Gel Extraction Kit 
(#28704, QIAGEN) or Monarch® DNA Gel Extraction Kit (#T1020S, NEB), following the 
manufacturer’s protocol. 
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7.1.3 Plasmid amplification and purification 
7.1.3.1 Chemical transformation 
Plasmid DNA was transformed into OneShot™ TOP10 Chemically Competent E. coli 
(#C404003, Invitrogen, ThermoFisher) following the manufacturer’s rapid chemical 
transformation procedure and plated on Luria broth (LB) agar plates containing 100 µg/ml 
ampicillin. After overnight incubation at 37oC, single colonies were inoculated into liquid LB 
with 100 µg/ml ampicillin and incubated overnight in a shaking incubator at 37oC, 225 rpm.  
 
7.1.3.2  Glycerol stocks 
After overnight incubation, 500 µl of bacterial culture was mixed with 500 µl of 50% glycerol, 
snap frozen in dry ice and stored at -80oC. 
 
7.1.3.3  Purification  
Plasmid DNA was extracted from bacterial cultures using QIAGEN Plasmid Plus DNA 
purification kits (Mini, Midi, Maxi or Mega) following the manufacturer’s protocol.  
 
7.1.4 Gibson Assembly 
Reactions were set up on ice with a total volume of 20 µl (components specified in the relevant 
sections) using the Gibson Assembly® MasterMix (#E2611S, NEB). A control reaction was 
always set up in parallel with water replacing the insert, to give an indication of how successful 
the cloning had been. Reactions were incubated at 50oC for 1 hour then diluted 1:4 in nuclease-
free water and 2 µl of each was chemically transformed into 50 µl of OneShot™ TOP10 
Chemically Competent E. coli (Section 7.1.3.1). At least 4 colonies from the transformation 
plate were inoculated for minipreps and plasmid DNA was purified. 
 
 
 
 
 
 
 
iPSC culture  148 
7.2 iPSC culture 
BOB is a male human iPSC line re-programmed from fibroblasts using Sendaiviral vectors. 
The cells originally carried a single point mutation in the A1AT gene, which was corrected to 
wildtype using zinc finger nuclease technology245. A reciprocal translocation, t(6;8)( 
p21.1;8q24.1), is present but the karyotype is stable. This line was established at the WSI and 
it has been used and characterised extensively within the institute. All BOB cell lines (parental 
and KO lines) were kindly provided by the Gene Editing facility at WSI. These were grown in 
feeder-free conditions in TeSR™-E8™ medium (#05990, STEMCELL) at 37oC, 5% CO2 and 
medium was changed every day. Details provided here are relevant to all iPSC culture 
discussed in subsequent sections. 
 
7.2.1  Coating culture dishes 
Cells were maintained in culture dishes coated in either Synthemax®-II-SC (#CLS3535, 
Corning) or Vitronectin-XF™ (#07180, STEMCELL). Synthemax®-II-SC powder was 
resuspended in sterile cell culture water to 1 mg/ml. From this stock, it was further diluted to 
25 µg/ml in sterile cell culture water, added to the dish (10 ml/10 cm2 dish) and incubated at 
room temperature for 2 hours. Vitronectin-XF™ was diluted to 10 µg/ml in PBS or sterile 
water, added to the dish (6 ml/10 cm2 dish) and incubated at room temperature for 1 hour. In 
both cases, coated dishes were used on the day or stored at 4oC in parafilm for up to 3 days. 
 
7.2.2  Thawing BOB lines 
Cryovials were briefly warmed in a 37oC water bath to thaw the cell suspension. Cells were 
transferred to a Falcon containing a 4-fold excess of TeSR-E8 medium. Centrifugation was 
carried out at 300 g for 3 minutes and the supernatant was removed. Cells were resuspended in 
4 ml of medium plus 10 µM ROCK inhibitor (Y-27632, #72304, STEMCELL). Coating 
solution was aspirated from a 6 cm2 dish and the cell suspension was transferred to the dish.  
 
7.2.3  Passaging BOB lines as single cells 
All values given are for a 6 cm2 dish; these were scaled based on surface area as required. For 
general maintenance, cells were passaged every 6-7 days once dense colonies had formed. 
Medium was aspirated and cells were washed once with 4 ml of PBS. Cells were incubated 
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with 2 ml of accutase at 37oC for 5-10 minutes until cells detached. An equal volume of TeSR-
E8 medium was added, cells were pipetted 5-10 times to make a single cell suspension and 
transferred to a Falcon tube. A small aliquot of cells was mixed 1:1 with Trypan blue. A live 
cell count was calculated using a Countess™ II Automated Cell Counter (ThermoFisher). Cells 
were centrifuged at 300 g for 3 minutes and the supernatant was removed. Cells were 
resuspended in 2 ml of fresh medium. Coating solution was aspirated from the culture dish and 
10 ml of medium was added with 10 µM ROCK inhibitor. The desired number of cells were 
transferred to the culture dish and incubated at 37oC, 5% CO2.  
 
7.2.4  Freezing BOB lines 
Cells were processed as described in Section 7.2.3. After resuspension, the desired number of 
cells (generally 2x105 cells/vial) were transferred to a Falcon tube containing KnockOut™ 
Serum Replacement (KOSR, #10828028, Gibco, ThermoFisher) to a total volume of 500 
µl/vial. Another Falcon tube was prepared with 500 µl/vial of KOSR + 20% DMSO. 500 µl of 
both solutions was added to each vial and inverted several times to mix. Cryovials were stored 
in a polystyrene rack at -80oC for 48 hours before transfer to liquid nitrogen. 
 
 
7.3 Engineering knockout iPSC lines 
All KO BOB lines were produced by the Gene Editing facility at WSI. An asymmetrical exon 
in the gene of interest was substituted with a puromycin cassette and a frameshift indel was 
introduced into the other allele. A template vector with an EF1a-puromycin cassette was cloned 
for each gene, with two 1.5 kb homology arms designed to match the sequence around the 
targeted exon. Two gRNAs targeting each exon were designed (Appendix A.1). The template 
vector (2 µg), both gRNA vectors (3 µg) and hSpCas9 (4 µg) were transfected into 2x106 cells 
using the Human Stem Cell Nucleofector® Kit 2 (#VPH-5022, Lonza). Cells were plated in 
10 cm2 dishes and after 72 hours, cells were selected with 3 µg/ml puromycin. Single cells 
were expanded and genotyped for the presence of a frameshift indel by Sanger sequencing. I 
repeated genotyping for all lines detailed in this thesis (described in Section 7.4). KO lines 
were maintained in 1 µg/ml puromycin (#ant-pr-1, InvivoGen). 
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7.4 Genotyping of knockout lines 
7.4.1 DNA extraction 
For genotyping, gDNA was extracted from cell pellets using the Gentra Puregene Core Kit A 
(QIAGEN) following the manufacturer’s protocol. DNA was quantified using a NanoDrop® 
ND-1000 UV-Vis Spectrophotometer or a Thermo Scientific™ Multiskan™ GO Microplate 
Spectrophotometer. 
 
7.4.2 Genotyping PCR 
For each KO gene (in iPSCs and HAP1 cells), primers were designed to cover the edited region 
(Appendix A.1). PCR was performed on gDNA extracted from all edited lines using 
Platinum™ Taq DNA Polymerase High Fidelity (#11304011, Invitrogen, ThermoFisher) 
(Table 7.1). PCR products were visualised on an agarose gel (Section 7.1.1) to confirm the 
correct band was present. These were then column purified (Section 7.1.2.1) and sent for 
Sanger sequencing (Eurofins) (Appendix A.1).  
 
Table 7.1. Genotyping PCR. Top - reaction composition, bottom - thermocycler conditions. 
Reagent Volume/amount 
10X buffer 2.5 µl 
MgSO4 1 µl 
10 mM dNTP 0.5 µl 
10 µM forward primer 0.5 µl 
10 µM reverse primer 0.5 µl 
Taq polymerase enzyme 0.1 µl 
DNA ~500 ng 
Nuclease-free water to 25 µl total  
 
Cycle Number Denature Annealing Extension 
1 94˚C, 30 seconds   
2-31 (30 cycles total) 94˚C, 10 seconds Varied with primer Tm, 30 
seconds 
68˚C, 1 min/kb 
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7.5 Protein-level knockout confirmation 
7.5.1 Protein lysis 
Cells were washed twice with ice-cold PBS then lysis buffer was added (RIPA buffer (#20-
188, Merck) diluted in distilled water, plus 1:100 protease/phosphatase inhibitor (#5872, Cell 
Signaling Technology)); the volume was dependent on cell number. Cells were incubated on 
ice for 5-10 minutes then scraped and transferred to Eppendorfs. Samples were centrifuged at 
14,000 g for 15 minutes at 4oC. Supernatant was transferred to fresh Eppendorfs and stored at 
-80oC. 
 
7.5.2 Protein quantification 
Protein lysates were quantified using the Pierce™ BCA Protein Assay Kit (#23227, Thermo 
Scientific), following the manufacturer’s microplate protocol. Absorbance was measured using 
a Thermo Scientific™ Multiskan™ GO Microplate Spectrophotometer.  
 
7.5.3 Protein separation 
SDS-PAGE was performed to separate proteins. NuPAGE™ LDS Sample Buffer (#NP0007, 
ThermoFisher Scientific) and NuPAGE™ Sample Reducing Agent (#NP0009, ThermoFisher 
Scientific) were mixed with protein lysate. Samples were heated to 70oC for 10 minutes then 
placed on ice prior to loading into a pre-cast gel (NuPAGE™ Novex 4-12% Bis-Tris Gel,  
1.5 mm x 15 well, #NP0336BOX, ThermoFisher). A protein molecular weight marker was also 
loaded. The gel was set up in an XCell SureLock™ Mini-Cell and covered with 1X NuPAGE™ 
MOPS SDS Running Buffer (#NP0001, ThermoFisher) supplemented with NuPAGE™ 
Antioxidant (500 µl/200 ml, #NP0005, ThermoFisher). Samples were run at 150 V until 
sufficient separation was achieved. 
 
7.5.4 Western blotting 
NuPAGE™ Transfer Buffer (#NP0006, ThermoFisher) was diluted in deionised water and 
supplemented with NuPAGE™ Antioxidant (1%) and methanol (10%). PVDF membrane was 
briefly soaked in methanol and placed on top of the gel, assembled with filter paper and blotting 
pads in an XCell II™ Blot Module. The module was filled with the prepared transfer buffer 
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and run at 30 V for 1 h. The membrane was then incubated in blocking buffer (5% non-fat 
milk) dissolved in Tris-Buffered Saline supplemented with 0.1% Tween-20 (TBS-T). 
Incubation was carried out for 20 minutes - 2 hours at room temperature on a shaker. The 
membranes were then incubated with primary antibody (diluted in blocking buffer, Table 7.2) 
overnight at 4oC on a shaker. Five washes were carried out with TBS-T for 5 minutes at room 
temperature. The membrane was then incubated with secondary antibody (diluted in blocking 
buffer, Table 7.2) at room temperature for 1 hour on a shaker. Finally, the membrane was 
washed again 5 times with TBS-T for 5 minutes. To visualise, the membrane was sprayed with 
ECL reagent (#K-12049-D50, Advansta) and incubated for 1 minute before reading on an 
ImageQuant™ LAS 4000 using chemiluminescence. 
 
Table 7.2. Antibodies for Western blotting. 
 
 
7.6 Proteomics 
Liquid chromatography-mass spectrometry was performed on the parental BOB line and KO 
derivatives, by Clara Alsinet (previous postdoctoral fellow in the Adams’ lab) in collaboration 
with Jyoti Choudhary and Theodoros Roumeliotis (previously in the Proteomics facility at 
WSI). Sample preparation and processing were carried out as described in.324 Data for the 
parental BOB line and ARID1A/ARID2/PBRM1 KO clones was published in that manuscript 
as part of a separate project.  
 
 
 
Antibody Supplier Product # Dilution (in 5% milk) Secondary antibody 
Primary antibodies 
Arid1b Abcam ab57461 1:1000 Goat anti-mouse 
Arid2 SantaCruz sc-166117 1:1000 Goat anti-mouse 
Arid1a (PSG3) SantaCruz sc-32761 1:1000 Goat anti-mouse 
β-Actin (8H10D10) Cell Signalling 
Technology 
#3700 1:1000 Goat anti-mouse 
Secondary antibody 
Goat anti-mouse 
IgG H&L (HRP)  
Abcam ab97023 1:10,000 - 
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7.7  Cloning of a neomycin-resistant gRNA library  
7.7.1 Insertion of neomycin resistance gene 
Empty Yusa v1.1 library backbone DNA (Addgene #67974) was kindly provided by Fiona 
Behan (postdoctoral fellow in the Garnett lab, WSI). The backbone was digested with Kpn2I 
at 37oC for 2 hours (Table 7.3), visualised on an agarose gel to confirm digestion (Section 
7.1.1) and then column purified (Section 7.1.2.1). A 901 bp DNA fragment (fragment A, 
Appendix A.1) (GeneArt Strings, ThermoFisher) was designed, containing a neomycin 
resistance gene coding region and sequence complementary to the backbone. An additional 
120 bp DNA oligonucleotide (fragment B, Appendix A.1) (Ultramer®, Integrated DNA 
Technologies) was also designed to extend the overlap upstream of the initial Kpn2I site in the 
PGK promoter. Both fragments were cloned into the digested backbone by Gibson Assembly 
(Table 7.3) (Section 7.1.4). DNA from four colonies was sent for Sanger sequencing (Eurofins) 
with six primers which together provided sequence covering the full edited region (Appendix 
A.1). This backbone is referred to hereafter as ‘neoR’. 
 
Table 7.3. Cloning to insert neomycin resistance gene. Top - restriction digest, bottom - Gibson 
Assembly. 
Reagent Volume/amount 
NEB 3.1 buffer 15 µl 
Kpn2I (BspEI) (#R0540S, NEB) 10 µl 
Yusa v1.1 backbone 10 µg 
Nuclease-free water to 150 µl total 
 
Reagent Volume/amount 
Kpn2I-digested backbone 195.8 ng 
Fragment A 111.4 ng 
Fragment B 14.84 ng 
2X Gibson Assembly MM 10 µl 
Nuclease-free water to 20 µl total 
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7.7.2 Testing the neoR library backbone 
The neoR library backbone was packaged into a lentivirus and titred (Section 7.8). BOB-Cas9 
cells were detached and counted. Cells were transduced with the lentivirus at an MOI of 0.3, 
and 200,000 cells/well were seeded in a 6-well plate with 2 ml total volume. Untransduced 
cells were also seeded in parallel. Fresh medium was added the following morning. After 48 
hours, cells were passaged and a sample was fixed and analysed by flow cytometry to measure 
BFP expression (Section 7.9). For a clonogenic assay, 10,000 transduced cells were seeded per 
well in 5 wells of a 6-well plate. One well was seeded with untransduced cells. On the day after 
seeding, 0, 0.1, 0.3, 0.6 or 1 mg/ml G418 was added to the transduced cells. The same 
experiment was repeated with 10,000 cells/well in a 12-well plate to allow for further flow 
cytometry analysis. After 5 days in G418, media was aspirated from the 6-well plate and cells 
were washed twice with ice-cold PBS. Cells were incubated in 4% paraformaldehyde (PFA) 
for 20 minutes at room temperature and then washed twice with PBS. Crystal violet (0.5% in 
methanol) was then added to each well, incubated briefly and then wells were washed with 
water. Images were taken after plates had dried. After 5 days in G418, cells in the 12-well plate 
were fixed and BFP expression was measured by flow cytometry (Section 7.9). 
 
7.7.3 Insertion of AjuI restriction sites 
The neoR backbone was digested with BbsI at 37oC for 16 hours (Table 7.4), visualised on an 
agarose gel to confirm digestion (Section 7.1.1) and the linearised band was gel extracted 
(Section 7.1.2.2). A 94 base DNA oligonucleotide (fragment C, Appendix A.1) (Ultramer®, 
Integrated DNA Technologies) was designed to contain the same sequence as the backbone 
but replacing the BbsI recognition site with AjuI restriction sites. The fragment was inserted 
into the digested backbone by Gibson Assembly (Table 7.4) (Section 7.1.4). DNA from six 
colonies was sent for Sanger sequencing (Eurofins) with primers covering the edited region 
(Appendix A.1). 
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Table 7.4. Cloning to insert AjuI sites. Top - restriction digest, bottom - Gibson Assembly. 
Reagent Volume/amount 
NEB 2.1 buffer 10 µl 
BbsI (#R0539S, NEB) 4 µl 
neoT2A backbone 10 µg 
Nuclease-free water to 100 µl total 
 
Reagent Volume/amount 
BbsI-digested backbone 435 ng 
Fragment C 11.62 ng 
2X Gibson Assembly MM 10 µl 
Nuclease-free water to 20 µl total 
 
7.7.4 Insertion of IRES element 
PCR was performed to amplify a region containing part of the neomycin resistance gene and 
an IRES sequence (Table 7.5, primers detailed in Appendix A.1) from an unpublished plasmid 
kindly provided by Luca Crepaldi (Parts’ lab, WSI). 5 µl of the reaction was visualised on an 
agarose gel (Section 7.1.1) to confirm the correct product size was amplified and then the 
remainder was column purified (Section 7.1.2.1). 
 
Table 7.5. Amplification of neomycin resistance gene and IRES sequence. Top - reaction 
composition, bottom - thermocycler conditions. 
Reagent Volume/amount 
KAPA HF HS 2X MM (#KK2601, Kapa Biosystems) 12.5 µl 
5 µM forward primer 1.5 µl 
5 µM reverse primer 1.5 µl 
Plasmid DNA 1 ng 
Nuclease-free water to 25 µl total  
 
Cycle Number Denature Annealing Extension 
1 95˚C, 3 minutes   
2-31 (30 cycles total) 98˚C, 20 seconds 60˚C, 15 seconds 72˚C, 15 seconds 
32   94˚C, 1 minute 
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An edited clone containing the AjuI sites (Section 7.7.3) was then digested with RsrII and 
BsrGI at 37oC for 16 hours (Table 7.6). The backbone was visualised on an agarose gel (Section 
7.1.1) to confirm digestion and then column purified (Section 7.1.2.1). A 123 bp DNA 
oligonucleotide (fragment E, Appendix A.1) (Ultramer®, Integrated DNA Technologies) was 
designed with an overlap between the IRES sequence and the BFP coding region in the 
backbone. Gibson Assembly was performed to insert the neo-IRES PCR amplicon and the 
DNA oligonucleotide into the digested backbone (Table 7.6) (Section 7.1.4). DNA from twelve 
colonies was sent for Sanger sequencing (Eurofins) with primers covering the edited region 
(Appendix A.1). One successfully edited clone was taken forward, referred to hereafter as 
‘neoR-IRES’. 
 
Table 7.6. Cloning to insert IRES element. Top - restriction digest, bottom - Gibson Assembly. 
Reagent Volume/amount 
10X NEB CutSmart buffer 10 µl 
RsrII (#R0501S, NEB) 2 µl 
BsrGI-HF (#R3575S, NEB) 2 µl 
neoR(AjuI) backbone 5 µg 
Nuclease-free water to 100 µl total 
 
Reagent Volume/amount 
RsrII/BsrGI-digested backbone 106.2 ng 
Fragment D 29.5 ng 
Fragment E 7.6 ng 
2X Gibson Assembly MM 10 µl 
Nuclease-free water to 20 µl total 
 
7.7.5 AjuI digestion of backbone  
Various protocols were trialled to optimise digestion of the neoR-IRES backbone with AjuI. 
Both AjuI (#ER1951, ThermoFisher) and FastDigest AjuI (#FD1954, ThermoFisher) were 
tested with varying amounts of DNA, DNA:enzyme unit ratios, total reaction volumes and 
incubation times (from 2-16 hours). An example reaction setup is shown in Table 7.7 (reactions 
were always incubated at 37oC). Digests were visualised on an agarose gel (Section 7.1.1) then 
the digested product was gel extracted and purified (Section 7.1.2.2). 10 ng of digested and 
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undigested plasmid were transformed into OneShotTOP10 cells (Section 7.1.3.1). Colonies 
were counted after overnight incubation and the % of background was calculated as the number 
of colonies present with digested plasmid relative to undigested plasmid. 
 
Table 7.7. Restriction digest of neoIRES backbone with AjuI (or FastDigest AjuI). 
Reagent Volume/amount 
10X Buffer R (10X FastDigest Buffer) 5 µl 
50X SAM (20X SAM) to 1X 
AjuI (FastDigest AjuI) 1 µl 
neoR-IRES backbone 1 µg 
Nuclease-free water to 20 µl total 
 
To confirm that AjuI was cutting at both restriction sites, PCR was carried out to amplify a 194 
bp covering the region (Table 7.8) (Appendix A.1). The product was column purified (Section 
7.1.2.1) and digested with FastDigest AjuI (Table 7.7). Digested and undigested PCR products 
were visualised an agarose gel (Section 7.1.1). 
 
Table 7.8. Amplification of AjuI sites. Top - reaction composition, bottom - thermocycler conditions. 
Reagent Volume/amount 
Q5 HS HF 2X MM 12.5 µl 
10 µM forward primer 1.25 µl 
10 µM reverse primer 1.25 µl 
neoIRES backbone 1 µg 
Nuclease-free water to 25 µl total  
 
Cycle Number Denature Annealing Extension 
1 98˚C, 30 seconds   
2-31 (30 cycles total) 98˚C, 10 seconds 67˚C, 30 seconds 72˚C, 30 seconds 
17   72˚C, 2 minutes 
 
7.7.6 Testing the neoR-IRES library backbone 
The neoR-IRES library backbone was tested as described in Section 7.7.2. The neoR library 
backbone was also tested again in parallel for comparison, using the 6-well clonogenic assay. 
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7.7.7 MluI/AgeI digestion of backbone  
The neoR-IRES library backbone was digested with MluI and AgeI to prepare for transfer of 
gRNAs (Table 7.9). Digestion was carried out at 37oC for 8 hours, then the reaction was 
visualised on an agarose gel (Section 7.1.1) and the digested product was gel extracted and 
purified (Section 7.1.2.2). To confirm efficient digestion, 10 ng of digested and undigested 
plasmid were transformed into OneShotTOP10 cells (Section 7.1.3.1). Colonies were counted 
after overnight incubation and the % of background was calculated as the number of colonies 
present with digested plasmid relative to undigested plasmid. 
 
Table 7.9. Restriction digest of neoIRES backbone with MluI/AgeI. 
Reagent Volume/amount 
10X NEB CutSmart Buffer 30 µl 
AgeI-HF (#R3552S, NEB) 5 µl 
MluI-HF (#R3198S, NEB)   7.5 µl  
neoIRES backbone 10 µg 
Nuclease-free water to 300 µl total 
 
7.7.8 PCR of existing genome-wide gRNA library 
DNA for the Yusa v1.1 library was kindly provided by Fiona Behan (Garnett lab, WSI). To 
amplify gRNAs from the library, PCR was performed using primers that covered the gRNA 
and extended across the MluI/AgeI restriction sites (Table 7.10, primers detailed in Appendix 
A.1). An initial optimisation experiment was carried out to identify the best annealing 
temperature and primer set. Two primer sets were tested as described in Table 7.10, with six 
annealing temperatures between 66-71oC. 5 µl of each PCR product was visualised on an 
agarose gel (Section 7.1.1) and the condition with the strongest band was chosen (67oC 
annealing temperature with primer set 2). Using these optimised conditions, 11 PCR reactions 
were performed with 100 ng of library DNA input per reaction. All reactions were pooled and 
visualised on an agarose gel (Section 7.1.1). The 599 bp band was then gel extracted and 
purified (Section 7.1.2.2). 
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Table 7.10. Amplification of gRNAs from Yusa v1.1 library. Top - reaction composition, bottom - 
thermocycler conditions. 
Reagent Volume/amount 
Q5 HS HF 2X MM (#M0494S, NEB) 12.5 µl 
10 µM forward primer 1.25 µl 
10 µM reverse primer 1.25 µl 
Yusa v1.1 library DNA 100 ng 
Nuclease-free water to 25 µl total 
 
Cycle Number Denature Annealing Extension 
1 98˚C, 30 seconds   
2-16 (15 cycles total) 98˚C, 10 seconds 67˚C, 30 seconds 72˚C, 30 seconds 
17   72˚C, 2 minutes 
 
 
7.7.9 Gibson Assembly to clone gRNA library 
Twelve Gibson Assembly reactions were performed to insert the gRNA fragment into the 
MluI/AgeI digested backbone (Table 7.11, Section 7.1.4). All reactions were pooled and 
column purified using the Monarch kit (Section 7.1.2.1), with a 12 µl final elution volume.  
 
Table 7.11. Gibson Assembly reaction to clone gRNA library. 
Reagent Volume/amount 
Digested backbone 439.2 ng 
gRNA PCR product 88.84 ng 
2X Gibson Assembly MM 10 µl 
Nuclease-free water to 20 µl total 
 
7.7.10 Bacterial amplification of gRNA library 
Endura ElectroCompetent cells (#60242-1, Lucigen) were thawed on ice and 25 µl of cells was 
added to 2 µl of purified Gibson Assembly product in a chilled Eppendorf. This was transferred 
to a chilled 1.0 mm electroporation cuvette, ensuring even distribution and no bubbles. 
Electroporation was performed with the following parameters: 10 µF, 600 Ohms, 1800 Volts. 
Immediately after the pulse, 975 µl of recovery medium was added and cells were transferred 
Cloning of a neomycin-resistant gRNA library  160 
to a 15 ml BD Falcon polystyrene tube with snap-cap. Cells were incubated at 37oC, 225 rpm 
for 1 hour. This was repeated 9 times and all cultures were pooled after incubation.  
For colony counting to estimate transformation efficiency, dilutions of 10-3, 10-4, 10-5 
and 10-6 were prepared and 50/100/150 µl of each were plated on LB agar plates containing 
100 µg/ml ampicillin. These were incubated for 16 hours at 37oC. The rest of the culture was 
divided between 6 flasks, each containing 500 ml of liquid LB plus 100 µg/ml ampicillin. These 
were incubated for 16 hours at 37oC, 225 rpm. 
Colonies were counted on each dilution plate and an average value was calculated and 
extrapolated to the total culture volume, giving an estimate of the library coverage achieved. 
Bacterial stabs for 94 colonies were made in a 96-well plate containing LB agar with 100 µg/ml 
ampicillin. The plate was incubated for 16 hours at 37oC and sent for plasmid purification and 
Sanger sequencing (Eurofins) with primers covering the gRNA region (Appendix A.1). 
The liquid cultures were pooled and split into 12x 250 ml centrifuge bottles. Centrifugation 
was performed at 6000 g for 15 minutes at 4oC. The pellets were resuspended, pooled and 
transferred to 15 ml Falcons then centrifugation was repeated. Supernatant was removed and 
plasmid purification was performed using Megaprep and Maxiprep kits (Section 7.1.3.3). All 
DNA was pooled and quantified using a NanoDrop® ND-1000 UV-Vis Spectrophotometer.  
Details of PCR amplification, purification and sequencing of the gRNAs in the resulting 
neoR-IRES library are provided in Section 7.12. 
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7.8 Lentivirus production and titration 
7.8.1  Lentivirus production 
All values given are for lentivirus production in a T150 flask (Table 7.12); these were scaled 
according to surface area for different culture dishes. HEK293T cells were cultured in IMDM 
(#12-722F, Lonza) supplemented with 10% Fetal Bovine Serum (FBS) (#A3160401, Gibco, 
ThermoFisher) and incubated at 37oC, 5% CO2. Cells were seeded at a density of 18x106 
cells/T150 24 hours prior to transfection. Immediately before transfection, medium was 
aspirated and replaced with 12.5 ml Opti-MEM™ (#31985062, Gibco, ThermoFisher). 
Transfer vector and packaging plasmids pMD2.G (Addgene #12259) and psPAX2 (Addgene 
#12260) were diluted in Opti-MEM™. PLUS™ reagent (#15338100, ThermoFisher) was then 
added and the mixture was inverted 10-15x and incubated for 5 minutes at room temperature. 
Lipofectamine™ LTX (#15338100, ThermoFisher) was added, the solution was inverted 10-
15x and incubated for 30 minutes at room temperature. The lipofectamine/DNA complex was 
then carefully added to the cells. After 16 hours, virus medium was aspirated and replaced with 
24 ml complete IMDM. Approximately 30 hours later, virus supernatant was collected and 
filtered with a 0.45 µm low protein-binding filter (#SLHP033RS, Merck). Aliquots were stored 
at -80oC and were frozen for at least 2 hours before being used in experiments. 
 
Table 7.12. Composition of lentiviral transfection complex. 
Reagent Volume/amount 
Opti-MEM™ 7.5 ml 
Transfer vector 7.5 µg 
psPAX2 18.5 µg 
pMD2.G 4 µg 
PLUS™ reagent  30 µl 
Lipofectamine™ LTX 90 µl 
 
7.8.2  Lentivirus titration 
All lentiviruses described in this thesis were titrated by measuring fluorescent marker 
expression using flow cytometry (Section 7.9). Cells were detached and diluted to the 
concentration that would be required for the assay in which the lentiviruses would be used. For 
HAP1 cells, polybrene was added to a final concentration of 8 µg/ml; for iPSCs no polybrene 
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was used. Cell suspension was then added to a 6-well plate and varying volumes of virus were 
added to each well. As a control, one well was cultured without virus. After 48 hours, cells 
were detached and prepared for flow cytometry (Section 7.9). Untransduced cells were used to 
set a gate for fluorescent marker expression. The % of positive cells was used as an indicator 
of the MOI at each dose, and a line of best fit was plotted to allow calculation of the virus 
volume required for any given MOI. The amount of virus, cell number and total volume were 
then scaled based on the culture surface area used in further experimental transductions. 
 
 
7.9 Analysis of cells by flow cytometry 
7.9.1 Cell fixation 
iPSCs or HAP1 cells were detached, transferred to an Eppendorf and centrifuged at 300 g for 
3 minutes. Supernatant was removed and cells were washed with 500 µl PBS to remove 
residual medium. Centrifugation was repeated (300 g, 3 minutes), PBS was removed and cells 
were resuspended in 100 µl of 4% PFA (#F8775, Sigma). Fixation was carried out at room 
temperature for 15 - 20 minutes, then 500 µl PBS was added. Cells were centrifuged (300 g, 3 
minutes) and the supernatant was discarded. Cells were resuspended in 500 µl PBS, centrifuged 
(300 g, 3 minutes) and supernatant was removed. Finally, cells were resuspended in PBS 
(volume dependent on pellet size, generally ~ 500 µl) and transferred to a Falcon® 5 ml Round 
Bottom Polystyrene Tube (#352054, Corning).  
 
7.9.2 Flow cytometry analysis 
Cells were analysed using a BD LSRFortessa™ (or occasionally BD LSRII) with BD 
FACSDiva™ software. Expression of BFP (405 (450/50)) and GFP (488 (530/30)) were 
detected on the Fortessa or LSRII, and mCherry (561 (610/20)) was detected only on the 
Fortessa. Results were then further analysed and plotted using FlowJo.  
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7.10 Engineering stable Cas9 lines 
7.10.1 Cas9 transduction 
A plasmid expressing Cas9 and blasticidin resistance (Addgene #68343) was packaged into a 
lentivirus (Section 7.8.1). Cells were detached and transduced in suspension. For iPSC lines, 
7.5x105 cells were transduced with 450 µl of lentivirus and seeded in a 6 cm2 dish. For HAP1 
cells, 5x105 cells were transduced with 100 µl of lentivirus plus 8 µg/ml polybrene and seeded 
in a T25 flask. In both cases, control cells containing no lentivirus were seeded in parallel. The 
following morning, fresh complete medium was added. At 48 hours post-transduction, 10 
µg/ml blasticidin was added (#antbl-1, InvivoGen). Complete death in the control flask 
confirmed successful blasticidin selection. All iPSC and HAP1 Cas9-expressing cell lines were 
continuously cultured in blasticidin, except during screens, to ensure high Cas9 activity was 
maintained. After ~2 weeks of selection, Cas9 activity was assessed (Section 7.10.2) to confirm 
that lines were functional before freezing stocks and using in further assays.  
 
7.10.2 Quantification of Cas9 activity 
Two vectors were used to assess Cas9 activity; one expressing BFP and GFP (control, Addgene 
#67979) and one expressing BFP, GFP and a gRNA targeting GFP (reporter, Addgene 
#67980). Both vectors were packaged into lentiviruses (Section 7.8.1). Cells were detached 
and transduced in suspension; one condition with no lentivirus, one with the control and one 
with the reporter. For iPSC lines, 2x105 cells/well were seeded in a 12-well plate with 50 µl of 
lentivirus. For HAP1 lines, 2x105 cells/well were seeded in a 6-well plate with 100 µl of 
lentivirus and 8 µg/ml polybrene. Fresh complete medium was added the following morning 
and after 48 hours cells were fixed and analysed by flow cytometry (Section 7.9). BFP and 
GFP expression were measured, using untransduced cells and cells transduced with the control 
vector to set gates for both markers. 
 
  
NeoR-IRES library screen in iPSCs  164 
7.11 NeoR-IRES library screen in iPSCs 
7.11.1 Library transduction 
The neoR-IRES gRNA library was packaged into a lentivirus and titred in all stable Cas9 iPSC 
lines (parental and KOs) (Section 7.8). For each screened line, cells were split into three 
separate populations at the passage prior to transduction. Each population was then detached 
and counted as single cells, and three separate transduction replicates were set up. For each 
replicate, a total of 54x106 cells were transduced with the library lentivirus at an MOI of 0.3 in 
594 ml total (50x106 cells were seeded but extra cells were transduced to allow for volume lost 
in pipetting). Cells were then seeded at 2x106 cells/dish in a 15 cm dish (25 dishes total, for 
screens I performed) or 3.4x106 cells in a T225 (17 flasks total, for screens CGaP performed). 
A small sample (3 ml of transduced cell suspension) was seeded in a 6 cm2 dish for each 
replicate, and untransduced cells were also seeded in parallel at the same density. After 48 
hours, 1 mg/ml G418 was added to all transduced cells. The small samples of transduced and 
untransduced cells were fixed and BFP expression was analysed by flow cytometry to measure 
transduction rate (Section 7.9). Untransduced cells were re-seeded and maintained in parallel 
with the screens. 
 
7.11.2 Passage of cells during screen 
For the screens that I performed, cells were passaged as clumps on day 8 post-transduction. 
Medium was aspirated and cells were washed with PBS. Gentle Dissociation Reagent (#07174, 
STEMCELL) was added (10 ml/15 cm dish) and cells were incubated at 37oC for 10 minutes. 
An equal volume of TeSR-E8 was then added and the suspension was mixed no more than 5 
times with a stripette. All cells were combined in a single bottle for each replicate and mixed 
gently by inversion.  
To give a more accurate estimate of cell count, 3 ml of cell suspension was transferred to 
1.5 ml Eppendorfs (1 ml/Eppendorf) and mixed further to dissociate clumps to single cells. 
Cells were centrifuged for 3 minutes at 300 g, media was aspirated and 500 µl of accutase was 
added. Cells were incubated in the Eppendorfs for 5-10 minutes at 37oC. An equal volume of 
TeSR-E8 was added and 10 µl from each Eppendorf was mixed with Trypan blue and counted 
using a Countess™ II Automated Cell Counter. Based on the average cell count, cells were 
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diluted in TeSR-E8 and 50x106 cells total were maintained per replicate. Cells were seeded at 
the same density of 2x106 cells/152 cm2, but in 5x 5-layer flasks (#11597421, Corning).  
For screens that CGaP performed, the same protocol was followed but cells were passaged 
as clumps on day 6 post-transduction, maintaining 100x106 cells total per replicate in 10x T225 
flasks. Cells were then passaged as clumps again on day 8/9 post-transduction, maintaining 
50x106 cells total per replicate in 5x 5-layer flasks (#11597421, Corning). 
At the point of passage, a small sample of cells from each replicate was fixed and BFP 
expression was analysed by flow cytometry (Section 7.9). Untransduced cells that had been 
maintained in parallel were also fixed and analysed as a control. 
 
7.11.3 Harvesting of cells at screen endpoint 
Cells were maintained in 1 mg/ml G418 until day 13 post-transduction. Cells were then 
detached as single cells using accutase, counted and 60x106 cells were transferred to a 50 ml 
Falcon. A small sample of cells from each replicate was also fixed and BFP expression was 
analysed by flow cytometry (Section 7.9). Untransduced cells that had been maintained in 
parallel were also fixed and analysed as a control. Cells were centrifuged at 300 g for 3 minutes 
and the supernatant was aspirated. Pellets were resuspended in PBS, transferred to a 15 ml 
Falcon and centrifuged again. PBS was aspirated and the pellets were stored at -80oC until 
DNA extraction.  
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7.12 Sequencing of neoR-IRES library gRNAs 
7.12.1 DNA extraction  
For each screen replicate, gDNA was extracted from pellets of 60x106 cells using a Blood & 
Cell Culture DNA Maxi Kit, with each pellet split over two columns (#13362, QIAGEN).  
 
7.12.2 First round PCR & purification 
PCR was performed to amplify the gRNA region of the gDNA in each screen sample and the 
plasmid DNA from the neoR-IRES library (Table 7.13, primers detailed in Appendix A.1). A 
total of 72 PCR reactions with 2 µg gDNA/reaction were performed for every screen sample 
to ensure high representation of the library. For sequencing of the library from plasmid DNA, 
the same PCR was performed but with 10 reactions and 15 ng plasmid DNA/reaction.  
 
Table 7.13. First round gRNA PCR. Top - reaction composition, bottom - thermocycler conditions. 
Reagent Volume/amount per rxn 
Genomic DNA 2 µg 
Q5 HS HF 2X MM 25 µl 
Primer mix (10 µM of both forward and reverse) 1 µl 
Nuclease-free water to 50 µl total 
 
Cycle Number Denature Annealing Extension 
1 98˚C, 30 seconds   
2-29 (28 cycles in total) 98˚C, 10 seconds 61˚C, 15 seconds 72˚C, 20 seconds 
30   72˚C, 2 minutes 
 
To confirm successful amplification, 5 µl of each reaction was visualised on an agarose gel 
(Section 7.1.1). For each sample, 5 µl of all PCR reactions was pooled and purified using a 
QIAquick PCR Purification Kit (#28104, QIAGEN), following the manufacturer’s protocol. 
The PCR products were then quantified using a High Sensitivity Qubit and diluted to 40 pg/µl.  
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7.12.3 Second round PCR & purification 
A second PCR was performed to add sequencing tags to the initial product (Table 7.14, primers 
detailed in Appendix A.1). 
 
Table 7.14. Second round gRNA PCR. Top - reaction composition, bottom - thermocycler conditions. 
Reagent Volume 
1st PCR Product (40 pg/µl dilution) 5 µl (200 pg) 
Primer mix (5 µM of both forward and reverse) 2 µl 
Nuclease-free water 18 µl 
KAPA HF HS 2X MM (#KK2601, Kapa Biosystems) 25 µl 
 
Cycle Number Denature Annealing Extension 
1 98˚C, 30 seconds   
2-9 (8 cycles in total) 98˚C, 10 seconds 66˚C, 15 seconds 72˚C, 20 seconds 
10   72˚C, 5 minutes 
 
For each sample, 1 µl of PCR product was run on a Bioanalyser to confirm that the correct 
band (~300 bp) was present at ~ 2 ng/µl. AMPure SPRI beads were added to the PCR products 
at a ratio of 0.8:1, mixed by pipetting and incubated at room temperature for 5 minutes. The 
Eppendorfs were placed on a magnetic rack for 5 minutes to allow the beads to be pulled out 
of the solution, and the supernatant was discarded. Samples were then washed twice with 200 
µl of 80% ethanol for 30 seconds. Ethanol was discarded, the tube was centrifuged briefly to 
remove residual ethanol and then left to air dry for 5 minutes. The Eppendorfs were removed 
from the magnet and 35 µl of nuclease-free water was added; samples were left for 3 minutes 
to allow the DNA to elute. Tubes were placed back on the magnet for 3 minutes and the DNA 
solution was transferred to a clean Eppendorf.  The Bioanalyser was used to confirm that the 
clean-up was successful and samples were stored at -20oC prior to sequencing.  
Single-end sequencing was performed on an Illumina HiSeq 2500 (primer detailed in 
Appendix A.1). Generally, six screen samples (replicates from two screens) were multiplexed 
and run together in two lanes. The neoR-IRES library was sequenced alone in two lanes. 
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7.12.4 Sequencing data analysis 
After sequencing, reads were aligned to the gRNA sequences by the internal CASM pipeline. 
I then performed all analysis of gRNA sequencing data, with guidance and scripts kindly 
provided by Vivek Iyer (previous senior bioinformatician, Adams’ lab) and Francesco Iorio 
(group leader, WSI). Details of the data analysis are provided in the relevant results chapters. 
 
7.13 Assays to test library toxicity and expression issues 
7.13.1 Comparison of BFP expression in BOB and BOB-Cas9 cells 
BOB and BOB-Cas9 cells were detached as single cells, counted and transduced in suspension 
with the neoR-IRES library lentivirus. Both lines were seeded at 1.8x105 cells/well in a 6-well 
plate with 0-90 µl of lentivirus and 2 ml total volume. After 72 h, cells were fixed and BFP 
expression was analysed by flow cytometry (Section 7.9).  
 
7.13.2 Assay to measure BFP expression in single colonies 
After completion of genome-wide screening with the neoR-IRES library, a small fraction of 
BOB-Cas9 cells were maintained in culture. Cells were seeded at a low density and after 
several days in culture, medium was aspirated and PBS was added. Under the microscope, 18 
single colonies were scraped from the dish and transferred to a 24-well plate. Additionally, 2 
colonies were picked from a population of untransduced BOB-Cas9 cells cultured for the same 
period of time These were cultured for 2 weeks and at the point of passage, a sample of cells 
were fixed and analysed by flow cytometry to measure BFP expression (Section 7.9). 
 
7.13.3 Assay to test cross-resistance to G418 
A BOB-Cas9 clonal line with ~100% BFP expression was mixed with an untransduced BOB-
Cas9 clonal line (from the assay described in Section 7.13.2). Cells were detached as single 
cells, counted and combined in various ratios: 0:100, 30:70, 50:50, 75:25, 100:0 (BFP 
positive:untransduced). From these mixtures, 24,000 cells total/well were seeded in 12-well 
plates +/- 1 mg/ml G418. The remaining cells for each condition were fixed and analysed by 
flow cytometry to measure BFP expression (Section 7.9). After 5 days in culture, this analysis 
was repeated.  
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7.14 Karyotyping of iPSCs 
iPSCs were harvested for karyotyping at 50-70% confluency. First, medium was aspirated and 
fresh TeSR-E8 medium with 10 µM ROCK inhibitor was added to the cells. Cells were then 
transferred to Sandra Louzada Gomes Pereira (FISH facility at WSI) to perform the rest of the 
assay. Nocodazole was added to a final concentration of 25-100 ng/ml and incubated for 2-3 
hours at 37oC, 5% CO2. Medium was transferred to a Falcon and cells were washed with PBS 
pre-warmed to 37oC. 1 ml of 37oC accutase was added and cells were incubated at 37oC, 5% 
CO2 for 3-5 minutes. Cells were resuspended using the medium removed previously and 
centrifuged at 300 g for 5 minutes. Supernatant was aspirated and cells were resuspended 
gently in 8-10 ml of hypotonic buffer (0.4% KCl in 10 mM HEPES, pH 7.4). Cells were 
incubated for 10-20 minutes at 37oC, 5% CO2. 1 ml of fixative (4:1 methanol:glacial acetic 
acid) was added and the tube was gently inverted. Cells were centrifuged at 300 g for 5 minutes, 
supernatant was removed and cells were resuspended. 1 ml of fixative was slowly added, mixed 
by pipetting and hypotonic buffer was added to a total volume of 10 ml. Cells were centrifuged 
at 300 g for 5 minutes and supernatant was removed. Cells were resuspended in 1 ml of fixative 
and 10-12 µl was dropped on to a clean microscope slide. Preparation of human 24-colour M-
FISH probes and slide treatments were performed as described in 325,326. Ten metaphases were 
analysed per sample. 
 
 
7.15 Staining for pluripotency markers 
This assay was performed with the assistance of Mary Goodwin (CGaP, WSI). 
 
7.15.1 Seeding and fixation  
BOB-Cas9 cells (untransduced and cells that had been screened with the neoR-IRES library) 
were detached as single cells, counted and seeded at 10,000 cells/well in a CELLSTAR® black 
96-well plate (#655090, Greiner Bio-One). Cells were fixed after 72 hours: medium was 
aspirated and 50 µl of 4% PFA (#F8775, Sigma) was added to each well. Fixation was carried 
out at 4oC for 20 minutes. PFA was aspirated and cells were washed twice with 100 µl/well of 
PBS for 5 minutes at room temperature. Prior to staining, 100 µl/well of PBS was added, the 
plate was sealed in parafilm and stored at 4oC.  
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7.15.2 Staining 
PBS was aspirated and 100 µl/well of 1% blocking solution (1g BSA/100 ml of 0.1% Triton 
X-100 in PBS) was added. Blocking solution was aspirated and 50 µl/well of diluted primary 
antibody (Table 7.15) was added (four wells/antibody for each cell line). As a control, 50 
µl/well of 1% blocking solution was added (two wells/antibody for each cell line). Plates were 
sealed with parafilm and incubated overnight at 4oC. DAPI solution (10 mg/ml) was added to 
each secondary antibody dilution to a final dilution of 1:1000, and these were kept on ice and 
protected from light. Primary antibody was aspirated and cells were washed three times with 
100 µl/well PBS for 5 minutes. 50 µl/well of diluted secondary antibody plus DAPI was added, 
the plate was wrapped in foil and incubated at room temperature for 1 hour. Secondary antibody 
was aspirated and cells were washed 3 times with 100 µl/well PBS for 5 minutes. After the 
final wash, 100 µl/well of PBS was added and plates were sealed with a foil cover and stored 
at 4oC prior to analysis. 
Cells were analysed using an ArrayScan VTI HCS Reader. For each well, 10,000-12,000 
DAPI positive cells were analysed for the presence of OCT4, NANOG or SOX2. The mean % 
of positive cells was calculated across the 4 technical replicates for each condition and the % 
of positive cells in the relevant control wells was subtracted to remove any background.  
 
Table 7.15. Antibodies for pluripotency test. 
 
 
 
 
 
Antibody Supplier Product # 
Dilution (in 1% 
blocking solution) Secondary antibody 
Primary antibodies 
Oct4 
Santa Cruz 
Biotech SC-5279 1:100 Donkey anti-mouse 
Sox2 R&D Systems AF2018 1:100 Donkey anti-goat 
Nanog R&D Systems AF1997 1:100 Donkey anti-goat 
Secondary antibodies 
Donkey anti-
mouse (AF647) Invitrogen A31571 1:1000 - 
Donkey anti-goat 
(AF488) 
Invitrogen A11055 1:1000 - 
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7.16 Validation assays 
7.16.1 HAP1 cell culture 
HAP1 cells (parental and knockout derivatives, Table 7.16) were purchased from Horizon 
Discovery (Cambridge, UK). All lines were cultured in IMDM (#12440053, Gibco, 
ThermoFisher) supplemented with 10% FBS at 37oC, 5% CO2. Knockout lines were genotyped 
to confirm their mutational status as described in Section 7.4. 
 
Table 7.16. Details of HAP1 cell lines. 
Cell line Mutation Product code 
HAP1 parental control N/A C631 
HAP1 ARID1A knockout 13 bp deletion in exon 2 HZGHC000618c010 
HAP1 ARID1B knockout 13 bp deletion in exon 2 HZGHC000582c007 
HAP1 ARID2 knockout 7 bp deletion in exon 3 HZGHC000907c009 
HAP1 PBRM1 knockout 8 bp deletion in exon 3 HZGHC001135c010 
 
7.16.1.1 Thawing HAP1 cells 
Cryovials were heated in a 37oC water bath to thaw the cell suspension. A 4-fold volume of 
medium was added and centrifuged at 300 g for 3 minutes. The supernatant was aspirated, cells 
were resuspended and transferred to a flask containing fresh medium.  
 
7.16.1.2 Passaging HAP1 cells 
(All volumes given are for a T75 flask.) Medium was aspirated and cells were washed with 10 
ml PBS. To detach cells, 2 ml of trypsin-EDTA (#25200056, Gibco, ThermoFisher) was added 
and incubated at 37oC for 3-5 minutes. An equal volume of medium was added to neutralise 
the trypsin and cells were transferred to a new flask, diluted to 1:15 for general maintenance. 
If an exact density was required, 10 µl of cell suspension was mixed 1:1 with Trypan Blue and 
live cell count was then calculated using a Countess™ II Automated Cell Counter. 
 
7.16.1.3 Freezing HAP1 cells 
Cells were detached as described above, and centrifuged at 300 g for 3 minutes. The 
supernatant was aspirated and cells were re-suspended in complete medium supplemented with 
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20% FBS and 10% DMSO. Cells were transferred to a cryovial and stored in a polystyrene 
rack at -80oC for 48 hours before being transferred to liquid nitrogen. 
 
7.16.2 Cloning single gRNAs for validation 
For validation of the ARID1A/ARID1B synthetic lethal interaction, gRNAs were selected from 
the neoR-IRES genome-wide library. For each gRNA, a pair of single-stranded DNA 
oligonucleotides containing the gRNA sequence (sense and anti-sense) were ordered, with 
overlaps to allow for cloning (Appendix A.1). Each oligonucleotide pair was phosphorylated 
and annealed (Table 7.17) in a thermocycler at 37oC for 30 minutes followed by 95oC for 5 
minutes, then left to cool to room temperature. Annealed oligonucleotides were diluted to 7.1 
fmol/µl in EB buffer (Qiagen).  
 
Table 7.17. Cloning single gRNA plasmids. Top - annealing gRNA oligonucleotides, bottom left - 
restriction digest with BbsI, bottom right - ligation of gRNAs into backbone. 
Reagent Volume 
100 µM top strand oligo 1 µl 
100 µM bottom strand oligo 1 µl 
10X T4 ligase buffer  1 µl 
T4 PNK enzyme (#M0201, NEB) 0.5 µl 
Nuclease-free water 6.5 µl 
 
Reagent Volume 
20 ng/µl digested backbone 1 µl 
7.1 fmol/µl annealed oligo 2 µl 
10X ligase buffer 1 µl 
T4 ligase enzyme (#M0202S, NEB) 1 µl 
Nuclease-free water 5 µl 
 
gRNA backbones containing either mCherry (Addgene #67977) or BFP (Addgene #67974) 
were digested with BbsI for 3 hours at 37oC then heat inactivated at 65oC for 20 minutes (Table 
7.17). Digestion was confirmed on an agarose gel (Section 7.1.1) and both vectors were column 
purified (Section 7.1.2.1) then diluted to 20 ng/µl in nuclease-free water (QIAGEN).  
 
Reagent Volume/amount 
Plasmid 5 µg 
10X CutSmart Buffer 5 µl 
BbsI (#R0539S, NEB) 1 µl 
Nuclease-free water to 50 µl total 
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Ligations were performed to insert each gRNA into either the mCherry or BFP backbone; these 
were incubated at 16oC for 2 hours (Table 7.17). For each ligation, 2.5 µl was chemically 
transformed into 25 µl of OneShot TOP10 cells (Section 7.1.3.1). Three colonies per ligation 
were then inoculated in liquid LB broth + 100 µg/ml ampicillin and plasmid DNA was purified 
(Section 7.1.3.3). Successful cloning was confirmed by Sanger sequencing (Eurofins) of the 
gRNA region (Appendix A.1). One clone for each gRNA was packaged into a lentivirus and 
titred in BOB-Cas9 cells (Section 7.8). An mCherry backbone containing a gRNA targeting 
ACCSL and a BFP backbone containing a gRNA targeting AIP1L (the same backbones used 
for ARID1A/ARID1B gRNA cloning) were kindly provided by Nicola Thompson (PhD student 
in the Adams’ lab). 
 
7.16.3 Competitive growth assays for ARID1A/ARID1B SLI validation 
7.16.3.1  Double gRNA assay 
Cells were detached as single cells, counted and transduced in suspension. BOB-Cas9 cells 
were seeded at a density of 180,000 cells/well in a 6-well plate with 2 ml total volume. Each 
well was transduced with two lentiviruses, both containing a single gRNA plasmid, aiming for 
an MOI of ~0.6 for each. The following combinations of gRNA plasmids were transduced: 
ARID1B/ACCSL, ARID1A/AIPL1, ACCSL/AIPL1. A control well with no lentivirus was also 
included. Fresh complete medium was added the following morning. After 48 hours, cells were 
passaged to a new 6-well plate and a sample from each condition was fixed for flow cytometry 
analysis (Section 7.9). BFP and mCherry expression were measured to establish a baseline 
level; the % of cells in each population (two single positives and a double positive) was 
normalised against the untransduced population to calculate relative abundance. Cells were 
maintained for 2 weeks post-transduction, then were fixed for flow cytometry analysis (Section 
7.9). BFP and mCherry expression were measured again and the % of cells in each population 
was normalised against the untransduced population to calculate relative abundance. The 
log2(fold-change) in relative abundance between day 14 and day 2 was calculated, as a measure 
of change in expression. The expected growth phenotype of the double positive population was 
calculated as the sum of the changes in both single positive populations.  
 
 
Validation assays  174 
7.16.3.2  Single gRNA assay 
BOB-Cas9, ARID1A_C09-Cas9 and ARID1B_C03-Cas9 lines were seeded and assayed in the 
same way as described in Section 7.16.3.1, but each line was transduced with only a single 
gRNA lentivirus per well. BOB-Cas9 cells were transduced with AIPL1, ARID1A and ARID1B 
gRNA plasmids. ARID1A_C09-Cas9 cells were transduced with AIPL1 and ARID1B gRNA 
plasmids. ARID1B_C03-Cas9 cells were transduced with AIPL1 and ARID1A gRNA plasmids. 
The % of BFP positive cells on day 14 was calculated as a log2(fold-change) relative to day 2.  
 
7.16.4 Sanger arrayed library gRNAs 
An internal facility at WSI hold glycerol stocks for all gRNAs in the Sanger Human Whole 
Genome CRISPR arrayed library. I provided a 96-well block containing liquid LB broth + 100 
µg/ml ampicillin and the facility inoculated each well with a single gRNA plasmid (Appendix 
A.1). I cultured these overnight in a shaking incubator at 37oC, 225 rpm, prepared glycerol 
stocks and purified plasmid DNA (Section 7.1.3). Each plasmid was sent for Sanger sequencing 
(Eurofins) with a primer complementary to the U6 promoter (Appendix A.1) to confirm the 
correct gRNA was present. These were then packaged into lentiviruses (Section 7.8.1). 
 
7.16.5 Competitive growth assays for validation of screen hits 
Cells were detached, counted and transduced in suspension (as described in Sections 7.2.3 and 
7.15.1.2). HAP1-Cas9 cells (parental and KOs) were seeded at a density of 90,000 cells/well 
in a 12-well plate with 1 ml total volume. BOB-Cas9, ARID1A_C09-Cas9, ARID1B_C03-
Cas9, ARID2_C11-Cas9 and PBRM1_F09-Cas9 cells were seeded at 100,000 cells/well in a 
12-well plate or 200,000 cells/well in a 6-well plate with 1 ml or 2ml total volume, respectively. 
Polybrene was added to a final concentration of 8 µg/ml (for HAP1-Cas9 lines only) and each 
well was transduced with a lentivirus containing a single gRNA plasmid, aiming for an MOI 
of 0.5-0.8. A control well with no lentivirus was always included. Fresh complete medium was 
added the following morning. After 48 hours, cells were passaged to a new plate and a sample 
of each condition was fixed for flow cytometry analysis (Section 7.9). BFP expression was 
measured to establish a baseline level. Cells were maintained for 2 weeks post-transduction, 
then cells were fixed for flow cytometry analysis (Section 7.9) (iPSCs did not survive past 1 
week). Expression of BFP was measured again on day 14 for HAP1-Cas9 cells and a log2(fold-
change) was calculated relative to day 2, to assess change over time.  
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7.17 Methods for in vivo CRISPRa project  
7.17.1 Cell culture 
B16-F0-dCas9 cells were cultured in DMEM-high glucose medium (#11965092, Gibco, 
ThermoFisher), supplemented with 10% FBS, 1% penicillin/streptomycin/glutamine and 15 
µg/ml blasticidin. Cells were incubated at 37oC, 5% CO2. For passaging, medium was aspirated 
and the cells were washed once with 10 ml PBS (values given for a T150 flask). Cells were 
then incubated in 5 ml of trypsin-EDTA at 37oC for 5 minutes until they detached. An equal 
volume of medium was added, cells were re-suspended and seeded in a new flask with fresh 
medium, generally at a dilution of 1:15-1:30. Cells were counted by mixing 1:1 with trypan 
blue and analysing live cell number using a Countess™ II Automated Cell Counter 
(ThermoFisher). 
 
7.17.2 Preparation of the CRISPRa library 
The mCRISPRa-v2 m6 subpooled library was obtained from Addgene (#84003), transformed 
into ElectroMAX™ DH5α-E™ Competent Cells (#11319019, Invitrogen, ThermoFisher) and 
re-amplified in liquid culture following the Weismann lab protocol (available on the Addgene 
page). DNA was extracted using a QIAGEN EndoFree Plasmid Mega Kit (#12381, QIAGEN). 
 
7.17.3 Titration of CRISPRa lentiviruses 
Lentiviruses were prepared as described in Section 7.8.1. To measure the titre of the 
lentiviruses, cells were detached and diluted to 9x104 cells/ml. Polybrene was added to a final 
concentration of 8 µg/ml. 2 ml of cell suspension was then added to a 6-well plate and different 
volumes of virus were added to each well. As a control, one well was cultured without virus. 
After 48-72 hours, cells were detached and prepared for flow cytometry (Section 7.9) 
Untransduced cells were used to set a gate for BFP expression. The % of BFP positive cells 
was used as an indicator of the MOI at each dose, and a line of best fit was plotted to allow 
calculation of the volume required for any given MOI. The amount of virus, cell number and 
total volume were scaled based on the culture surface area used in further transductions. 
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7.17.4 CRISPRa screen 
7.17.4.1 In vitro phase 
A total of 12x106 cells were transduced with the m6 library lentivirus at an MOI of 0.3 in 180 
ml total volume with 8 µg/ml polybrene. The cell suspension was split into 6x T150 flasks. A 
culture of untransduced cells was maintained in parallel as a control. Medium was changed the 
following day. Cells were passaged after 48 hours and 16x106 cells were re-seeded in 5 µg/ml 
of puromycin was added. A small sample of transduced and untransduced cells were analysed 
by flow cytometry to measure BFP expression and confirm successful transduction (Section 
7.9). After a further 4 days, cells were passaged again, maintaining 12x106 cells. As before, 
some cells were taken for analysis by flow cytometry (Section 7.9). On day 9, cells were 
detached, counted, centrifuged at 300g for 5 minutes then diluted in PBS. In parallel, aliquots 
of 5.5x106 (500x) cells were pelleted and frozen at -80oC.  
 
7.17.4.2 In vivo phase 
Seventy wildtype (C57BL6/NTac) female mice aged 6-8 weeks were intravenously 
administered (via the tail vein) 100 µl of cells in PBS at a concentration of 5.5x106 cells/ml.  
Mice were then Schedule 1 sacrificed at two timepoints: 4 hours post-dosing and day 19 post-
dosing (35 mice per timepoint), and saline cardiac perfused (to remove any blood from the 
lungs, thus removing circulating tumour cells). The lungs were then collected and snap-frozen.   
 
7.17.5 Processing of CRISPRa screen samples 
gDNA was extracted from both the lung samples and the ‘day 0’ B16-F0-dCas9 cells using the 
Puregene kit (Qiagen) according to the manufacturer’s protocol. PCR reactions were performed 
with 500 ng of gDNA per reaction, using the Phusion® High-Fidelity PCR Master Mix with 
HF Buffer (#M0531L, NEB) to amplify the gRNAs. The forward primer contained an 8mer 
barcode, 5’ Illumina adapters and homology to the CRISPRia-v2 plasmid. The reverse primer 
contained 3’ Illumina adapters and homology to the CRISPRia-v2 plasmid. For each lung, 16 
PCR reactions were performed and all products were pooled. A portion of this was purified to 
select for only the ~280 bp product, using a Select-a-Size DNA Clean & Concentrator kit 
according to the manufacturer’s protocol (#D4080, Zymo). PCR was also performed on gDNA 
from the B16-F0-dCas9 cells collected on the day of dosing and the library plasmid DNA. 
Purity of all PCR samples was confirmed by analysis on a Bioanalyser. The samples were then 
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combined in two pools (each containing 35 lung samples + 2 cell samples + 1 plasmid sample) 
and sequenced on a HiSeq2500. Two sequencing primers were used: a bespoke primer and a 
standard Illumina primer. 
 
7.17.6 Analysis of sequencing data 
All sequencing results were processed and further analysed by Vivek Iyer using the methods 
described in Section 6.2.3. 
 
7.17.7 Validation of screen hits  
7.17.7.1 Preparation of single gRNA plasmids 
Single gRNAs (detailed in Section 6.2.4) were individually cloned into the CRISPRia_v2 
backbone, following the Weissman lab protocol (this can be accessed at 
https://weissmanlab.ucsf.edu/CRISPR/CRISPR.html). Plasmids were sent for Sanger 
sequencing (Eurofins) to confirm successful insertion of the gRNAs. The gRNA plasmids were 
packaged into lentiviruses (Section 7.8.1) and titred in B16-F0-dCas9 cells (Section 7.17.3). 
 
7.17.7.2 In vitro phase 
A total of 5x105 cells were transduced with each lentivirus at an MOI of 0.3 and 8 µg/ml 
polybrene, in a total volume of 5.5 ml. Cells were seeded in a T25 flask. Untransduced cells 
were maintained in parallel as a control. Cells were processed, selected and analysed by flow 
cytometry in the same way as described for the screen (Section 7.17.4.1). 
 
7.17.7.3 In vivo phase 
On day 10 post-transduction, cells were detached, counted and diluted to 2x106 cells/ml in 
PBS. Intravenous administration was performed via the tail vein with 100 µl of cell suspension 
(2x105 cells per mouse). In every cohort, 8-10 wildtype (C57BL/6NTac) mice aged 6-8 weeks 
were dosed per gRNA (both sexes were used for different cohorts, but same sex used within a 
cohort). On day 10 post-dosing, lungs were collected from all mice and metastases were 
counted by eye. The number of metastases present in mice carrying cells transduced with each 
gRNA was compared to those carrying the control gRNAs (NTC pool) in the same cohort. A 
Mann-Whitney test was performed to determine the significance of any differences observed. 
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Appendix A 
Datasets that were too large to be included in the main thesis have been provided in a digital 
format and have been referenced throughout. The contents of each file are detailed below. 
 
A.1 Oligonucleotide sequences 
Sequences and details are provided for all oligonucleotides, primers, and gRNAs used for the 
work described in this thesis. They are grouped into different sheets based on the section of 
work that they relate to. 
 
A.2 Mass spectrometry data 
The log2(fold-change) in protein abundance for each KO line (compared to the parental BOB 
line) is shown for all targeted proteins. 
 
A.3 NeoR-IRES library backbone 
The plasmid map and full sequence of the final neoR-IRES library backbone is provided. 
 
A.4 gRNA library read counts 
The raw gRNA read counts from HiSeq2500 analysis of the neoR-IRES, Yusa v1, and Yusa 
v1.1 gRNA libraries are provided. 
 
A.5 Bayes Factors for iPSC screens 
The gene-level BFs obtained from BAGELR analysis of each screen are shown. 
 
A.6 Scaled Bayes Factors for iPSC screens 
Gene-level BFs were scaled based on an FDR of 0.05, with any value greater than 0 
representing a significant hit. Scaled BFs for all screens are shown. 
 
A.7 MAGeCK depletion values for iPSC screens 
The gene-level depletion (negative FDR) values obtained from MAGeCK analysis of each 
screen are shown.  
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A.8 Biological replicate overlaps 
Genes that were significantly depleted in the biological replicates of the parental BOB and 
TP53 KO line screens are shown. 
 
A.9 KO-specific depleted genes 
This file shows genes that were significantly depleted in each KO line (based on BAGELR 
analysis) but not in the parental BOB line screens. Results are provided for three filtering 
strategies. Genes with a scaled BF > 0 (highlighted in red) were significantly depleted. 
 
A.10 MAGeCK enrichment values for iPSC screens 
The gene-level enrichment (positive FDR) values obtained from MAGeCK analysis of each 
screen are shown.  
 
A.11 PBAF/BAF mutant cancer cell lines 
Of the cell lines screened by the Sanger109 and Broad,261 those lines that harbour LOF (nonsense 
or frameshift indel) mutations in ARID1A, ARID1B, ARID2 or PBRM1 are listed. These were 
used for the association analyses described in Chapter 4.  
 
A.12 Sanger Institute screen data 
Scaled BFs (FDR 0.05) are provided for all cancer cell line screens screened by Sanger, as 
published by Behan et al. (2019).109 
 
A.13 Broad Institute screen data 
Raw gRNA counts from the Broad cancer cell line screens261 were re-processed using the 
pipeline applied by Behan et al.109 (by Clare Pacini, a postdoctoral fellow in Francesco Iorio’s 
lab). Scaled BFs (FDR 0.05) obtained from BAGELR analysis are shown for all lines. 
 
A.14 Candidate PBAF-BAF gene SLIs 
Genes that were identified after filtering for hits specific to PBAF/BAF gene KO lines (as 
described in Section 4.3) are provided, with the scaled BFs shown for all screens that were 
used in the filtering. Their status at each stage of the filtering is indicated in the final columns. 
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Figure B.1. Karyotype of KO BOB-Cas9 cells. M-FISH of ARID1A_C09-Cas9 (a), ARID1B_C03-
as9 (b), ARID2_C11-Cas9 (c), and PBRM1_F09-Cas9 (d) cell lines. Ten randomly selected metaphases 
were analysed for each line; a representative karyotype is shown for each. A balanced translocation 
between chromosomes 6 and 8 is indicated. 
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Table B.1. Essential genes identified in parental BOB screens and published hESC screens. 
Gene 
CDIPT 
CYC1 
FANCA 
FDXR 
H2AFZ 
MBTPS1 
MRPL50 
RPL32 
RPL34 
RPS25 
SCAP 
SDE2 
SETD1B 
SNRNP40 
TBCB 
WDR1 
CTDSPL2 
 
